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Cardiac injury is increased following ischemia-reperfusion. Mitochondria are the 
“effector organelles” that are damaged during ischemia (ISC) when there is no blood 
flow. Resumption of metabolism by damaged mitochondria during reperfusion (REP) 
results in increased cell injury. Current therapeutic interventions to pre-condition and 
post-condition the heart during ISC are ineffective during certain conditions like aging 
and diabetes due to defects in the signaling cascades. In contrast, mitochondrial-based 
strategies are effective in protecting the heart during ISC-REP. Hence direct therapeutic 
targeting of dysfunctional mitochondria will provide the potential to bypass the upstream 
signaling defects and intervene directly upon the effector organelle. 
Novel mitochondrial-targeted therapy relies on understanding the sites in the electron 
transport chain (ETC) that are damaged by ISC and produce cell-injury during REP. 
This project identifies a novel pathological role of cytochrome c in depleting cardiolipin 
during ischemia after which the mitochondria are in a defective condition that leads to 
additional cell death during reperfusion. During ischemia oxidants from complex III 
oxidize cytochrome c, forming a peroxidase, which causes oxidative damage and 
depletion of cardiolipin. Depletion of cardiolipin disrupts normal physiology and 
augments cell death. Identification of the innovative pathobiology during ISC-REP 
recognizes a novel therapeutic target, cytochrome c peroxidase, which can be a focal 
point for new therapeutic interventions to decrease cardiac injury. 
In order to maintain homeostatis, living organisms have the methionine sulfoxide 
reductase system, which reduce both free and protein bound Met(O) back to methionine 
(Met) in the presence of thioredoxin. Oxidized Trx is inactive and unable to bind to 
ASK1 thereby activating ASK1 and causing cell death via p38/JNK pathways thereby 
 xxvii 
 
contributing to the pathogenesis of myocardial ISC-REP injury. In this study we have 
shown that inhibition of ASK1 protects the heart during REP via the modulation of 
mitochondria that sustained damage during ISC. The mitochondrial-based mechanism 
of cardioprotection with ASK1 inhibition enhanced the functional integrity of the inner 
mitochondrial membrane retaining cytochrome c thereby decreasing cell death. This 
therapeutic intervention is a key step to achieve the ultimate goal to improve clinical 
outcomes in patients that suffer an acute myocardial infarction.
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CHAPTER I: INTRODUCTION 
 
 
 
 
I. 1. Mitochondria biology and structure 
Mitochondria are distinct, membrane-bound organelles found in most eukaryotic cells. 
The size of these organelles range from 0.5 to 1.0 μm in diameter and their number in a 
cell varies in each organism and tissue type from one to over a thousand. Since 
mitochondria generate most of the cell’s adenosine triphosphate (ATP), they are often 
termed “powerhouse of the cell”. In addition to generating energy, mitochondria are 
involved in other cellular processes such as calcium homeostasis, ammonia 
detoxification (urea cycle), fatty acid oxidation, certain heme synthesis reactions, steroid 
synthesis, cell signaling, cellular differentiation and cell death [1, 2]. Mitochondria are 
implicated in diseased conditions including cardiac dysfunction, neurodegeneration and 
congenital metabolic disorders, as well as, aging [3-5]. The mitochondrion has its own 
independent genome that is replicated and transcribed entirely in this organelle similar 
to bacterial genome, presumably due to the bacterial origin of mitochondria [6-8]. As 
 2 
 
shown in Figure 1.1, the organelle is composed of compartments that include the outer 
membrane, the intermembrane space, the inner membrane, the cristae and the matrix, 
each responsible for specialized functions. Both the outer and inner membranes are 
made of phospholipid bilayers and have different properties [6-8].
 3 
 
 
Figure 1.1. Schematic depiction of a mitochondrion. The organelle is composed of 
compartments that include the outer membrane, the intermembrane space, the inner 
membrane, the cristae and the matrix [8]. 
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The outer mitochondrial membrane (OMM) encloses the entire organelle and has a 1:1 
weight ratio of protein: phospholipid which is similar to that of the plasma membrane [6, 
8]. The membrane allows passage of molecules 5000 Daltons or less through channels 
which are formed by a large variety of integral proteins called porins. Larger proteins are 
transported across the outer membrane by binding to the multisubunit protein complex 
called translocase of the outer membrane (TOM) [9]. Studies have been reported that 
the outer membrane associates with the endoplasmic reticulum (ER) forming a structure 
called MAM (mitochondria-associated ER-membrane) which is involved in lipid transfer 
between ER and mitochondria and also in calcium signaling [10-12].  
The space between the outer membrane and the inner membrane is termed the 
mitochondrial intermembrane space (IMS). IMS contains small molecules including ions, 
carbohydrates and sugars that are permeable to the outer membrane resulting in a 
similar concentration as the cytosol. However, large proteins like cytochrome c are 
transported across the outer membrane via the TOM complex [6, 13-15].  
The inner mitochondrial membrane (IMM) has numerous invaginations called cristae 
which increase the surface area of the inner membrane. Proteins are embedded in the 
inner membrane that perform important functions including oxidative phosphorylation, 
specific transport of proteins that regulate metabolite passage, protein import and 
mitochondrial fusion. The IMM is enriched with phospholipids, particularly cardiolipin, 
which makes the membrane impermeable to molecules [6, 16]. Proteins are transported 
across the inner membrane using translocase of inner membrane (TIM) and metabolite 
transporters comprising malate-aspartate shuttle system and  glycerol-3-phosphate 
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shuttle that allow tightly controlled exchange of metabolites and protein import across 
the IMM [9]. 
The space enclosed by the inner membrane is called the matrix. It contains proteins, 
enzymes, special mitochondrial ribosomes (rRNAs), transfer RNAs (tRNAs), and 
circular forms of mitochondrial DNA (mtDNA) present in two to ten copies per 
mitochondrion [17]. Some key functions of matrix localized enzymes include oxidation of 
pyruvate and fatty acids, the citric acid cycle and the urea cycle (in liver and kidney 
mitochondria) [6].  
Mitochondria have their own genetic material and fully functional machinery to 
synthesize their own RNAs and proteins. Mitochondrial DNA is a double-stranded 
circular sequence which consists of 16,569 base pairs that encodes a total of 37 genes: 
22 tRNA, 2 rRNA, and 13 polypeptides. The thirteen polypeptides encode for the 
subunits of electron transport chain complexes I, III, IV, and ATP synthase (Table 1.1). 
The rest of the mitochondrial proteins are encoded by nuclear DNA which are 
subsequently translocated and integrated into the mitochondria using TOM/TIM system 
[17, 18].  
Significant oxidative stress generates reactive oxygen species (ROS) from the electron 
transport chain (ETC) which result in spontaneous and relatively frequent mutations in 
mtDNA due to close proximity of mtDNA to the electron transport chain (ETC) and due 
to the lack of the efficient defense mechanisms [19, 20]. Mitochondrial DNA mutations 
trigger a vicious cycle that lead to enzymatic abnormalities and further oxidative stress. 
Such mutations are inherited (only maternal mtDNA is passed to the offspring) and lead 
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to diseases that include Kearns-Sayre syndrome, MELAS syndrome and Leber's 
hereditary optic neuropathy [21]. However, mutations in nuclear genes lead to 
mitochondrial abnormalities such as coenzyme Q10 deficiency, Barth syndrome and a 
wide variety of clinical disease phenotypes, including certain mitochondrial myopathies 
[22, 23]. 
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Table 1.1. The mtDNA encodes proteins of the electron transport chain 
complexes 
 
Complex Number of subunits Subunits encoded by mtDNA 
Complex I 46 ND1, ND2, ND3, ND4, ND4L, ND5, ND6 
Complex III 11 CytB 
Complex IV 13 COX1, COX2, COX3 
Complex V 8 Atp6, Atp8 
 
COX- Cyclooxygenase; ND- NADH dehydrogenase; Cyt- Cytochrome; ATP- 
adenosine triphosphate.
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I. 2. Cellular respiration and oxidative phosphorylation 
The most important role of mitochondria is to generate energy for cellular respiration in 
the form of ATP by phosphorylation of ADP. The key pathways localized to the inner 
membrane and matrix include the tricarboxylic acid cycle, fatty acid β-oxidation and 
pyruvate dehydrogenase which lead to oxidation of amino acids, fatty acids and 
pyruvate [6]. The initial steps involve conversion of pyruvate (by pyruvate 
dehydrogenase) or fatty acids (in β-oxidation pathway) to acetyl CoA. The acetyl-CoA is 
oxidized to CO2 by the citric acid cycle also known as the tricarboxylic acid cycle 
(TCA)/Krebs cycle. Oxidation of one pyruvate molecule generates three molecules of 
nicotinamide adenine dinucleotide (NADH), one flavin adenine dinucleotide (FADH2) 
and one guanosine triphosphate (GTP) molecule [24, 25]. NADH and FADH2 are 
cofactors that transfer electrons into the respiratory chain to drive ATP synthesis. The 
respiratory chain is localized in cristae of the IMM. NADH is diffusible but impermeable 
to inner membrane whereas FADH2 (from TCA cycle) is covalently bound to the 
succinate dehydrogenase which is the only enzyme of TCA cycle located in the inner 
membrane. GTP is readily converted into ATP. NADH and FADH2 generated by the 
TCA cycle transfer electrons to O2 through four multimeric respiratory complexes (I-IV) 
resulting in an electrochemical gradient across the membrane which in turn is used by 
by the F0F1 complex (ATP synthase) to generate ATP. The coupled processes of the 
electron transport chain-dependent NADH and FADH2 oxidation and the 
phosphorylation of ADP to ATP driven by electron transport chain (ETC) dependent 
proton motive force (PMF) are termed oxidative phosphorylation [26-28].  
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Oxidative phosphorylation is a highly sophisticated system evolutionarily developed to 
increase recovery of energy contained in glucose molecules [29]. Oxidation of glucose 
through glycolysis, citric acid cycle and oxidative phosphorylation theoretically 
generates a maximum of 38 ATP molecules (3 ATP per NADH and 2 ATP per FADH2). 
However, this number is not reached in reality due to the losses in energy, such as the 
cost of moving two equivalents of NADH (generated in glycolysis) from cytoplasm to 
matrix, translocation of Pi and ADP into the mitochondria, and ATP out of the 
mitochondria. Furthermore, inefficiencies in oxidative phosphorylation due to leakage of 
protons across of the mitochondrial membrane and slippage of the ATP synthase/proton 
pump reduce the ATP yield. Therefore, the theoretical efficiency of oxidative 
phosphorylation is not reached and the observed yield is closer to 30 ATP molecules 
per one molecule of glucose (2.5 ATP per NADH and 1.5 ATP per FADH2) [30]. 
I. 3. Mitochondrial Electron Transport Chain 
The electron transport chain (ETC) is comprised of multi-subunit enzyme complexes 
and additional mobile electron carriers, ubiquinone (coenzyme Q10) in the inner 
membrane and cytochrome c located in the intermembrane space [26, 28]. These 
complexes diffuse in the inner mitochondrial membrane individually or are organized 
into larger supercomplexes called respirasomes [31]. 
Electrons are transferred from complex I (NADH: ubiquinone oxidoreductase; EC 
1.6.5.3) and II (succinate: ubiquinone oxidoreductase, EC 1.3.5.1) to ubiquinone, which 
carries them to complex III (ubiquinol: cytochrome c oxidoreductase, EC 1.10.2.2). From 
complex III, the mobile cytochrome c carries the electrons to complex IV (cytochrome c 
oxygenase, EC 1.9.3.1) where molecular oxygen is reduced to water. However, other 
 10 
 
enzymes comprising the electron-transferring flavoprotein (ETF): ubiquinone 
oxidoreductase; s, n-glycerophosphate dehydrogenase; dihydroorotate dehydrogenase 
provide electrons to the ETC at the ubiquinone and the reactions occur usually at a very 
low rate. Additionally in the liver, electrons generated during oxidation of sulfur-
containing amino acids by sulfite oxidase can be fed into the ETC at cytochrome c [29]. 
Electrons are transferred via productive collisions from high redox potential molecules 
such as NADH, FADH2 with ETC complexes. The energy lost as a result of the transfer 
of electrons is utilized by complexes I, III and IV to pump protons from the mitochondrial 
matrix into the IMS (Figure 1.2). The released energy generates a potential difference 
(ΔΨm) and proton gradient (ΔpH) across the membrane. This electrochemical proton 
gradient is used by the ATP synthase which allows the flow of H+ through the enzyme 
back into the matrix to generate ATP from adenosine diphosphate (ADP) and inorganic 
phosphate. Apart from the ATP synthesis, proton motive force is used for chemical, 
osmotic and mechanical work such as mitochondrial Ca2+ uptake, ATP/ADP exchange 
by the adenine-nucleotide translocator (ANT), import of nDNA-encoded preproteins, 
functioning of mitochondrial antiporters (aspartate/glutamate, H+/K+, H+/Na+, 2H+/Ca2+) 
and symporters (H+/pyruvate and Pi/ADP) [29, 32-34]. The proton motive force is 
dominated by ΔΨm and the ΔpH component contributes approximately 15% to its total. 
Therefore, ΔΨm can be considered as a crucial indicator of mitochondrial function and 
metabolic activity [29, 35, 36]. 
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Figure 1.2. Schematic representation of mitochondrial electron transport chain. 
The sites of proton pumping (red arrows) are located in complex I, III and IV. From each 
NADH two electrons are passed into molecular oxygen (O2) resulting in translocation of 
ten protons (H+). Six protons are pumped into IMS when succinate/FADH2 is used as an 
electron donor. NADH, nicotinamide adenine dinucleotide; FMN, flavin mononucleotide; 
Fe-S, iron-sulfur cluster; Q, ubiquinone; cyt c, cytochrome c; C, complex. Adapted from 
[37]. 
 12 
 
I. 3. 1. NADH: ubiquinone oxidoreductase 
During oxidative phosphorylation complex I transfers two electrons from NADH to 
ubiquinone with pumping of four protons from the matrix to the intermembrane space 
[6]. Complex I is comprised of forty six unique protein subunits with an approximate total 
size of 980 kDa. Despite such complexity, only fourteen subunits are essential for its 
catalytic function: seven highly hydrophobic mtDNA-encoded subunits (ND1, ND2, ND3, 
ND4, ND4L, ND5, ND6) and seven hydrophilic nuclear-encoded subunits (NDUFV1, 
NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7, NDUFS8). The function of the 
remaining 31 additional proteins is largely unknown. Electron microscopy analysis 
reveals that complex I assumes an L-shaped conformation and consists of a peripheral, 
matrix-protruding arm and an inner membrane-embedded arm. The matrix protruding 
arm contains NADH dehydrogenase activity with flavin mononucleotide (FMN) and an 
inner membrane-immersed arm consisting of all mtDNA-encoded subunits with 
ubiquinone-and rotenone-binding site [38, 39]. 
Fully assembled mammalian complex I accepts electrons from NADH into FMN cofactor 
located in the NDUFV1 subunit. Then electrons are transported through the protein by 
eight iron-sulfur clusters: N3 (NDUFV1), N1b (NDUFS1), N4 (NDUFS1), N5 (NDUFS1), 
N6a (NDUFS8), N6b (NDUFS8) and N2 (NDUFS7). In six of the FeS clusters (N2, N3, 
N4, N5, N6a, and N6b) iron atoms are coordinated to four sulfur atoms ([4Fe-4S]) and 
the other two (N1a, N1b) display a [2Fe-2S] configuration. After reaching FeS N2 
cluster, electrons are transferred to the coenzyme Q or ubiquinone-binding site [38, 40]. 
The Thermus thermophiles crystal structure studies predict that coenzyme Q binding is 
located at subunits NDUFS2 and NDUFS7. Another study using site-directed 
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mutagenesis of NDUFS2 and NDUFS7 subunits confirm this observation [41]. Complex 
I inhibitors act at the terminal electron donating step by inhibition of ubiquinone 
reduction. One of them is the naturally found plant alkaloid rotenone, commonly used to 
study complex I dependent effects in the mitochondria. Photoaffinity labeling techniques 
and mutagenesis studies from Y. lipolytica, R. capsulatus reveal that NDUFS2, 
NDUFS7, ND1 and ND5 subunits contribute to the rotenone inhibition site within 
complex I [42]. The net reaction of complex I activity is summarized below: 
NADH + Q + 5H+matrix                NAD
++ QH2 + 4H
+
IMS 
Altered complex I activity during pathologic conditions is often observed in a variety of 
diseases resulting from mutations in mtDNA that leads to decreased integrated 
respiration [21, 43, 44]. Mutations in the subunits of complex I have been associated 
with neurological and neuromuscular diseases, including Leigh syndrome [45-47], 
Leber's hereditary optic neuropathy [48, 49] and even with etiology of Parkinson’s 
disease [50, 51]. Moreover, enzymatic activity may be regulated by specific post-
translational modifications of particular subunits which include phosphorylation [52], 
glutathionylation [53-55], acetylation/deacetylation [56] and even S-nitrosylation [57, 58].  
I. 3. 2. Succinate: ubiquinone oxidoreductase 
Complex II is the only enzyme that participates both in TCA cycle and ETC by 
catalyzing the oxidation of TCA intermediate succinate to fumarate with the electron 
transfer directly to the quinone pool. Complex II consists of four protein subunits and a 
bound flavin adenine dinucleotide (FAD) cofactor, iron-sulfur clusters, and a heme 
group [6]. The protein subunits are encoded by nuclear-DNA that include two 
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hydrophilic subunits, SDHa and SDHb which protrude into matrix and two hydrophobic 
subunits SDHc and SDHd embedded in inner membrane. The heme group does not 
participate in electron transfer to coenzyme Q, but is important in decreasing production 
of reactive oxygen species. The electrons from succinate are accepted at FAD cofactor 
located in SDHa. Next, the electrons are transferred through three iron-sulfur clusters, 
([2Fe-2S], [4Fe-4S] and [3Fe-4S]), within SDHb into membrane-anchored subunits that 
contain the quinone-binding site [6, 59]. However, transfer of electrons through complex 
II does not transport protons across the membrane as summarized in equation below: 
FADH2 + Q              FAD + QH2 
Molecules such as TTFA (thenoyltrifluoroacetone) bind to the ubiquinone pocket and 
are speculated to play a protective role in blocking the unfavorable reverse electron flow 
from complex II into I, which can result in superoxide generation by complex I [29, 60]. 
The activity of succinate:ubiquinone oxidoreductase is tightly regulated despite its 
simple structure. However, post-translational modifications such as 
acetylation/deacetylation [61], glutathionylation [62] and phosphorylation [63] in the 
flavoprotein part of the complex (SDHa) result in altered enzymatic activity. On the other 
hand, mutations in SDHa subunit have been reported to cause a classical mitochondrial 
neurogenerative disease, encephalomyopathy in childhood while the mutations found in 
the genes of the other three subunits have been associated with sporadic 
paragangliomas and/or pheochromocytomas and the inherited autosomal cancer-
susceptibility syndromes [64]. Also, mev-1 mutation in C. elegans gene encoding the 
homolog of SDHc subunit results in premature aging and hypersensitivity to oxidative 
stress [65]. 
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I. 3. 3. Ubiquinone: cytochrome c oxidoreductase 
Complex III or mitochondrial bc1 complex is a multi-subunit enzyme encoded by both 
the mtDNA (cytochrome b) and the nuclear genome (remaining ten peptides). Structural 
studies have shown that the functional complex III is present as a dimer wherein each 
monomer contains three protein subunits with redox prosthetic groups: cytochrome b 
(two b-type hemes, bLand bH); cytochrome c1 (c-type heme, c1); and the Rieske iron-
sulfur protein harbors a [2Fe-2S] cluster [66].  
Complex III has two reaction centers for ubiquinol, Qo and Qi. Qo is located on the outer 
face of the inner membrane while Qi is localized facing the mitochondrial matrix [67]. 
Electron transport through bc1 complex, termed Q cycle, involves a concerted oxidation 
of QH2 coupled with proton pumping across the membrane. Initially, QH2 is oxidized at 
the Qo site resulting in bifurcation of the electron transfer. One electron is given to the 
[2Fe-2S] cluster within Rieske subunit, which is then oxidized by cytochrome c1. 
Further, cytochrome c1 is oxidized by cytochrome c resulting in transfer of a single 
electron and translocation of two protons into the IMS. The second electron bifurcated 
at the Qo site, as a result of oxidation of QH2 results in formation of a semiquinone 
which subsequently is oxidized by donating the electron to the chain of hemes bL and 
bH. Reduced heme bH gives one electron to Qi site resulting in the formation of 
semiquinone. The second half of the cycle is initiated again by a second round of QH2 
oxidation at Qo resulting in another molecule of reduced cytochrome c, another two 
protons translocation into the intermembrane space. The successive reduction of 
hemes bL and bH causes the complete reduction of semiquinone at Qi to ubiquinone. 
The quinone reduction at Qi involves an uptake of two protons from matrix. Therefore, 
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as a result of the Q cycle, for every pair of electrons taken from QH2 to two molecules of 
cytochrome c, four protons are translocated to the intermembrane space and two 
protons are removed from the mitochondrial matrix [68]. The overall reaction is 
summarized below: 
QH2+ 2cyt-c (Fe
3+
ox) + 2H
+
matrix                  Q + 2cyt-c (Fe
2+
red) + 4H
+
IMS 
Two types of complex III-specific inhibitors have been reported based on their targets. 
Myxothiazol and stigmatellin bind to the distinct pockets within the Qo site and block the 
transfer of electrons into complex III from reduced QH2. Antimycin A (second class 
inhibitor) blocks the electron transfer from bH heme to oxidized Qi site by binding to the 
ubiquinone [69]. 
Complex III gene mutations cause exercise intolerance and cardiomyopathy [19]. 
Additionally, mutations in mtDNA-encoded cytochrome b have been reported to cause 
septo-optic dysplasia [70] and multisystem disorders like deafness, mental retardation, 
retinitis pigmentosa, cataract, growth retardation and epilepsy [71]. Furthermore, 
Bjornstad syndrome (deafness, hair abnormalities) [72] and the Finnish lethal GRACILE 
syndrome (growth retardation, amino aciduria, iron overload, lactic acidosis and 
cholestasis) [73] are due to mutations in BCs1L assembly protein which assists in the 
maturation of the Rieske protein. 
I. 3. 4. Cytochrome c oxidase 
Complex IV (cytochrome c oxidase) belongs to the heme-copper oxygen reductase 
superfamily which catalyzes the complete reduction of dioxygen to water and 
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translocates protons to the intermembrane space [8]. Complex IV can exist as a 
monomer, which is sufficient for electron transfer and oxygen reduction but for proton 
translocation across the inner membrane the cytochrome c oxidase must be present as 
a dimer. Each monomer is composed of several metal prosthetic groups (two hemes 
and two copper centers) and thirteen proteins. Among the thirteen proteins, three of 
them are encoded by mtDNA (COX1, COX2, and COX3) and the other ten by nuclear 
DNA. COX1 contains twelve transmembrane α helices that are organized in three 
groups of four helices with a central pore. The first group contains heme a, the second 
contains a heme a3-copper CuB center, and the third group is empty. Subunit COX2 
contains a binuclear copper center CuA. The nuclear encoded subunits (COX4 -COX8) 
are considered to contribute to the stability, assembly and regulation of the oxygenase. 
However, their exact functions are only partially understood [6, 25, 74]. 
Electrons from reduced cytochrome c are transferred to the binuclear CuA center in 
COX2 and then to heme a. Finally electrons are transferred to heme a3-CuB center from 
heme a resulting in conversion of ½ O2 to H2O at the heme a3-CuB center which 
involves a rapid four electron reduction along with immediate oxygen-oxygen bond 
cleavage to avoid superoxide formation. Electron transfer through complex IV is coupled 
with the translocation of four protons from the matrix to the intermembrane space [25, 
29]. The net reaction is summarized below: 
4cyt-c (Fe2+red) + 8H
+
matrix + O2              4cyt-c (Fe
3+
ox) + 4H
+
IMS + 2H2O 
The oxygen binding site of complex IV also binds ligands such as carbon monoxide 
(CO), nitric oxide (NO), cyanide anions (CN-), azide anions (N3
-), and hydrogen sulfide 
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(H2S), resulting in competitive inhibition of the oxidase activity, which in turn leads to 
chemical asphyxiation [29]. 
Genetic mutations altering complex IV functionality and/or structure usually result in 
very severe and often fatal metabolic dysfunctions. The majority of cytochrome c 
oxidase disorders are caused by mutations in nuclear-encoded assembly proteins such 
as SURF1, SCO1, SCO2, COX10 and COX15 [75] that result in oxidase deficiency with 
variety of clinical phenotypes including Leigh syndrome, fatal infantile hypertophic 
cardiomyopathy and other neuropathies [76, 77]. 
I. 4. Mitochondria as generators of reactive oxygen species 
In most mammalian cells, mitochondria are important generators of Reactive Oxygen 
Species (ROS) [78-80]. Small amounts of ROS can function as “signaling ROS” that  
trigger ischemic preconditioning by activating protein kinases such as protein kinase C 
(PKC) or p38 MAP kinase leading to the subsequent translocation of transcription factor 
NF-κB to the nucleus where it regulates gene expression [81, 82]. However, excessive 
generation of ROS act as “cytotoxic ROS” that damage cardiomyocytes ultimately 
permeabilizing the mitochondrial membrane. Increased ROS from mitochondria 
contribute to the pathological redox signaling, releasing H2O2 from the organelle to the 
rest of the cell resulting in oxidative damage of target proteins which alters activity of 
enzymes, kinases, phosphatases and transcription factors [79, 83]. 
In mitochondria, superoxide (O2
•−) is produced by one-electron reduction of dioxygen 
(O2). Theoretically, several electron donors and redox couples in the mitochondria can 
thermodynamically favor the formation of O2
•−. However, small-molecule electron 
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carriers like NADH, NADPH, CoQH2 and glutathione (GSH) do not react with O2 to 
generate O2
•−. Instead, mitochondria produce O2
•− mainly at active sites of redox 
prosthetic groups within proteins or when reduced electron carriers such as CoQH2 are 
bound to proteins. Alterations in protein due to mutation, post-translational modification 
or conformational changes enable O2 to interact more rapidly with the electron carrier 
which increases dramatically the production of O2
•− [84]. This makes the electron 
transport chain a perfect candidate for ROS production. Indeed, it is now very well 
documented that complex I and III are the main sites of superoxide generation during 
pathologic conditions [85]. 
Better understanding of mitochondrial ROS production will lead to the rational design of 
therapies to minimize oxidative damage by O2
•−. However, direct measurement of O2
•− 
within mitochondria is a challenge because MnSOD rapidly dismutates it to form H2O2. 
The difficulties in assessing mitochondria-generated superoxide can be overcome by 
the measurement of H2O2 release from the mitochondria that has already exceeded the 
threshold of ROS scavenging systems capacity [86-88].  
I. 4. 1. Complex I-mediated ROS production 
As mentioned earlier, Complex I comprises forty six polypeptides which includes FMN, 
FeS clusters and likely two semiquinones. Oxygen mostly likely has access to electron 
carriers mainly at FMN, CoQ sites and terminal FeS centers which can possibly donate 
an electron reducing O2 to O2
•− [89, 90]. Isolated complex I increases O2
•− production in 
the presence of NADH and inhibitor rotenone. Rotenone binds to the CoQ-binding site 
of complex I and enhances O2
•− generation I which suggests that the N2 Fe-S or the 
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tightly bound quinones are the loci for O2
•− release [91, 92]. It is now well understood 
that complex I produces O2
•− when O2 reacts with fully reduced FMN which in turn is 
dependent on the NADH/NAD+ ratio. Excess NADH leads to the fully reduced state of 
FMN, which favors the reduction of O2 at the flavin cofactor [93-95]. Hence inhibition of 
the electron transport chain by chemicals, damage, mutation, ischemia, loss of 
cytochrome c or decrease in ATP demand affects respiration thereby increasing 
NADH/NAD+ ratio ultimately causing excessive ROS generation [84, 93, 96]. In contrast, 
physiological respiring mitochondria on NADH-linked substrates produce less O2
•− from 
complex I because the NADH/NAD+ ratio is very low [97]. 
Reverse electron transfer (RET) is another mechanism by which complex I produces 
large amounts of superoxide [84, 89, 97]. RET occurs when electrons from succinate, α-
glycerophosphate or fatty acid oxidation reduce the CoQ pool which along with 
significant proton motive pushes electrons back from CoQH2 into complex I ultimately to 
the FMN site resulting in reduction of NAD+ to NADH [98]. Under above mentioned 
conditions complex I produces extensive amounts of superoxide, especially in brain, 
heart, muscle and liver mitochondria [84, 89, 97]. Moreover, this generation of ROS is 
abolished in the presence of rotenone, which confirms that electrons enter complex I 
through the Q-binding site during RET [99]. However, the site in complex I of the RET-
linked superoxide generation is unclear [100]. One possibility is that RET results in 
higher generation of O2
•− from reduced FMN by forcing electrons back from complex I to 
FMN [84]. Additional RET-related O2
•− production occurs at semiquinones formed in the 
Q-binding site of complex I during proton pumping [94, 99]. However, other reports 
provide evidence that the one-electron donor to oxygen in complex I is located prior to 
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the Q-binding site [101]. Their results also suggest that the superoxide generation site 
can be the iron-sulfur cluster N2, based on its physico-chemical properties and ability to 
interact with endogenous ubiquinone. Notably, the ROS production from complex I is 
considered to be directed into the matrix of the mitochondria [102]. 
I. 4. 2. Complex III-mediated ROS production 
Complex III for a long time has been considered the dominant source of superoxide 
production. Inhibition of the Qi center by antimycin A, results in large amounts of O2
•− 
release due to the reaction of O2 with ubisemiquinone bound to the Qo site. However, 
the Qi center can also be a site of O2
•− production especially when electron flow into Qo 
is limited [91, 103]. Complex III exists as dimer which allows adequate residual electron 
flow into the the complex. As a result, electrons tunnel between the b hemes located at 
the Qi centers of each monomer [104] which increases ROS generation from the Qi 
center [105, 106]. On the other hand, an altered Fe-S center [107] will inactivate the Qo 
center which along with loss of cytochrome c, limits electron flow to Qo center which 
further augments ROS release from complex III [94, 104]. Superoxide generated at the 
Qo site in complex III is released into the intermembrane space but O2
•− from Qi is 
targeted to the matrix [108, 109]. Interestingly, under conditions of a high proton motive 
force, as a result of reduced Q pool (from succinate), the main site of O2
•− generation 
remains at the complex I through RET mechanism [84]. 
 
 
 22 
 
I. 4. 3. Other sites of ROS production in the mitochondria 
Other sites in the mitochondria located outside the ETC contribute to O2
•− production. 
However, it is unclear whether they generate quantitatively significant amounts of 
mitochondrial ROS when compared to the ETC generated ROS [110].  
Studies on the lower organisms or from the in-vitro isolated mammalian complex II have 
reported that the catalytic activity of electron transport chain complex II can contribute to 
O2
•−  generation in the mitochondria. Two regions of this enzyme that are suspected for 
ROS production are: the FAD cofactor which is modulated by FADH• semiquinone and 
the Q-binding site [111-113]. However, the main source of complex II-driven superoxide 
generation in intact mitochondria is based on the RET into the complex I, which results 
in O2
•− release from the sites within complex I. In addition, the damaged or mutated 
complex II increases O2
•− production by itself [84, 114, 115]. 
Enzymes containing flavin prosthetic groups in their redox active center are suspected 
to generate O2
•−. These enzymes function mainly by donating electrons into NADH or 
ubiquinol. However, under conditions of high proton motive force, ubiquinol remains 
highly reduced, which leads to a blockade of the electron transfer to NADH and in turn 
to ubiquinol generating O2
•−. For example, the α-ketoglutarate dehydrogenase (αKGDH) 
contains a flavin center which produces ROS when its electron acceptor NAD+ is limiting 
[116]. Furthermore, enzymes transferring electrons to the ubiquinol pool, such as 
succinate dehydrogenase and electron transfer flavoprotein (ETF), increase superoxide 
generation by the RET mechanism by donating electrons to CoQ [86]. Additionally, ETF: 
CoQ reductase may produce ROS by itself directed to the intermembrane space [109]. 
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Another Q-linked enzyme located on the outer surface of the inner membrane is α-
glycerophosphate dehydrogenase (αGPDH) which donates electrons from α-
glycerophosphate to ubiquinol. This leads to increased ROS production, mainly by RET, 
although some is released from the enzyme itself. However, the physiological relevance 
of αGPDH contribution to O2
•− generation is unclear due to a very low expression of this 
enzyme in most of mammalian tissues, though it may be important in the brain [116, 
117].  
In addition, many other mitochondrial enzymes which are not connected to NADH or 
CoQ can be induced to produce O2
•− or H2O2. For example, adrenodoxin 
reductase/adrenodoxin/ cytochrome P450 produces ROS in the mitochondrial matrix by 
receiving electrons from the NADPH pool [118]. Another one which has recently been 
reported is the mitochondrial intermembrane space protein, p66shc, which uses electron 
transferred from reduced cytochrome c to generate peroxide that in turn appears to 
activate the apoptotic program [119]. Last but not least, monoamine oxidase is a 
flavoenzyme (containing FAD) located within the outer mitochondrial membrane, facing 
the intermembrane space. In mitochondria, monoamine oxidase catalyzes oxidative 
deamination of monomaines resulting in formation of aldehydes, ammonia and H2O2 
[120]. However, their contribution to the overall production of ROS by mitochondria is 
still unclear [110]. 
I. 4. 4. Mitochondrial ROS scavenging system 
Mitochondrial ROS is measured using O2
•−-sensitive dyes such as hydroethidine and 
MitoSOXTM [121-123], spin trapping [88], by measuring the reaction of O2
•− with 
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compounds to form chemiluminescent products [124, 125] and also by measuring the 
inactivation rate of aconitase [126]. However, the assessment of O2
•− generation in 
mitochondria is extremely difficult due to its extremely short half-life and also due to the 
rapid dismutation into hydrogen peroxide (H2O2) which further diffuses out from the 
mitochondria. H2O2 which diffuses out is typically measured by oxidation reaction of 
H2O2 with non-fluorescent dye (eg. Amplex Red) and a peroxidase (Horse Radish 
Peroxidase) to form a fluorescent product [86, 127, 128].  
The process of dismutation of O2
•− to H2O2 occurs either spontaneously or is catalyzed 
by mitochondrial antioxidant systems that are capable of neutralizing excess ROS [79]. 
Tetrameric mitochondrial manganese superoxide dismutase (MnSOD or SOD2) located 
in the matrix catalyzes the production of H2O2 from O2
•− as shown in the following 
reaction [129]: 
       MnSOD 
                                     O2
•− + O2
•− + 2H+                     H2O2 + O2 
 
Due to a high intra-mitochondrial concentration (3-10 µM) and reaction rate (k = 2.3x109 
M-1s-1) of MnSOD, the steady-state superoxide content in matrix of normally respiring 
mitochondria is very low [130]. However, in the presence of redox-active transition 
metals like copper and iron, H2O2 can form very active and damaging hydroxyl radicals 
(•OH).  •OH radicals are highly unstable and reactive for which no scavenging enzyme 
system exists [131]. These forms of ROS may cause direct damage to membrane lipids, 
proteins and mitochondrial DNA [132, 133]. Therefore, mitochondrial matrix contains a 
special system of peroxidases that remove H2O2 before it can react with active forms of 
metals. These include peroxiredoxins, glutathione peroxidases and trace amounts of 
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catalase [134, 135]. The glutathione peroxidase (GPx) reaction is coupled to the 
glutathione disulfide-reduced glutathione couple (GSSG/GSH) and the rate of H2O2 
removal depends on GSH concentration [136, 137]. 
                                                                 GPx 
H2O2+ 2 GSH                   2H2O + GSSG 
 
The above mentioned highly efficient antioxidant systems in the mitochondria neutralize 
ROS under normal conditions. Probably this is why the normal respiring mitochondria 
generate low levels of H2O2.  However, damaged mitochondria during stress produce 
high levels of ROS that exceed the capacity of the antioxidant system and can result in 
cell death [87]. 
I. 5. Mitochondria regulate apoptosis and mitophagy 
During stress, damage to mitochondria concomitantly activate both mitophagy and 
mitochondrial apoptosis/permeabilization. The final outcome depends on the balance 
between these pathways. Exposure to modest stress activates mitophagy wherein 
damaged mitochondria are sequestered by autophagosomes and degraded before 
apoptosis or necrosis can be triggered. However, during severe stress conditions 
apoptosis is the major pathway to minimize tissue damage upon cell death [138].  
I. 5. 1. Intrinsic apoptotic signalling 
Apoptosis is programmed cell death. It results in chromatin condensation, DNA 
fragmentation, cell shrinkage, and plasma membrane blebbing with release of apoptotic 
bodies, which are phagocytized by other cells in the organism [139]. There are two 
principal apoptotic pathways: the extrinsic or the death receptor-mediated pathway, and 
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the intrinsic or the mitochondrial-mediated pathway. The extrinsic pathway is triggered 
by tumor necrosis factor-α (TNF-α), TRAIL (TNF-related apoptosis-inducing ligand) and 
Fas receptors which activate downstream caspase 8 and caspase 10 [140, 141]. The 
intrinsic pathway involves mitochondria to intensify or augment the pathway by 
responding to stress signals including loss of growth factors, hypoxia, oxidative stress, 
and DNA damage [142].  
Apoptosis by mitochondria is highly regulated by the BCL-2 family of proteins. 
Antiapoptotic members of the family BCL-2 and BCL-XL promote survival. The pro-
apoptotic BCL-2 family proteins are BH3-only proteins, which include BH3 interacting 
domain death agonist (BID), BCL2/adenovirus E1B 19-kDa protein-interacting protein 3 
(BNIP3), Nip3-like protein X (NIX), BCL2/adenovirus E1B 19-kDa protein-interacting 
protein 3-like (BNIP3L),  p53 upregulated modulator of apoptosis (PUMA), and the 
effector proteins the BCL2-associated X protein (BAX) and BCL2-antagonistic/killer 
(BAK). The majority of the pro-apoptotic proteins are cytosolic, with the exception of 
Bak, which is localized at the OMM [143]. The cytosolic BH3-only proteins neutralize the 
antiapoptotic BCL-2 proteins thereby causing cell death by activating BAX and BAK 
[144, 145]. Additonally, following apoptotic stimuli, Bid is cleaved by death receptor-
dependent caspase-8, after which it translocates to the mitochondria and interacts 
directly with BAX and BAK to induce their activation. Upon activation, BAK and BAX 
undergo conformational changes forming homo-oligomers in the OMM. Homo-
oligomerization of BAK and BAX, form pores in the OMM causing mitochondrial outer 
membrane permeabiliation (MOMP) [146]. Permeabilization of the outer membrane 
results in the release of pro-apoptotic proteins from the IMS such as cytochrome c, 
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second mitochondria-derived activator caspase (SMAC)/direct IAP-binding protein with 
low pI (DIABLO), HtrA2/Omi, apoptosis-inducing factor, and endo-nuclease G into the 
cytosol, which activates apoptosis [138, 147, 148]. In the cytosol, cytochrome c binds to 
dATP, Apaf-1 and the initiator caspase 9 which forms an apoptosome activitaing 
caspase 9 which in turn activates caspase-3, the ‘executioner’ of the apoptotic pathway 
[149]. Smac/DIABLO and HtrA2/Omi promote caspase activation by neutralizing IAPs 
(inhibitor of apoptosis proteins) in the cytosol [150, 151],  whereas EndoG and AIF 
initiate a caspase-independent pathway by translocation to the nucleus where they 
trigger DNA fragmentation and chromatin condensation [152, 153]. 
In parallel, there exists a crosstalk between BCL-2 proteins and mitochondrial 
permeability transition pore (MPTP). Opening of MPTP in the inner mitochondrial 
membrane activates the intrinsic pathway leading to cell death [154]. Reports in the 
literature suggest that MPTP contains a voltage-dependent anion channel (VDAC, 
porin) in the OMM, the adenine nucleotide translocase (ANT) in the IMM and 
cyclophilin-D in the matrix, although the exact structure of MPTP is still unknown [155]. 
Opening of the MPTP causes rapid influx of solutes and water into the mitochondrial 
matrix. This collapses the proton gradient thereby disrupting ATP synthesis. MPTP 
opening induces mitochondrial swelling and cell death through apoptosis or necrosis 
and has been implicated in ischemia-reperfusion injury, cardiomyopathies, and 
congestive heart failure [147, 156, 157]. It has been reported that BCL-XL can bind 
directly to the components of MPTP controlling the pore opening and closing whereas 
BCL-2 increases the calcium threshold which makes the mitochondria more resistant to 
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MPTP. Also, BAX promotes MPTP opening through a mechanism which is different 
from MOMP [158-160].  
Apoptosis is an energy-dependent process, thus the presence of ATP is necessary to 
execute the apoptotic program. Therefore, substantial ATP depletion limits caspase 
activation and leads to necrosis. Necrosis is characterized by cell swelling, plasma 
membrane disruption releasing cytosolic components which trigger an inflammatory 
response [142]. During severe oxidative stress, apoptosis progresses to necrosis as a 
result of ATP loss which inhibits energy-dependent processes (e.g. functioning of ion 
pumps) resulting in swelling and rupturing of the cell membrane [161]. Rupture of the 
plasma membrane can be facilitated by proteolytic degradation of crucial cytoskeletal 
and membrane proteins, such as calpain-mediated cleavage of ankyrin and fodrin, 
anchor proteins for Na+/K+-ATPase [162]. 
I. 5. 2. Mitochondria and mitophagy 
BCL-2 and BCL-XL regulate autophagy via their interaction with activating molecule in 
BECLIN1-regulated autophagy (AMBRA1) that activates the BECLIN1-VPS34-VPS15 
complex which induces autophagy. Upon induction of autophagy, BCL-2 releases 
BECLIN1 and AMBRA1. However, it is still unclear what triggers the dissociation of 
AMBRA1 from BCL-2 [163-166]. Similarly, BNIP3, a pro-apoptotic BH3-only protein is a 
potent inducer of mitophagy [167]. Another protein which regulates both apoptosis and 
autophagy is the p53 tumor suppressor protein. Under physiological conditions, the E3 
ubiquitin ligase mouse double minute 2 (MDM2) degrades p53 maintaining low levels.  
In response to oxidative stress, p53 escapes degradation by an unknown mechanism 
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and its levels increase in the cell. P53 causes cell death by regulating gene expression 
and by direct action on the mitochondria. In the nucleus, p53 activates expression of 
autophagic genes like AMP-activated protein kinase, tuberous sclerosis protein 2, and 
sestrin1/2 [168, 169] along with proapoptotic genes which include Bax [170], Bak [170, 
171], Noxa [172], and Puma [173]. It also represses the transcription of antiapoptotic 
BCL-2, BCL-XL, and MCL-1 [171, 174, 175]. In parallel, p53 translocates to 
mitochondria where it inhibits BCL-2/BCL-XL and activates BAX and BAK causing 
MOMP [176-178].  
The phosphatase and tensin homolog induced putative kinase 1 (PINK1)/Parkin 
pathway is another important regulator of mitophagy. In normal healthy mitochondria 
with an intact membrane, serine/threonine kinase PINK1 is rapidly imported and 
cleaved by mitochondrial proteases. Upon collapse of the Δψm, the import and 
degradation of PINK1 are blocked, and PINK1 accumulates on the outer mitochondrial 
membrane which signals the cytosolic E3 ubiquitin ligase Parkin [179, 180]. Parkin 
rapidly translocates to mitochondria where it ubiquitinates mitochondrial proteins like 
VDAC1, MIRO, mitofusin-1 and mitofusin-2.  Ubiquinated proteins signal induction of 
mitophagy [181-183]. However, the exact mechanism on how accumulation of PINK1 on 
the OMM activates and recruits Parkin is still unclear [138]. Alternatively, mitochondria 
can also be cleared via an ubiquitin-independent pathway which involves direct binding 
of ATG8 family proteins to autophagy receptors on the mitochondria [184, 185].  
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I. 5. 3. Interplay between Mitophagy, Mitochondrial Biogenesis and Mitochondrial 
dynamics 
In response to mitophagy, cells compensate energy production without affecting 
contractility using their reserve pool of mitochondria. However, excessive mitophagy 
results in depletion of the bioenergetic reserve leading to cell death. Under such 
conditions, the cell replaces the mitochondria cleared by mitophagy through a tightly 
coupled process called mitochondrial biogenesis. The transcriptional coactivator 
peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) is a key regulator 
of mitochondrial biogenesis [186]. PGC-1α is induced at birth wherein there is a striking 
increase in mitochondrial biogenesis [186, 187]. In addition, Parkin has been shown to 
be a central regulator of both mitophagy and mitochondrial biogenesis. Recently, PARIS 
(ZNF746), a Parkin substrate is shown to repress the expression of PGC-1α by binding 
to insulin response sequences in the PGC-1α promoter. Activation of Parkin during 
mitophagy promotes degradation of PARIS and subsequent activation of PGC-1α 
transcription [188].  
Mitochondria are highly dynamic organelles capable of changing both size and shape. 
The main regulators of this process are the fission and fusion proteins [138]. Fission 
produces mitochondria that are fragmented and discontinuous whereas fusion produces 
elongated, tubular, interconnected mitochondrial network [189, 190]. Dysfunction or loss 
of fusion proteins is lethal as it causes the total loss of mtDNA from the cells. In 
mammals, the fusion proteins are the dynamin-related GTPases mitofusins (Mfn) and 
optic atrophy protein 1 (Opa1). Mfn exists in two isoforms, Mfn1 and Mfn2, both 
localized in the outer mitochondrial membrane (OMM) which interact with their 
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homologous proteins in the adjacent mitochondria causing OMM fusion. Opa 1 is 
located in the inner mitochondrial membrane (IMM) and plays a role in IMM fusion and 
cristae remodeling [190]. On the other hand, mitochondrial fission 1 protein (Fis1) and 
dynamin-related protein 1 (Drp 1) participate in fission. While Fis1 is transmembrane 
protein which binds to the OMM, Drp1 is located in the cytosol and translocates to 
mitochondria and interacts with Fis 1 in the event of mitochondrial fission [189]. The loss 
of fusion responses predisposes toward cell death and following fission, the 
mitochondrial fragments are selectively degraded through lysosomal machinery. A fine 
balance exists between mitophagy and biogenesis that is responsible for mitochondrial 
quality control [191-193]. However, the mechanisms through which mitochondrial 
dynamics trigger cell death are not fully understood. 
I. 6. Mitochondria and ischemia-reperfusion injury 
Heart attack/ myocardial ischemia is a major cause of morbidity and mortality 
worldwide. Myocardial ischemia exists when there is an inadequate supply of oxygen 
and nutrients to the myocardium as a result of blockade of blood flow through coronary 
arteries. The depletion of oxygen and metabolic substrates decreases the energy 
available to cardiomyocytes and leads to cardiac injury (infarction) [5]. The extent of the 
injury is determined by various factors including the duration of ischemia and the 
severity of ischemia (zero-flow versus low-blood flow). Reperfusion following ischemia 
to restore cardiac tissue survival also increases cardiac injury over and above that 
sustained during ischemia and independently contributes to myocardial cell death. This 
phenomenon is called reperfusion injury [78, 149, 194-197]. However, the cardiac 
response to ischemia-reperfusion insult can be manipulated to decrease the severity of 
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tissue injury which has motivated intense studies on the mechanisms of 
cardioprotection. 
1. 6. 1. Mitochondrial damage during ischemia 
Mitochondria are the cellular powerhouses that generate ATP for cell survival. But 
during cardiac ischemia, they are both sources and targets of cellular damage. Ischemia 
disrupts the ETC in mitochondria which leads to a decrease in respiration rate and an 
increase in production of reactive oxygen species (ROS). Global ischemia in animal 
models decreases the activity of complex I, complex III, cytochrome c content and 
respiration through complex IV [5, 198]. Studies in different animal models have shown 
that the consequences of ischemic damage depend on the duration of ischemia. Brief 
periods of ischemia for 15 min did not damage the ETC; cardiac contractile function is 
recovered with no myocyte cell death. This phenomenon is called “stunning” wherein 
the myocardium is not contracting properly and is viable. The stunned myocardium 
eventually will recover function if blood flow is restored [199, 200]. Ischemia for shorter 
time periods (15-20 min) decreases complex I activity [201, 202] while prolonged 
ischemia (30-45 min) results in damage distal to complex I. Longer periods of iscchemia 
decreases activity of complex III, leads to loss of cardiolipin and cytochrome c content, 
and impaired complex IV respiration rate [102, 203, 204]. 
Ischemia decreases complex I activity due to increased ROS generation as a result of 
electron leakage from the complex [102, 201, 205-207]. Additionally, complex I undergo 
ischemia-mediated post-translational modifications including phosphorylation [208] and 
S-nitrosylation [57] (as discussed earlier in section I.3). However, there are conflicting 
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reports regarding the ischemia-induced damage to NADH ferricyanide oxidoreductase 
(NADH dehydrogenase, NFR) which is the proximal component of complex I. While 
some reports have shown that the decreased NFR activity appears likely due to the loss 
of the flavin mononucleotide (FMN) component [206, 207], other studies have pointed 
out that the increased ROS production by complex I due to ischemia without apparent 
decrease in NFR activity indicates a site of damage distal to NADH dehydrogenase part 
of complex I [102, 209]. During ischemia, complex I is considered to be both the target 
and a source of damage. Rotenone treatment immediately before ischemia decreased 
damage to the distal parts of the ETC [210] by preserving complex IV respiration, 
cardiolipin and cytochrome c content [210]. Consistent with the retention of cytochrome 
c, proximal blockade of ETC during ischemia preserved the integrity of inner and outer 
mitochondrial membrane [209]. In addition, complex I blockade with rotenone before 
ischemia decreased ROS production and mitochondrial Ca2+ loading [85, 211, 212]. 
Therefore, it has been suggested that the proximal electron transport chain mediates 
the damage to its distal part during the progression of ischemia [210]. 
Several studies have shown that myocardial ischemia does not damage complex II [5]. 
However, studies showed that in vivo regional or global ischemia/reperfusion  resulted 
in loss of protective glutathionylation of key sulfhydryl groups in the complex II which 
results in decreased complex II enzyme activity [62]. Recent work by Quinlan et al. 
demonstrated that complex II is an important contributor to physiological and 
pathological ROS production [213]. This work suggests that the flavoprotein subunit of 
complex II generates ROS in both the forward reaction with electrons supplied by 
succinate, and the reverse reaction with electrons supplied from the reduced ubiquinone 
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pool when complex III is inhibited [213]. Thus, complex II can also be a potential source 
of damage during ischemia or early reperfusion due to distal blocks in the ETC. 
Ischemia decreases complex III activity as a result of the functional inactivation of iron-
sulfur [2Fe-2S] protein subunit. Ischemic damage did not affect the remaining eleven 
subunits of the complex. The electron paramagnetic resonance (EPR) signal from [2Fe-
2S] cluster decreases after ischemia without loss of the protein, suggesting that it is the 
disruption of the cluster which decreases the complex activity [214]. Studies with 
complex III blocker, myxothiazol decreased superoxide generation during simulated 
ischemia in cardiomyocytes which highlights the role of complex III as a major site of 
ROS production during ischemia [212]. As discussed in section I.3, the majority of ROS 
produced in complex III originates from the Qo center. However, the Qi center also 
releases superoxide when electron transfer into Qo is blocked. ROS generated from 
complex III causes oxidative modification and depletion of cardiolipin and subsequent 
release of cytochrome c from the inner membrane. Therefore, apart from complex III 
damage, progressive loss of cytochrome c  during ischemia sets a distal block in the 
ETC  resulting in impairment of Qo center which in turn increases ROS generation at the 
Qi site [104, 105].  
During ischemia, the activity of cytochrome c oxidase is decreased by two different 
mechanisms. First, ischemia leads to posttranslational modifications of complex IV, 
mainly phosphorylation of COXI, COXIVi1, and COXVb causes functional inactivation of 
the complex [215]. Second, studies from different animal models (rabbit, rat, canine) 
suggest that selective depletion of cardiolipin during ischemia affects the cytochrome c 
oxidase enzyme activity [216-218]. Cardiolipin is a phospholipid enriched in the inner 
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mitochondrial membrane and is the only phospholipid whose content decreases during 
ischemia. Decrease in cardiolipin content corresponds to the decrease in intergrated 
respiration through complex IV [219]. Potential mechanisms of overall cardiolipin loss 
during ischemia include hydrolysis by phospholipase A2 or oxidative damage [220, 221]. 
The mechanism of cardiolipin oxidation may result from the formation of cytochrome c-
cardiolipin peroxidase, which can occur in pathologic settings, under conditions of 
oxidative stress (increased H2O2) [222]. As mentioned earlier, the ROS generated from 
Qi center (in complex III) most likely causes cardiolipin modifications [222], although 
other sites of superoxide generation should not be excluded from the consideration. 
Cardiolipin contains linoleic acid (C18:2) acyl groups with two unsaturated cis double 
bonds. Oxidative damage to cardiolipin during ischemia generates peroxy-groups that 
are unstable and decompose rapidly leading to direct depletion of cardiolipin from the 
inner membrane [223]. Alternatively, the peroxy-acyl groups can form complexes with 
proteins that cause delocalization of cardiolipin from the membrane [221]. Hence, the 
peroxidation of cardiolipin, if not counteracted by synthesis of new cardiolipin leads to 
increase in generation of monolysocardiolipin which activates pro-apoptotic factors 
leading to cell death [224, 225]. However, the remaining cardiolipin in the inner 
membrane that did not delocalize showed no signs of modification.  
Cytochrome c is localized to the the inner membrane via its interactions with cardiolipin 
[226]. Depletion of cardiolipin results in redistribution of cytochrome c from the inner 
membrane into the inter-membrane space [227]. In normal conditions the outer 
membrane is impermeable to cytochrome c, however during ischemia the integrity of 
the outer membrane lipid bilayer is disrupted [149]. Results from the different 
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experiments suggest that during ischemia, loss of BCL-2 triggers oligomerization of the 
pro-apoptotic BAX and BAK in the outer membrane forming pores. This leads to an 
increase in the permeability of the outer membrane allowing delocalization of 
cytochrome c from the inter-membrane space into the cytosol following its detachment 
from cardiolipin (two-step process) [228]. Consequently, cytochrome c and the 
accompanying pro-apoptotic proteins including SMAC/DIABLO, HtrA2/Omi, apoptosis-
inducing factor and endo-nuclease G activate apoptotic pathways leading to cell death 
[146, 229]. 
1. 6. 2. Mitochondrial damage during reperfusion 
The restoration of blood flow to an organ or to tissue is termed reperfusion. The 
presence of damaged mitochondria following ischemia persist during reperfusion 
leading to reduced energy production, increased ROS and activation of cell death 
programs by cytochrome c release [222]. Pathological ETC function as a consequence 
of ischemic damage is supported by experimental evidence that blockade of complex I 
with amobarbital or nitric oxide before ischemia followed by reperfusion improved 
contractile recovery and decreased infarct size following reperfusion [211, 230-232]. 
Also, the distal blocks in ETC during ischemia due to damage of complex III and loss of 
cytochrome c result in excessive ROS generation which causes increased cardiac injury 
during reperfusion. Interestingly, the net release of ROS from ischemic damage can be 
abolished by proximal blockade of the ETC with rotenone [210].  
Amobarbital (Amytal®) is a short-acting barbiturate that reversibly inhibits complex I at 
the rotenone-binding site [233, 234]. Amobarbital treatment during ischemia protects the 
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distal electron transport chain by preserving respiration through complex III and 
complex IV, improving complex I activity along with retention of cytochrome c within 
mitochondria, all of which are measured following reperfusion [209, 230]. This 
demonstrates that though rotenone and amobarbital are chemically distinct compounds, 
inhibiting the rotenone binding site protected mitochondrial ETC from ischemic damage. 
Moreover, this inhibition of electron transport during ischemia reduced calcium loading 
during reperfusion. Diminished calcium loading along with lower ROS levels would 
result in decreased susceptibility to MPTP opening and smaller cardiac infarction [211, 
232]. Therefore, the reduction of electron flow through ETC applied before the ischemic 
insult exhibits cardioprotection following reperfusion. Hence, ischemic damage to the 
electron transport chain is considered an important link between ischemia and the 
progression of cardiac injury during reperfusion [222].   
There are conflicting reports on the damage caused to mitochondria during reperfusion. 
Some studies suggest that ischemic damage to complexes I, III and IV further 
deteriorates oxidative phosphorylation [201] and complex activities [201, 235] during 
reperfusion, suggesting that additional mitochondrial injury occurs. Also, early in 
reperfusion, a detectable burst ROS generation is recorded [194, 236-239]. Damage to 
the ETC during ischemia increases net release of H2O2 during reperfusion with 
glutamate as a substrate [102]. With succinate and rotenone the H2O2 generated 
following ischemia from complex III is substantially increased [85, 88, 240]. Hence, 
ischemic damage to the ETC augments oxidative injury during reperfusion, especially at 
complex I and III wherein there is an increase in ROS generation due to distal blocks in 
the ETC which could result in additional damage [201, 235]. In addition, post-ischemic 
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mitochondria generate reactive and damaging hydroxyl radical (•OH) measured by 
electron spin resonance (ESR) spin-trapping [194, 241]. 
Prompt reperfusion or reoxygenation rapidly restores the substrates essential for ATP 
generation, increases the oxygen supply and normalizes the extracellular pH to restore 
cellular homeostasis. However, abrupt normalization concurrently causes reperfusion 
injury [242]. Rapid normalization of the extracellular pH creates an extreme H+ gradient 
across the plasma membrane that triggers Na+/H+ exchange leading to high Na+ influx 
which in turn triggers Na+/Ca+2 exchanger in a “reverse mode,” resulting in intracellular 
Ca+2 overload [243]. The increase in intracellular Ca+2, enhances mitochondrial calcium 
overload triggering mitochondrial permeability transition (MPTP) that contributes to 
additional cardiac injury during reperfusion [244, 245]. The MPTP can be blocked by 
pharmacological inhibitor, cyclosporine A. Opening of the  MPTP can lead to cell death 
through apoptosis (release of cytochrome c) or necrosis (depletion of ATP) [246, 247]. 
Morphological and biochemical studies suggest that mitochondria are largely intact 
following ischemia [204, 216]. However, during reperfusion increased calcium 
availability enhances mitochondrial calcium loading as result of which mitochondria 
“swell” and cause cell death [244, 248].  
In contrast, experimental studies suggest that ischemic damage to the mitochondria 
persists during reperfusion without apparent evidence of additional substantial damage 
to the distal ETC caused by reperfusion. The decreased cardiolipin and cytochrome c 
contents as well as cytochrome c oxidase respiration persist but do not worsen during 
reperfusion [203, 223]. However, during ischemia, distal blocks formed as a result of 
loss of cardiolipin and cytochrome c [216], functional inactivation of Fe-S peptide of 
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complex III [214] result in decreased respiration through complex IV [204] following 
reperfusion. Apart from this, ischemia increases ROS generation during reperfusion 
from complex I even in the absence of complex I damage [78, 92, 219]. From these 
studies it is clear that enhanced mitochondrial damage, increased ROS along with 
calcium loading predispose MPTP pore opening during early reperfusion which 
translates the ischemic mitochondrial damage into reperfusion injury [222]. Amobarbital 
treatment before ischemia along with postconditioning during early reperfusion 
improved calcium tolerance and inner membrane potential recorded following 
reperfusion [249]. In another study, postconditioning (brief periods of ischemia) during 
early minutes of reperfusion, inhibited MPTP opening by reducing oxidative stress at the 
cellular level without any effect on oxidative phosphorylation or membrane polarization 
[250]. These results suggest that reperfusion injury can be minimized if the 
mitochondrial damage during ischemia is prevented.  
Current therapeutic interventions to pre-condition, post-condition, or pharmacological 
treatment to activate signaling pathways of protection in the heart are ineffective during 
certain conditions including aging and diabetes due to defects in the signaling cascades 
[251-253]. Hence direct therapeutic targeting of dysfunctional mitochondria will provide 
the potential to bypass the upstream signaling defects and intervene directly with the 
effector organelle. Novel mitochondrial-targeted therapy relies on understanding the 
sites in the ETC that are damaged by ischemia and produce cell-injury during 
reperfusion. The main objective of the current study is to delineate sites of ETC that are 
responsible for ischemic damage. This will allow us to identify a key mechanism of 
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ischemic damage after which the mitochondria are in a “locked in” defective condition 
and lead to additional cell death during reperfusion. 
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CHAPTER II: Electron flow into cytochrome c and reactive oxygen 
species from the electron transport chain convert cytochrome c to a 
peroxidase during ischemia-reperfusion 
 
 
 
 
II. 1. Introduction 
Mitochondria are the cellular powerhouses that generate ATP for cell survival. But 
during a pathological condition like cardiac ischemia, they are both sources and targets 
of cellular damage [5]. The sequence of events leading to myocardial ischemic damage 
involves increased generation of reactive oxygen species (ROS) [102], mitochondrial 
membrane permeabilization [154], depletion of cytochrome c and activation of apoptotic 
pathways [149]. Blockade of electron transport chain during ischemia decreases 
myocardial damage. This supports the concept that ETC itself plays a major role in 
ischemic damage [209]. 
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II. 1. 1. Localization of the segment of mitochondrial ETC responsible for ischemic 
damage 
Given the importance of ETC as a source of damage during ischemia, blocking it with 
inhibitors to manipulate electron flow through the respiratory complexes allows one to 
isolate the segment responsible for ischemic damage [254]. Experiments using an in-
situ global ischemic model with rotenone, an irreversible inhibitor of complex I, markedly 
attenuated the ischemic damage to cardiolipin, cytochrome c and respiration through 
complex IV. This observation provides evidence that proximal blockade of ETC during 
ischemia protects distal respiration [210]. Similar to rotenone, a chemically distinct 
compound, amobarbital competes for binding at the “rotenone-site” of complex I [233]. 
Amobarbital treatment immediately before ischemia decreases the net release of H2O2 
due to the preservation of oxidative phosphorylation and cytochrome c content [230]. 
Thus, the site within ETC that causes damage is located distal to complex I. 
To localize the site of ischemic damage distal to complex I, antimycin A, an irreversible 
inhibitor, is used to block the electron transport distal to complex III. Antimycin A, 
inhibits the Qi center of complex III thereby causing a net increase in ROS production 
from the semiquinone bound Qo site [109]. The ROS generated from the Qo site in 
complex III is released into the intermembrane space [78, 108]. Antimycin A, given 
immediately before ischemia, preserves complex IV respiration, cardiolipin and 
cytochrome c content. This evidence suggests that the site of ETC responsible for 
ischemic damage is located distal to quinol oxidation site of complex III [255]. 
Lastly, the contribution of complex IV in mediating ischemic damage was studied. 
Isolated perfused rabbit hearts which underwent global ischemia for 30 min were used. 
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Azide was given immediately before ischemia which blocked the ETC at complex IV. 
Interestingly, treatment with azide did not protect the ischemia-mediated decrease in 
respiration. Also, a decrease in cytochrome c content was observed similar to that of 
untreated ischemic hearts [254]. This evidence strongly supports that the segment 
located between the quinol oxidation site of complex III and complex IV is responsible 
for the ischemic damage to the ETC [254]. One of the key components of this site is the 
cytochrome c and cardiolipin complex located between complex III and complex IV 
which can potentially play an important role in ischemia mediated cardiac injury and is 
the focus of my research (Figure 2.1) [222].  
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Figure 2.1. Schematic representation of the mitochondrial electron transport 
chain localizing the ischemic defect. The segment located between the quinol 
oxidation site of complex III and complex IV is responsible for the ischemic damage to 
the ETC. Key components of this site are the cytochrome c and cardiolipin complex. Q, 
ubiquinone; cyt c, cytochrome c; CL-cardiolipin. Adapted from [37]. 
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II. 1. 2. Cytochrome c-cardiolipin interactions 
Cytochrome c is a small heme protein that transfers electrons between respiratory 
complexes III and IV located in the inner membrane of mitochondria. Cytochrome c is a 
positively charged protein with an iso-electric point of approximately pH 10, with 
approximately 30% of the protein surface having binding sites for anionic lipids [256-
259]. Complex interactions of cardiolipin with cytochrome c are responsible for localizing 
the later at the inner membrane. Various forces including electrostatic, hydrogen 
bonding and hydrophobic interactions are responsible for the formation of cytochrome 
c/cardiolipin complex. Under physiological conditions, electrostatic forces existing 
between negatively charged phosphate groups of the cardiolipin and positively charged 
lysine residues of cytochrome c are predominant [259]. Experimental studies have 
shown that anionic phospholipids have contact sites on cytochrome c at residues Lys72 
and Lys73 [256, 257]. Also, studies from interactions of the spin-labeled protein with 
spin-labeled phospholipids have shown that Lys72, Lys86, and Lys87 residues of 
cytochrome c are involved in cytochrome c-cardiolipin binding [226]. Recent studies 
have shown that additional electrostatic binding sites on cytochrome c which interact 
with membrane include Lys22, Lys25, His26, Lys27, and His33 [258]. Other than 
electrostatic interactions, hydrogen bonding between protonated acidic phospholipids 
and Asn52 stabilizes the protein binding with lipids [256, 257]. FRET studies depicted 
that the interactions between cytochrome and lipids are classified into two modes: an 
electrostatic low-affinity binding to deprotonated cardiolipin molecules and a high-affinity 
binding to partially protonated cardiolipin stabilized by electrostatic and hydrogen 
bonding. However, the type of interaction depends on pH, ionic strength, and the mole 
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fraction of cardiolipin [260]. Another type of interaction in the cytochrome- cardiolipin 
complex that are a result of nonpolar acyl residues of the lipid molecules and nonpolar 
regions of cytochrome c (normally buried inside the protein) are the hydrophobic 
interactions [259, 261, 262]. Thus, a single cardiolipin molecule interacts with 
cytochrome c by electrostatic interaction of a negatively charged phosphate groups with 
Lys72 as well as hydrophobic interaction by acyl chain insertion either in the channel 
surrounded by Asn52, Lys72, and Lys73 or between the nonpolar polypeptide strands 67-
71 and 82-85 [260, 263]. Experimental evidence from nuclear magnetic resonance 
studies suggests that the high affinity interactions between cytochrome c and cardiolipin 
are also a result of partial unfolding and partial insertion of the protein into the 
membrane [261, 264]. However, to a large extent, the interactions by insertion depend 
on pH, ionic strength, lipid composition and lipid/protein ratio. Hence, a decrease in 
cardiolipin content or alterations in the linoleate-fatty acyl chain saturation would 
diminish the affinity of cytochrome c to cardiolipin [264]. 
II. 1. 3. Structural rearrangements and peroxidase activity of cytochrome c 
Interactions of cytochrome c with negatively charged lipids in the membrane can disrupt 
the native structure of cytochrome c resulting in an intermediate conformation, between 
the native and the fully unfolded state, called a “molten globule” [265-268]. 
Exceptionally, solubilized cytochrome c is a heme-containing protein that reacts very 
slowly with H2O2 (0.2 M
-1s-1 at pH 7.0) [269] since the heme iron is occupied by ligands 
in all the six coordination positions [270]. The heme iron in cytochrome c has two axial 
bonds, one with His18 and the other with Met80 (Figure 2.2). In normal conditions, it is 
the Met80 bond with heme that blocks the interaction of iron with NO, O2, CO and H2O2 
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[271]. However, conditions including pH and temperature affect the heme binding to 
Met80 ligand in cytochrome c. Several in-vitro studies that include oxidation by HOCl 
[272], nitration of Tyr67 by ONOO
- [273] or carboxy-methylation of Met80 [274] were 
shown to disrupt the Fe-Met80 bond which facilitates the reactivity of iron thereby 
inducing the peroxidase activity. This change in reactivity of iron is a two-step process 
initiated with disruption of Fe-S(Met80) bond further resulting in rearrangements of the 
protein’s tertiary structure [275]. The changes in the heme environment are detected by 
looking at the CD spectra shifts in the 375-425 nm region (heme moiety), changes in the 
UV region (250-280 nm) as well as the quenching of the Trp59 fluorescence due to the 
closely located heme group. In addition, the disruption of the Fe-Met80 bond can be 
detected by measuring its characteristic absorbance at 695 nm [264, 271]. In short, 
structural changes along with loss of axial ligand (Met80) alter the redox catalytic 
reactivity of cytochrome c by enhancing its peroxidase activity in the presence of 
negatively charged phospholipid membranes [264, 271]. 
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Figure 2.2. Structure of the cytochrome c with native axial ligands. Cytochrome c 
has two axial bonds, one with His18 and the other with Met80. Met, methionine; His, 
histidine [264]. 
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The peroxidase function of cytochrome c requires direct physical interaction with 
cardiolipin. In general, >80% of the cardiolipin is localized to the inner mitochondrial 
membrane (IMM) wherein it is distributed at a ratio of 60:40 between the inner and the 
outer leaflets [276-280]. In addition to binding cytochrome c in the outer leaflet of the 
IMM, cardiolipin binds to other mitochondrial ETC proteins such as mitochondrial 
respiratory complexes I, III, and IV [281, 282]. However during apoptosis, cardiolipin 
content in the inner membrane decreases to 60% whereas its content in the outer 
mitochondrial membrane increases to 40%. In apoptotic cells, the decrease in the inner 
membrane cardiolipin levels is accompanied by changes in the intermembrane 
distribution of CL wherein approximately only 30-40% of the cardiolipin is confined to its 
inner leaflet [283, 284]. The mechanisms that are responsible for mitochondrial inter- 
and intramembrane cardiolipin translocation are not well understood. The transmigration 
of cardiolipin during apoptosis involves two proteins: tBid and phospholipid scramblase-
3 (PLS-3) [284, 285]. Although, tBid is localized to the outer mitochondrial membrane, it 
inserts into the inner and outer membrane through its cardiolipin-binding domain at the 
contact and noncontact sites [286, 287]. t-Bid treated mitochondria undergo significant 
changes in the intra- and intermembrane distribution of cardiolipin [279, 284]. PLS-3 is 
another mitochondrial protein that plays a role in bidirectional translocation of cardiolipin 
during apoptosis and is activated by calcium [285, 288]. During apoptosis, PLS-3 
undergoes posttranslational modification, phosphorylation of a specific Thr21 residue by 
protein kinase Cδ [289] leading to cardiolipin translocation through an unknown 
mechanism. Thus, during apoptosis, phosphorylation and activation of PLS-3 and tBid-
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dependent pathway causes transmembrane redistribution of cardiolipin which is a 
critical step for the mitochondria to initiate the apoptotic program [264]. 
II. 1. 4. Peroxidation of cardiolipin by cytochrome c 
The peroxidase activity of cytochrome c utilizes cardiolipin as the substrate and is 
mainly associated with participation in the execution of apoptosis [264]. The cytochrome 
c-catalyzed peroxidation has substrate specificity and the preferred oxidation substrates 
are polyunsaturated anionic phospholipids, particularly cardiolipin, phosphatidylserine, 
and phosphatidyl-inositol’s. Another study showed that saturated and monounsaturated 
cardiolipin molecules do not undergo peroxidation [224, 290-292]. Apoptosis induced by 
γ-irradiation, exposure to staurosporine or actinomycin D in cultured cells, showed 
accumulation of cardiolipin hydroperoxides [292-296]. Coinciding with this observation, 
exposure of mice to total body irradiation, formed cardiolipin hydroperoxy derivatives 
comprising (C18:2)3/(C18:2-OOH)1, (C18:2)2/(C18:2-OOH)2, (C18:2)1/(C18:2-OOH)3, 
(C18:2-OOH)4 which are detected via mass spectrometry [292]. Interestingly, other 
abundant phospholipids with polyunsaturated acyl chains phosphatidylcholines, 
phosphatidylethanolamine, and phosphatidylinositol are not oxidized [292]. This 
emphasizes the role of cytochrome c/cardiolipin peroxidase in determining the substrate 
specificity for cardiolipin oxidation [264]. 
Lipid peroxides are highly unstable and they decompose rapidly leading to direct 
depletion of cardiolipin from the inner membrane [223]. Alternatively, the peroxy-acyl 
groups can form complexes with proteins that cause depletion of cardiolipin from the 
membrane [221]. Depletion of cardiolipin results in translocation of cytochrome c from 
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the inner membrane into the inter-membrane space [227]. In normal conditions the 
outer membrane is impermeable to cytochrome c, however during pathological 
situations; the integrity of the outer membrane lipid bilayer is disrupted by the activation 
of cytosolic/mitochondrial phospholipases or insertion of pro-apoptotic proteins into the 
outer membrane [149, 220, 297]. This leads to an increase in the permeability of the 
outer membrane allowing release of cytochrome c and pro-apoptotic proteins (like Aif, 
SMAC/DIALBO) from the inter-membrane space into the cytosol (Figure 2.3). In the 
cytosol, cytochrome c binds to Apaf-I protein which activates caspase-9. Activated 
caspase-9 in turn activates caspase-3 which is the “executioner” of the apoptotic 
pathway [298]. Hence, the oxidation of cardiolipin, if not counteracted by synthesis of 
new cardiolipin activates apoptosis leading to cell death. The remaining cardiolipin in 
the inner membrane that did not delocalize showed no signs of modification [224, 225].  
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Figure 2.3. Cartoon depicting consequences of cytochrome c peroxidase. Cyt c; 
cytochrome c; CL, cardiolipin, AIF, apoptosis inducing factor 
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In a study by Kagan et al., actinomycin D induced apoptosis in different cell models, 
have shown that cytochrome c bound to cardiolipin acts as a peroxidase that selectively 
oxidizes cardiolipin. Peroxidation of cardiolipin increases outer mitochondrial membrane 
permeability, releasing of cytochrome c into the cytosol and thereby initiating the 
apoptotic program by activating caspase 3/7 [276]. Also, in-vitro direct measurements of 
peroxidase activity during induced oxidative stress in the liposomes are measured using 
chemiluminescence and fluorescence based assays with luminol and Amplex Red 
respectively. In addition, electron spin resonance spectroscopy of the EPE phenoxyl 
radical also confirmed the formation of cytochrome c peroxidase [276]. In addition, work 
by Vlasova et al. demonstrated that nitric oxide nitrosylates the heme of cytochrome c 
and blocks the cytochrome c peroxidase activity thereby preventing oxidation of 
cardiolipin [299].  
Under physiological conditions, complex III reduces cytochrome c while complex IV 
oxidizes it [6, 67]. Cytochrome c accepts electrons from complex III at a redox potential 
of +250 mV (vs SHE) while it donates electrons to the CuA site in complex IV at a redox 
potential of +285 mV (vs SHE) [300]. Any significant change of the redox potential of 
cytochrome c disrupts the electron transfer between the complexes [300, 301]. 
However, under H2O2-induced oxidative stress in cardiolipin liposomes, the redox 
potential of cytochrome c shifts negatively by 350-400 mV. This shift in redox potential, 
switches off the cytochrome c function as an electron transporter. This alteration inhibits 
the reduction of complex III by cytochrome c [301]. The peroxidase activity of 
cytochrome is functionally well characterized in in-vitro and in non-physiological cell 
death models [276, 301]. Although, its physiological relevance during diseased 
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conditions is still unknown. To understand the mechanistic importance of cytochrome c 
peroxidase formation and its ability to trigger apoptosis would be a great interest with 
respect to disease models.  
Hence, we intend to study the role of cardiolipin-cytochrome c peroxidase in ischemia, 
which is unknown and is the focus of my research. During ischemia, we hypothesize 
that excessive generation of ROS may oxidize the methionine residue (Met81) switching 
on its peroxidase activity ultimately oxidizing the linoleic fatty acyl chains of cardiolipin. 
This hypothesis is supported by experimental evidence (mass spectrometric data) which 
showed an increase in the amount of the monolysocardiolipin (degradation product of 
cardiolipin) in the samples generated following 30 min of ischemia when compared to 
the control non-ischemic hearts [302].  
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RESEARCH AIMS 
Mitochondrial electron transport chain (ETC) contributes to its own damage during ISC. 
Blocking ETC with inhibitors that disrupt electron flow through the respiratory complexes 
have shown that the locus of ischemic damage is between complexes III and IV. One 
key component of this site is the cytochrome c which interacts with cardiolipin. 
Cardiolipin is an oxidatively sensitive phospholipid that is unique to mitochondria and is 
modified during ischemia-reperfusion (ISC-REP) in the heart. Studies in non-
physiological cell stress models have shown that cytochrome c in its peroxidase mode 
catalyzes oxidation of cardiolipin during oxidative stress.  However, the role of 
cytochrome c peroxidase in ischemia is not yet known and is the focus of my research. 
This project proposes to identify cytochrome c peroxidase as a key contributor to 
mitochondrial driven ischemic injury which oxidizes cardiolipin resulting in cardiac injury. 
As depicted in Figure 2.4, we hypothesize that during ISC, oxidants from complex I and 
complex III modify cytochrome c and it creates an alternate route for electron transport. 
Oxidation of the cytochrome c at the methionine-81 residue serves as the marker for the 
peroxidase formation. As mentioned earlier, there is an increase in ROS production 
during ischemia which is converted to H2O2. H2O2 acts as a substrate for cytochrome c 
peroxidase or modified cytochrome c which causes the oxidation of cardiolipin to the 
peroxidized form. Modification and depletion of cardiolipin disrupts normal physiology, 
impairs electron transport, disrupts membrane integrity and augments cell death via the 
release of cytochrome c from mitochondria. Identification of this innovative pathobiology 
 56 
 
during ISC-REP recognizes a novel therapeutic target, cytochrome c peroxidase, which 
can be a focal point for new therapeutic interventions to decrease cardiac injury. 
Specific aims: 
1. Identify the oxidation of cytochrome c at the methionine-81 residue, a marker for 
cytochrome c peroxidase, during ischemia-reperfusion. 
2. Determine the contribution of ROS and electron flow through cytochrome c in 
oxidizing cytochrome c at the methionine residue. 
 57 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Schematic of alternate route for electron transport by cyt c-CL 
peroxidase during ISC-REP. ISC, ischemia; REP, reperfusion; Met, methionine; cyt c, 
cytochrome c; CL, cardiolipin; CL-OOH, peroxidized cardiolipin. 
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II. 2. Materials and Methods  
II. 2. 1. Materials 
All chemicals and reagents were purchased from Fisher Scientific, Pittsburgh, PA, or 
stated otherwise, except the ones used in mitochondria isolation and mitochondria-
related functional assays, which were purchased from Sigma-Aldrich, Saint Louis, MO. 
Animals 
Animals were housed in the fully AAALAC-accredited Animal Research Facility at the 
Virginia Commonwealth University. Experimental animals were purchased through, and 
maintained by the Animal Research Facility (ARF) of Virginia Commonwealth 
University. C57BL6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME). 
Mice were given heparin (1000 U/kg; i.p.) followed by deep anesthesia with 
pentobarbital (90 mg/kg; i.p.). Only mice which were 8-10 weeks old were used for the 
experiments. All animal experiments were conducted under the guidelines on humane 
use and care of laboratory animals for biomedical research published by the National 
Institutes of Health (revised 2011). 
II. 2. 2. Methods 
II. 2. 2. 1. Preparation of mouse heart for perfusion 
Male C57BL/6 mice (24.6 ± 0.9 g) were anesthetized with pentobarbital sodium (0.1 
mg/g i.p.) and anti-coagulated with heparin (1000 U/g i.p.). Hearts were excised and 
immediately immersed in a petri dish containing ice-cold (4°C) modified Krebs-Henseleit 
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buffer solution (composition, in mM: 115 NaCl, 4.0 KCl, 2.0 CaCl2, 25 NaHCO3, 1.1 
MgSO4•H2O, 0.9 KH2PO4, and 5.5 glucose; pH 7.4) oxygenated with 95% O2/5% CO2. 
Any attached connective tissue was carefully removed using fine surgical scissors. The 
heart was transferred to the perfusion apparatus and the aorta was carefully slipped 
onto the grooved tip of the perfusion cannula and secured in place with a ligature. 
Hearts were retrograde perfused via the aorta in the Langendorff mode with modified 
Krebs-Henseleit buffer. The temperature of the perfusate and the heart were rnaintained 
at 37 °C using a water jacket wamed by a water bath. Cardiac function was monitored 
with a balloon inserted into the left ventricle, and data were recorded digitally using the 
Powerlab recording system (AD Instruments, Colorado Springs, CO).  Hearts mounted 
on the Langendorff system were stabilized for 15 min by buffer perfusion after which 
coronary flow, heart rate and perfusion pressure was recorded. After stabilization, 
experimental hearts were either subjected to 45 min control perfusion (TC), or 25 min 
global ischemia (ISC) by stopping the coronary flow at 37 oC followed by 30 min 
reperfusion. Hearts were paced at 420 beats per min during the 15-min equilibration 
period and after 10 min of reperfusion. Throughout the reperfusion period, continuous 
timed samples of the coronary effluent were collected and kept on ice. 
II. 2. 2. 2. Isolation of mitochondria, cytosol, and heart tissue homogenates 
Adult male mice (body weight ~30 gram) were anesthetized by an intraperitoneal (i.p.) 
injection of pentobarbital (90 mg/kg), followed by rapid removal of the heart for the 
experiment. The heart was washed and placed in pre-chilled modified Chappell-Perry 1 
(CP1) buffer (pH 7.4) with the following composition: 100 mM KCl, 50 mM 3-(N-
morpholino) propanesulfonic acid (MOPS), 1 mM ethylene glycol-bis(2- 
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aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 5 mM MgSO4⋅7H2O, and 1 mM 
adenosine 5′-triphosphate disodium (ATP). 
A single, combined population of total cardiac mitochondria was isolated using the 
procedure described below. The entire mitochondrial isolation process was performed 
on ice with chilled buffers and equipment. Hearts were excised and only ventricles were 
used. Heart tissue was washed in the modified CP1 buffer. Further, the heart tissue was 
dried with Whatman filter paper, weighed, and then thoroughly minced in a glass 
beaker. The minced heart tissue was transferred to a glass tube for homogenization. 
Next, the cardiac tissue was homogenized in 3 ml of CP1 buffer using a polytron tissue 
blender (Kinematica, Bohemia, NY) for 2.5 s at a rheostat setting of 10,000 rpm. 50 µl of 
the homogenate was saved as the heart tissue extract. The polytron homogenate was 
centrifuged at 6,000 x g for 10 min at 4oC and supernatant was saved as a crude 
cytosol for further purification. The homogenate pellet was re-suspended in 3 ml of CP1 
buffer and incubated with 5 mg/g (wet weight) trypsin (#T0303, Sigma-Aldrich, Saint 
Louis, MO) for 15 min at 4oC. Next, 3 ml of CP2 buffer [CP1 buffer containing 0.2% 
bovine serum albumin (BSA) (#A7030, Sigma-Aldrich, Saint Louis, MO)] was added to 
decrease the trypsin digestion. Digested tissue was then homogenized (two strokes) 
with a tight Teflon pestle/glass tube homogenizer set at steady stirring speed of 600 
rpm. From the remaining homogenate, the undigested tissue and heavier cell fractions 
were separated by centrifugation at low speed 500 x g for 10 min at 4oC. The 
supernatant that contains the mitochondria was then transferred to a new tube and 
centrifuged at 3000 x g for 10 min at 4oC. The pellet containing the mitochondria was 
washed with 2 ml of KME buffer [100 mM KCl, 50 mM MOPS, and 0.5 mM EGTA] and 
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centrifuged at 3000 x g for 10 min. Lastly, the mitochondrial pellet was re-suspended in 
80-100 µl of KME and the protein concentration was measured by Lowry method using 
BSA as a standard and sodium deoxycholate (Sigma-Aldrich, Saint Louis, MO) as a 
detergent to solubilize the mitochondria. 
Crude cytosolic fraction was supplemented with protease and phosphatase inhibitor 
cocktails (Roche, Indianapolis, IN) and was further purified to separate any low-weight 
cell fraction by ultra-centrifugation at 100,000 x g for 30 min at 4oC. Also, heart tissue 
homogenate was supplemented with protease and phospatase inhibitor cocktails and 
further lysed in a whole cell extraction buffer (WCE buffer: 20 mM Hepes pH 7.0, 300 
mM NaCl, 10 mM KCl, 1 mM MgCl2, 20% glycerol, 1% Triton X-100) for 30 min at 4
oC. 
Cell debris was then removed from the lysates by centrifugation at 20,000 x g for 15 min 
at 4oC. The protein concentrations of the cytosols and whole cell extracts were 
determined using Bio-Rad protein assay (Bio-Rad, Hercules, CA) based on Bradford 
dye-binding method. 
II. 2. 2. 3.  Measurement of oxidative phosphorylation in intact mitochondria 
Polarographic measurement of oxygen consumption by intact mitochondria was 
performed in a glass chamber equipped with a Clark-type oxygen electrode 
(Strathkelvin Instruments, Glasgow, Scotland) as described below. The measurements 
were performed at 30oC in 500 µl of a respiration buffer (80 mM KCl, 50 mM MOPS, 1 
mM EGTA, 5 mM KH2PO4 and 1 mg/ml defatted BSA, at pH 7.4). For glutamate/malate-
dependent respiration (complex I) and succinate-dependent respiration (complex II), 
150 µg of mitochondrial protein was used, and for TMPD (N,N,N′,N′-tetramethyl-p-
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phenylenediamine)/ascorbate (complex IV), 50 µg of protein was used. Next, the 
selected substrates for complex I (20 mM glutamate+5 mM malate), complex II (20 mM 
succinate with 7.5 µM rotenone), or complex IV (1 mM TMPD/20 mM L- ascorbate with 
7.5 µM rotenone) of the respiratory chain were added to the chamber. State 3 
respiration was measured by the addition of 0.2 mM ADP (final concentration) followed 
by state 4 respiration. After state 4 was attained, 2 mM ADP (final concentration) was 
added to the chambers to measure the maximum rate of state 3 respiration. Finally, 
0.04 mM uncoupler DNP (2, 4-dinitrophenol) was used to measure the uncoupled 
respiration rate. In case of TMPD/ascorbate, only maximum rate of state 3 (2 mM ADP) 
was measured. At the end of that measurement, 2 mM azide was added to determine 
the specificity of complex IV-dependent oxygen consumption.  
ADP-stimulated (state 3) and ADP-limited (state 4) respiration rates were defined and 
calculated according to the method of Chance and Williams [303, 304]. Respiratory 
control ratios (RCR) were calculated as a ratio of stimulated state 3 to state 4 
respiration according to Estabrook [305]. 
II. 2. 2. 4. In-vitro modulation of electron transport chain 
Isolated mitochondria were incubated with succinate and rotenone in the presence of 
azide (to establish a distal block at complex IV) and compared with incubations from 
succinate and rotenone with or without antimycin A (A.A) or thenoyltrifluoroacetone 
(TTFA). 1 mg of isolated mitochondria was incubated with 20 mM succinate + 7.5 µM 
rotenone with or without 10 mM TTFA or 10 mM antimycin A or 2 mM azide. Incubation 
studies of mitochondria were carried out in MSM buffer for 50 min at 37oC with gentle 
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rotation. Then, the mitochondrial protein was spun down at 3000 g for 15 min and the 
pellet was re-suspended in immunoprecipitation buffer (Invitrogen).  
Following incubations, cytochrome c was isolated from mitochondria using Dynabeads® 
Protein G immunoprecipitation kit (Invitrogen) with cytochrome c primary antibody (BD 
Biosciences). Immunocaptured cytochrome c was separated using SDS/PAGE 
electrophoresis system, transferred to the PVDF membrane and blotted for Met(O) 
[Cayman Chemical] and cytochrome c [BD Biosciences] (control for equal mitochondrial 
protein loading) as explained later in Materials and Methods II. 2. 2. 6.   
II. 2. 2. 5. Immunoprecipitation of cytochrome c 
Cytochrome c was immunoprecipitated from isolated mitochondria using Dynabeads® 
Protein G immunoprecipitation (IP) kit (Invitrogen). Initially, Dynabeads® were 
completely resuspended by pipetting or by rotating on a roller for 5 minutes. Later, 50 µl 
(1.5 mg) of Dynabeads® were transferred to an eppendorf tube. Next, the supernatant 
was removed after immobilizing the beads on the magnet. To the Dynabeads®, 8 μg 
anti-mouse cytochrome c antibody (BD Biosciences), diluted in antibody binding and 
washing buffer [PBS buffer (Invitrogen)+0.02% Tween-20], was added and incubated 
with antibody at RT for 120 min. by rotation. After incubation with the antibody, the 
supernatant was removed after immobilizing beads with a magnet. The beads were 
washed 2X with washing buffer. After removing the the final wash, 0.5 mg mitochondrial 
protein suspended in IP buffer (Invitrogen) (20 µl saved as “Before IP”) was added to 
the Dynabeads®-antibody complex and was incubated with rotation for 120 min. at RT 
which allowed the antigen (Ag) to bind to the Dynabeads®-antibody complex. In the 
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next step, the supernatant was recovered by immobilizing beads on the magnet and 
transferred to a clean tube for further analysis (“After IP”). Following, the Dynabeads®-
Ab-Ag complex was then washed three times using washing buffer [PBS buffer, pH 7.4, 
Invitrogen; catalog # 10010-023]. In order to avoid co-elution of the proteins bound to 
the eppendorf tube wall along with the protein of interest, the Dynabeads®-Ab-Ag 
complex was resuspended in washing buffer and transferred to a clean tube. Again, the 
supernatant was removed and the elution buffer [50 mM glycine, pH 2.8] was added to 
resuspend the Dynabeads®-Ab-Ag complex and incubated with rotation for 5 min. at RT 
which dissociated the Ab-Ag complex. Finally, the supernatant containing eluted 
antibody and antigen was transferred to a clean tube. For the eluted protein to be used 
for Western Blotting, the pH of the eluate was adjusted by adding 1 µl of 2.8 M Tris pH 
8.5 for 45 µl of eluate. 
II. 2. 2. 6. Western blot analysis 
Samples containing an equal amount of protein samples were mixed with Lammelli 
sample buffer (Invitrogen, Carlsbad, CA) containing DTT (dithiotreitol) (Invitrogen, 
Carlsbad, CA) and incubated at 95oC for 5 min. Immediately after, samples were loaded 
on the gel. Proteins were separated using SDS/PAGE electrophoresis system 
consisting of 4-20% gradient Tris-glycine pre-cast gels (Invitrogen, Carlsbad, CA). After 
separation, gels were transferred to Immobilon-P PVDF (polyvinyldifluoridine) 
membrane (Millipore) using transfer buffer with 10% methanol and a semi-dry transfer 
apparatus (Bio-Rad). The blots were then incubated for 1 h at RT with 5% (w/v) non fat 
dry milk (Bio-Rad) in TBS-Tween20 buffer (10 mM Tris, pH 7.5, 150 mM NaCl, and 
0.1% Tween20). Next, the membranes were incubated overnight at 4oC with the primary 
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antibody prepared in 5% BSA or 1% (w/v) non-fat dried milk in TBS-Tween buffer. Next 
day, the blots were washed three times, 15 min each, with TBS-Tween buffer and were 
incubated with a 1:50,000 dilution of anti-mouse or anti-rabbit IgG F(ab)2 fragments 
conjugated with Horse Radish Peroxidase (HRP) in 5% BSA/TBS-Tween buffer for 1 hr. 
Lastly, blots were washed three times, 15 min each, with TBS-Tween. The 
immunoreactive proteins were visualized using Amersham ECL Plus western blotting 
detection reagents (GE Healthcare Lifesciences, Piscataway, NJ) or SuperSignal Femto 
maximum sensitivity substrate kit (Pierce). Protein bands on western blot were 
quantified by densitometric analysis by the using ImageJ software (NIH, Bethesda).  
II. 2. 2. 7. In solution enzymatic digestion of proteins 
In-solution digestion of immunoprecipitated cytochrome c or commercial cytochrome c 
(Sigma) was done using the trypsin or chymotrypsin enzyme. Initially, 5 µl of 0.5 M 
tris(2-carboxyethyl)phosphine (TCEP) was added to the sample protein mixture which 
was incubated at 37oC for 1 hr with shaking. Following 15 µl of 55 mM iodoacetamide 
(IAM) was added to the protein mixture and incubated for 1 hr at 37oC with rotating in 
the dark. Further the trypsin digestion buffer was prepared by adding 990 µl of 100 mM 
ammonium bicarbonate (NH4HCO3) (pH 7.8) and 10 µl of 100 mM CaCl2 which 
activates the enzyme to a 20 µg vial of sequencing Grade trypsin (Promega, #V511). 
Chymotrypsin digestion buffer was prepared by adding 500 µl of 1 mM HCl, 495 µl of 
100 mM NH4HCO3 (pH 7.8) and 5 µl of 100 mM CaCl2 to a 25 µg vial of Chymotrypsin 
Sequencing Grade (Roche, No. 11418467001). Then 100 µl of trypsin/chymotrypsin 
digestion buffer was added and the reaction was carried out at 37oC for one day with 
shaking. Next day, 200 µl of 10% TFA and 50 µl of 5% acetonitrile were added to stop 
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the reaction and the solution was subjected to reverse phase chromatography solid-
phase extraction of peptides. The resulting peptide mixture was evaporated to dryness 
using a speedvac and then re-suspended in 30 µl of 95/5 0.1% TFA (aq)/acetonitrile. 
The samples were stored at -80oC until given for mass spectrometric analysis. 
II. 2. 2. 8. Mass spectrometry analysis of immunoprecipitated cytochrome c 
Peptide identification was performed using a Thermo (San Jose, CA) LTQ XL linear ion 
trap mass spectrometer in Dr. Scott Gronert’s laboratory, Department of Chemistry, 
Virginia Commonwealth University. The LTQ XL was interfaced with a Thermo Surveyor 
capillary HPLC system. Peptides were separated on a reversed-phase, C18 column 
(150 µm × 10 cm, 5 µm particles, 300 Ao pores; Column Technology, Fremont, CA) at a 
flow rate of ~1 µl min-1 using 0.1% formic acid in water as mobile phase A and 0.1% 
formic acid in methanol as mobile phase B. Peptides were injected and a Michrom 
(Auburn, CA) CapTrap trapping column was used for rapid sample injection. The 
gradient started from 2% B, then increased to 15% B over 5 min, then increased to 80% 
B over 70 min, and finally increased to 95% B over 15 min. The eluted peptides were 
introduced into the LTQ XL with a nanospray source operating at a spray voltage of 2.1 
kV, a capillary voltage of 21 V, and a capillary temperature of 200°C. A full scan in the 
m/z range 300-2000 was performed to obtain precursor ions, followed by four data-
dependent CID MS/MS scans for the four most abundant precursor ions in the full scan. 
Dynamic exclusion was used, that is, if the same precursor ion was picked for 
fragmentation twice within a 30 s window, it was excluded from further analysis for 180 
s.  
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Database searching and data processing 
Peptide sequences and modifications were identified using the BioWorks version 3.3.1, 
SP1 implementation of Sequest (Thermo). No scan grouping was performed in 
preparing peak lists for database searching. The protein sequence database used 
consisted of the NCBI RefSeq version of the complete mouse proteome and reversed 
versions of all sequences. Reversed sequences permit false discovery rate estimation. 
Sequences were downloaded on June 27, 2011, and the final database contained 
70499 entries. Only fully-tryptic and chymotryptic peptides were considered and up to 
three missed cleavage sites were allowed. Fixed mass shifts were applied for alkylated 
cysteines (+57 Da) and oxidized methionines (+16 Da). Sequest output was refined 
using the Trans-Proteomic Pipeline (version 4.4; Institute for Systems Biology, Seattle, 
WA) software package. Specifically, PeptideProphet was used, in semi-supervised 
mode, to improve identification confidence. A PeptideProphet score threshold of 0.9 
was applied. 
II. 2. 2. 9. LC-MS/MS of cardiolipins 
Isolated mitochondria (1 mg) in 50 µL of 100 mM potassium phosphate buffer were 
mixed with 1,2-dipalmitoyl-sn-glycero-3-phospho-N-methylethanolamine (internal 
standard) and extracted with 1 mL of chloroform:methanol, 2:1 containing 2 mM 
butylated hydroxytoluene as an antioxidant. The lipids were given for mass 
spectrometric analysis to the VCU Lipidomics Core, Department of Biochemistry and 
Molecular Biology, Virginia Commonwealth University. 
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For LC-MS/MS analyses, a Shimadzu LC-30 AD binary pump system coupled to a SIL-
30AC autoinjector and DGU20A3 degasser coupled to an ABI 4000 quadrupole/linear 
ion trap (QTrap) (Applied Biosystems, Foster City, CA) operating in a triple quadrupole 
mode was used.  Q1 and Q3 were set to pass molecularly distinctive precursor and 
product ions (or a scan across multiple m/z in Q1 or Q3), using N2 to collisionally induce 
dissociations in Q2; the ion source temperature was 50°C. The lipids were separated by 
reverse phase LC using a Supelco 2.1 (i.d.) x 150 mm Ascentis C18 column (Sigma, St. 
Louis, MO) and a binary solvent system at a flow rate of 0.3 mL/min with a column 
temperature of 60°C. Prior to injection of the sample, the column was equilibrated for 
0.5 min with a solvent mixture of 30% mobile phase A (CH3OH/H2O, 50/50, v/v, with 2.5 
mL triethylamine and 2.5 mL glacial acetic acid) and 70% mobile phase B (IPA/ H2O), 
90/10, v/v, with 2.5 mL triethylamine and 2.5 mL glacial acetic acid). After sample 
injection (typically 40 µL), the A/B ratio was maintained at 30/70 for 2.0 min, followed by 
a linear gradient to 100% B over 7.0 min, which was held at 100% B1 for 4.3 min, 
followed by a 0.6 min gradient return to 30/70 A/B.  The column was re-equilibrated with 
30:70 A/B for 1.0 min before the next run.  Each cardiolipin was quantified during each 
run by MRM analysis, and in addition, the structure was confirmed via a MS2 scan 
within the linear ion trap during the elution of each peak.    
II. 2. 3. Statistical analysis 
Parameters were expressed as meanstandard error of the mean (SEM). The data 
consisting of two groups were analyzed by two-tailed Student’s t-test. Differences among 
multiple groups were compared by one-way analysis of variance with post hoc 
comparisons performed using the Student-Newman-Keuls test. All analysis was 
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executed using SigmaPlot ver.11 software (Systat Software Inc., Chicago, IL). A p<0.05 
was considered statistically significant.  
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II. 3. RESULTS 
During ischemia, the ETC is a major target of ROS produced by specific sites of ETC 
itself [5, 222]. As described in the background, previous work in the lab has shown that 
the locus of ischemic damage is between complex III and IV [254]. One of the key 
components of this site is the cytochrome c-cardiolipin complex which can potentially 
convert to a peroxidase during pathological conditions. Cytochrome c is a small heme 
protein located in the inner membrane of mitochondria that transfers electrons between 
electron transport chain (ETC) complexes III and IV [30, 43].  Excessive generation of 
reactive oxygen species (ROS) can oxidize a key methionine residue (Met81) of mouse 
cytochrome c, disrupting the Fe-Met81 bond [264]. Oxidized cytochrome c attains 
peroxidase activity as the heme catalytic center can now access H2O2, thereby 
catalyzing the oxidation of the unsaturated linoleic (C18:2) acyl chains in cardiolipin to 
form peroxy-groups [264, 276]. Hence, we propose that the oxidative stress condition of 
ischemia-reperfusion results in the formation of oxidized cytochrome c. Secondly; we 
will test the hypothesis that intra-mitochondrial ROS generation coupled with the 
electron flow into the cytochrome c segment of the ETC is required to oxidize 
cytochrome c.  
To test this hypothesis, we used a Langendorff mouse model of ischemia and 
reperfusion established in the laboratory [306]. In this model of ischemia-reperfusion, 
the isolated, buffer perfused C57BL6 mouse hearts underwent either 45 min of buffer 
perfusion or 25 min of ischemia and 30 min of reperfusion followed by isolation of 
mitochondria. Cytochrome c was immunocaptured from the isolated mitochondria and 
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the formation of methionine sulfoxide [Met(O)], a marker for cytochrome c peroxidase 
formation, was assessed via semiquantitative immunoblotting. To test the second 
hypothesis, mitochondria were incubated with specific substrates and inhibitors to 
isolate particular segments of the ETC. Following incubations, cytochrome c was 
immunocaptured and methionine sulfoxide [Met(O)] formation, was confirmed via 
immunoblotting and mass spectrometry. 
II. 3. 1. Immunoprecipitation of cytochrome c from isolated mitochondria. 
To establish the formation of cytochrome c peroxidase activity in oxidative stress 
conditions like ischemia-reperfusion, we have utilized immunoprecipitation as a technique 
to specifically pull down cytochrome c from a complex mixture of proteins in isolated 
mouse mitochondria. To confirm the specificity of the immunoprecipitation, freeze-thawed, 
buffer-solubilized whole isolated mitochondria were probed with the cytochrome c antibody 
immobilized on the Dynabeads® while negative control experiments were performed with 
mouse IgG antibody and no antibody. Immunocaptured cytochrome c from all the samples 
(cytochrome c antibody, IgG, no antibody) was subjected to SDS-PAGE followed by 
immunoblotting with anti-cytochrome c antibody.  
The specificity of immunocapture antibody to cytochrome c in the isolated mitochondria 
was confirmed by comparing its immunodetection signal to the negative controls 
(mouse IgG, and no IP antibody). As shown in Figure 2.5, cytochrome c bands were 
absent in the negative controls whereas signal for cytochrome c was observed with 
cytochrome c antibody used during immunoprecipitation. Also, the cytochrome c signal 
was much enriched in the eluate containing immunocaptured cytochrome c when 
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compared to supernatants collected “before IP” and “after IP”. This result demonstrates 
that the immunocapture technique was successful to separate cytochrome c and the 
cytochrome c antibody used for immunoprecipitation has high specificity to pull down 
cytochrome c from complex mixtures of proteins (e.g. isolated mitochondria). 
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Figure 2.5. Immunoprecipitation of cytochrome c from mitochondria. Western blot 
showing detection of cytochrome c. Cytochrome c content in samples before-IP, after-
IP, mouse IgG and no IP-cytochrome c antibody. Densitometry was measured using 
ImageJ (NIH, Bethesda).  Results were mean±SE. All results were compared using 
one-way ANOVA test. *p<0.05 vs. control-no Ab. n= 4 in all groups. One representative 
blot out of four independent experiments was shown. 
 74 
 
II. 3. 2. Quantification of immunoprecipitated cytochrome c using Dynabeads®. 
Spectrophotometric analysis of cytochrome c content in the mitochondria revealed that 
there is approximately 0.4 nmoles of cytochrome c/mg of isolated mitochondria [107, 
203] which is equivalent to 4.8 µg of cytochrome c/mg of isolated mitochondria. In order 
to determine the amount of immunocaptured cytochrome c from 0.5 mg of isolated 
mitochondria, we have run a SDS-PAGE with the 5 µl of immunocaptured cytochrome c 
(from total of 50 µl cytochrome c) along with known concentrations of commercial 
equine cytochrome c (25ng, 50ng, 100ng, 500ng, 750ng, 1000ng, 2500ng). 
From the semiquantitative calibration (Figure 2.6), the concentration of 
immunocaptured cytochrome c was projected to be approximately 40 ng from 5 µl of 
immunocaptured cytochrome c. Hence, from 50 µl of immunocaptured cytochrome c, a 
total of 400 ng/0.4 µg of cytochrome c was separated from 0.5 mg of isolated 
mitochondria. Thus, the amount of successfully immunocaptured cytochrome c from 0.5 
mg mitochondria was equivalent to 33.33 picomoles. However, the efficiency of the 
immunocapture protocol depends upon the amount of isolated mitochondria, 
cytochrome c antibody and the Dynabeads® utilized for the experiment. 
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Figure 2.6. Semi-quantification of immunoprecipitated cytochrome c using 
Dynabeads®. Western blot showing detection of cytochrome c. Immunocaptured 
cytochrome c content in samples was determined by establishing a semiquantitative 
range with known concentrations of commercial cytochrome c. Densitometry was 
measured using ImageJ (NIH, Bethesda).   
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II. 3. 3. Mass spectrometric analysis of cytochrome c containing the oxidized 
methionine residue. 
Murine cytochrome c has two methionines, one at 66 and the other at position 81. In order 
to confirm the specific oxidation of Met81 which indicates formation of cytochrome c 
peroxidase in a physiological model of isolated mouse mitochondria, we have used the 
mass spectrometric approach to detect methionine sulfoxide modification.  
As an initial control isolated mitochondria from mouse hearts were exposed to the oxidant, 
hypochlorous acid (10 nM HOCl for 15 min). Cytochrome c was immunocaptured and 
methionine sulfoxide [Met(O)] modification  was determined. Isolated mitochondria from 
mouse were exposed to HOCl after which cytochrome c was immunocaptured and 
analyzed for oxidation of the Met-81 residue (axial ligand to the heme group) using mass 
spectrometry and western blotting.  
As shown in Figure 2.8A, western blotting of immunocaptured cytochrome c from 
mitochondria exposed to HOCl show greater methionine sulfoxide formation compared 
to control mitochondria. Recovery of peptides containing the key Met-residue has been 
achieved with cytochrome c from the mouse species. Peptide fragment ions were 
indicated by a, b, or c if the charge was retained on the N-terminus and by x, y or z if the 
charge was maintained on the C-terminus. As shown in Figure 2.7, tryptic digest of 
murine cytochrome c using collision-induced dissociation as the fragmentation method 
yielded a short peptide MIFAGIK containing Met-81 (AA 81-87; MW 778.44) at the N-
terminal end. The combined sequence coverage with trypsin proteolysis is around 58% 
for the LTQ analysis. Previous studies have shown that b1 fragments cannot be 
 77 
 
detected using collision-induced dissociation [307]. Hence MIFAGIK containing a +16 
mass shift associated with methionine oxidation was not detected because of the lack of 
carbonyl group to initiate the nucleophilic attack on the carbonyl carbon located 
between the first two aminoacids, as a result of which the cyclic intermediate cannot be 
formed and thus cannot be identified [307].  
In order, to generate a fragment ion encompassing Met-81, trypsin was replaced by 
chymotrypsin and the peptide IPGTKMIF (AA 76-83; MW 906.51) was generated. With 
the help of Dr. David Simpson from Dr. Scott Gronert’s lab, we have confidently 
identified the peptide IPGTKMIF (Figure 2.8B), oxidized at methionine, using linear ion 
trap mass spectrometer, with good coverage of fragment ions around Met-81. The 
combined sequence coverage with chymotrypsin proteolysis is around 32% for the LTQ 
analysis. As shown in the Figure 2.8B, the b-ions bracket the modification site for 
unambiguous localization. Identification was further supported by a characteristic peak 
for the neutral loss of methane sulfenic acid, which is common in peptides containing 
oxidized methionine residues. The numerous water losses were consistent with the 
presence of threonine and the most intense y-ion was consistent with the proline effect. 
This work demonstrates the feasibility of cytochrome c analysis to identify site specific 
oxidation of Met81 using mass spectrometry. 
 78 
 
 
Figure 2.7. Trypsin proteolysis results in “MIFAGIKK” with methionine at the 
terminal residue. MS/MS spectrum of peptide containing residues 150-780 in the +1 or 
+2 charge state. Blue peaks are y ions and red peaks are b ions. Black peaks were not 
identified as b or as y ions. 
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Figure 2.8. Detection of IPGTKMIF containing oxidized methionine from the MITO 
treated with HOCl. (A) Western blot showing detection of Met(O) isolated mitochondria 
treated with or without HOCl (B) Annotated tandem mass spectrum for chymotryptic 
peptide IPGTKMIF, oxidized at methionine (measured precursor ion m/z = 922.4; 
precursor ion determined to be singly charged).  
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II. 3. 4. Cardiac function was decreased in mouse hearts following ischemia-
reperfusion 
Next, we examined if ischemia-reperfusion oxidizes cytochrome c immunocaptured from 
isolated from mouse hearts. To test this, the isolated, buffer perfused C57BL6 mouse 
hearts either underwent 45 min of buffer perfusion (TC perfusion) or 25 min of ischemia 
and 30 min of reperfusion (ISC-REP) following which the cardiac function, protein yield 
and the mitochondrial function was measured. 
During the entire perfusion on the Langendorff system, the cardiac function was 
monitored in mouse hearts which underwent TC perfusion and ISC-REP. The left 
ventricular developed pressure (LVDP) was recorded in both the groups. In the two 
groups, LVDP was similar in each group at the end of equilibration perfusion, before 
ISC-REP [TC perfusion: 84±4 mm Hg; ISC-REP: 86±12; p<0.05]. In ISC-REP hearts, 
LVDP was markedly decreased during reperfusion compared with the pre-ischemic 
value [TC perfusion: 74±7 mm Hg; ISC-REP: 26±7; p<0.05]. Thus, as shown in Figure 
2.9, the % LVDP recovery during reperfusion was decreased to approximately 31±6% in 
ischemia-reperfusion group. From the data it was clear that cardiac function was 
substantially decreased during ischemia-reperfusion. 
 81 
 
 
 
 
Figure 2.9. Cardiac function was decreased in mouse hearts following ischemia-
reperfusion. Left ventricular developed pressure (LVDP) was recorded (as mm Hg) in 
TC perfusion and ischemia (ISC)-reperfusion (REP) groups. Ischemia decreases the 
recovery of LVDP during reperfusion compared with untreated hearts (A). Results were 
presented as mean±SE. A difference of p<0.05 was considered significant. Results 
were compared using t-test. *p<0.05 vs.TC perfusion. n=5 in all groups.  
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II. 3. 5. Recovery of mitochondria from heart tissue was similar following 
ischemia-reperfusion.  
Following mitochondrial isolation, protein concentration was measured by the the Lowry 
method using BSA as a standard and sodium deoxycholate as a detergent to solubilize 
the mitochondria. The protein yield of isolated mitochondria following 25 min of 
untreated ischemia and 30 min of reperfusion was similar to the protein yield in the time 
control perfusion group (Figure 2.10). The protein yield averaged 21.0±2.0 mg/g wet 
weight in TC perfusion vs. 24.7±0.7 mg/g in ISC-REP hearts (p=ns). Thus, any 
differences between TC perfusion and ISC-REP (e.g. OXPHOS) were not due to a 
preferential selection of “good” or “bad” mitochondria during the isolation process. This 
was confirmed by the protein content between the two groups which provided a strong 
evidence of a similar recovery of mitochondria following isolation from heart tissue.  
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Figure 2.10. Ischemia-reperfusion did not alter the mitochondrial protein yield. 
The protein content of the one population mitochondria isolated from C57BL6 mice was 
unaltered in TC perfusion, ISC-REP groups (A). Results were presented as mean±SE. 
n= 5 in all groups. 
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II. 3. 6. Glutamate+malate and TMPD+ascorbate dependent oxidative 
phosphorylation was decreased following ischemia-reperfusion.  
The rates of oxidative phosphorylation were studied in mitochondria isolated from time 
control perfusion and ischemia-reperfusion groups using substrates that feed electrons 
to different entry points in the ETC. Glutamate+malate was used as the complex I 
substrate and TMPD/ascorbate (with rotenone) as electron donor to complex IV via 
cytochrome c. As shown in Figure 2.11, mitochondrial respiratory function was 
substantially decreased following ischemia and reperfusion. The maximal rates of 
oxidative phosphorylation were obtained by addition of saturating 2 mM ADP when 
glutamate+malate or TMPD/ascorbate were used as substrates. The maximal rate of 
respiration using a complex I substrate, glutamate+malate, (complex I→complex 
III→complex IV) was decreased by approximately 50% (TC: 438±36 nAO/min/mg 
protein; ISC-REP: 221±17, p<0.05). TMPD/ascorbate-dependent (complex IV) 
respiration was lowered by approximately 25% (TC: 1560±62 nAO/min/mg protein; ISC-
REP: 1184±88, p<0.05) following ischemia-reperfusion. Respiratory control ratios 
(RCRs) were reduced after ISC-REP with glutamate+malate as a substrate (Table 2.1). 
As a next step, the rates of uncoupled respiration by addition of 2, 4-ditrophenol (DNP) 
were measured. DNP is a protonophore that carries protons across the mitochondrial 
membrane. In its presence, the electron transport chain works independently from the 
phosphorylation apparatus. The use of DNP tests the relative contributions of the 
electron transport chain and ATP synthase/ANT/Pi transporter to the decreased rate of 
oxidative phosphorylation. The DNP-uncoupled respiration with the glutamate+malate 
was reduced to a similar extent when compared to the respiration rates without the 
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uncoupling agent (2 mM ADP rates) (Table 2.1). This observation suggests that the 
decrease in respiration was not caused by defects in ATP synthase, adenine nucleotide 
translocase (ANT) or phosphate (Pi) transporter, but was indeed localized to the 
electron transport chain. 
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Figure 2.11. Glutamate+malate and TMPD+ascorbate dependent oxidative 
phosphorylation was decreased following ischemia-reperfusion. Oxygen 
consumption by intact mitochondria was measured by Clark-type electrode at 30 oC as 
described in Materials and Methods. Incubations contained: 20 mM glutamate with 5 
mM malate (A) or 1 mM TMPD/20 mM L-ascorbate with 7.5 µM rotenone (B). Maximum 
rates of state 3 respiration with 2 mM ADP were shown (A). For TMPD/Asc-dependent 
respiration azide-sensitive data were depicted (B). Results were expressed as 
nanoatoms of atomic oxygen/min/mg of mitochondrial protein and were presented as 
mean±SE. * p<0.05 vs. TC perfusion. All results were compared using t-test. n=5 in all 
groups. 
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Table 2.1. Rates of oxidative phosphorylation in heart mitochondria isolated from 
TC perfusion and ISC-REP groups.  
 
Table 2.1. Ischemia-reperfusion affects mitochondrial oxidative phosphorylation. 
Mitochondria were isolated and rates of respiration were recorded. Based on state 3 
and state 4 rates, respiratory control ratios (RCRs) were calculated. During recording of 
2 mM ADP-dependent maximal state 3 rate, uncoupler 2,4-dinitrophenol (DNP) was 
added to establish relative contribution of phosphorylation apparatus to the observed 
defects in integral respiration. Results were presented as mean±SE. Values of state 3, 
state 4, 2 mM ADP and DNP rates are expressed in nanoatoms of atomic 
oxygen/min/mg of mitochondrial protein. A difference of p<0.05 was considered 
significant. All results were compared using t-test. *p<0.05 vs. TC perfusion. n=5 in all 
groups. ADP, adenosine di-phosphate; TMPD, N,N,N′,N′-tetramethyl-p 
phenylenediamine; RCR, respiratory control ratio; DNP, 2,4-dinitrophenol.  
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II. 3. 7. Cytochrome c from ISC-REP hearts exhibit increased methionine 
modification 
Mitochondria were isolated from the Langendorff perfused mouse hearts that underwent 
45 min buffer perfusion (TC perfusion) or 25 min of ischemia and 30 min of reperfusion 
(ISC-REP). Isolated mitochondria from TC perfusion and ISC-REP hearts were 
subjected to immunoprecipitation to capture cytochrome c using Dynabeads® Protein G 
immunoprecipitation kit loaded with cytochrome c primary antibody. The 
immunocaptured cytochrome c was blotted for methionine sulfoxide [Met(O)] and 
cytochrome c (control for equal mitochondrial protein loading). Met(O) formation was the 
mechanistic indicator for cytochrome c peroxidase formation. As shown in Figure 2.12, 
the densitometry ratio of Met(O) to cytochrome c in ISC-REP hearts showed 
approximately 80% increase in the methionine sulfoxide formation when compared to 
TC perfusion [Ratio Met(O)/cyt c; normalized to TC perfusion; TC perfusion: 1.0±0.0; 
ISC-REP: 1.8±0.24; p<0.05]. This data supports the formation of cytochrome c 
peroxidase indicated by an increased Met(O) signal during pathological setting of 
ischemia-reperfusion.  
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Figure 2.12. Ischemia-reperfused hearts show increased Met(O) compared to 
buffer perfused hearts. Western blot showing detection of Met(O) and cytochrome c at 
12 kDa in buffer perfused (TC) and ischemia-reperfused (ISC-REP) hearts. MITO from 
buffer perfused (TC) and ischemia-reperfused (ISC-REP) hearts were subjected to IP 
and the eluate containing cytochrome c was subjected to SDS-PAGE and 
immunoblotted for Met(O) and cytochrome c (control for equal mitochondrial protein 
loading). Densitometry was measured using ImageJ (NIH, Bethesda) and expressed as 
ratio of Met(O) signal to cytochrome c signal.  Results were expressed as mean±SE.* 
p<0.05 vs. TC perfusion. All results were compared using one-way ANOVA test. n=5 in 
all groups. Met(O), methionine sulfoxide. 
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II. 3. 8. Mass spectrometric analysis to detect oxidized Met81 in control and 
ischemia-reperfused samples 
Studies to identify and analyze IPGTKMIF peptide in cytochrome c immunocaptured from 
control and ischemia-reperfused were carried out using mass spectrometry. However, 
basal oxidation of methionine in IPGTKMIF peptide was observed even in the control 
samples. A quantification approach with Tandem Mass Tag (TMT) labeling that 
irreversibly reacts with the primary amines (-NH2) groups was used to label the 
peptides of immunocaptured cytochrome c from control and ischemia-reperfused 
samples. Moreover, isobaric labeling with TMT tag was not compatible with 
immunocapture technique as the cytochrome c separated through this procedure is in 
the glycine solution which is a primary amine and thus will provide a lot of background 
signal. The approach to separate glycine from cytochrome using 5KDa filters was 
unsuccessful as the peptides were no longer detectable via mass spectrometry 
probably due to considerable loss of protein. In addition, thioglycolate and N2 bubbling 
of the solutions used for immunocapture were also tested to reduce artifactual oxidation 
which might have occurred through sample handling. However, all these approaches 
could not prevent basal oxidation of methionine in control samples. One alternative, to 
quantify oxidation of methionine between control and ischemia-reperfused samples is to 
do an on-bead digestion of cytochrome c with chymotrypsin which will eliminate the 
problem of glycine for TMT-labeling. 
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II. 3. 9. Distal blockade of electron transport chain increases formation of 
cytochrome c peroxidase  
Given the importance of ETC as a source of ischemic damage, blocking it with inhibitors 
that manipulate electron flow through the respiratory complexes has shown that the 
segment located between complex III and complex IV is responsible for the ischemic 
damage [254]. One of key components of this site is the cytochrome c and cardiolipin 
complex located between complex III and complex IV which most likely plays an 
important role in ischemia mediated cardiac injury [254]. Hence, we hypothesize that 
during ischemia-reperfusion, an increase in intra-mitochondrial ROS generation coupled 
with the electron flow into the cytochrome c segment of the ETC is required to oxidize 
cytochrome c at the methionine residue converting to a peroxidase. To test this 
hypothesis, isolated mitochondria from C57BL6 mice were incubated with specific 
substrates and inhibitors to isolate particular segments of the ETC in such a way that the 
cytochrome c segment has access either to the ROS or electron flux or both.   
For the experiment, mitochondria were incubated with succinate and blockers including 
rotenone, theonyl trifluoroacetic acid (TTFA), antimycin A and azide. Succinate feeds 
electrons into the ETC through complex II. Rotenone binds to the CoQ-binding site of 
complex I and prevents reverse electron transfer from complex II to complex I. TTFA 
blocks complex II at the distal portion of the compex and increases ROS from complex 
II. Antimycin A, inhibits the Qi center of complex III thereby causing a net increase in 
ROS production from the Qo site. The ROS generated from the Qo site in complex III is 
released into the intermembrane space (IMS). Azide inhibits electron transport in 
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complex IV by binding tightly with the iron coordinated in Cyt a3 thereby increasing ROS 
release from upstream complex I and complex III. 
The isolated mitochondria from C57BL6 mice hearts were incubated with the following 
combinations of substrate and inhibitors in order to test the importance of ROS and 
electron flux into cytochrome c in generating modified cytochrome c. As shown in Figure 
2.13, (A) succinate + rotenone: Rotenone inhibits reverse electron transfer to complex I. 
This group was the control incubation (B) succinate + rotenone + TTFA: TTFA blocks at 
complex II. Here, in this group there would be increase in ROS from complex II and 
electron flux is blocked prior to complex III (C) succinate + rotenone + antimycin A: 
Antimycin A inhibits the Qi center of complex III. Therefore, in this group there would be 
an increase in ROS from complex III but no electron flux into cytochrome c (D) succinate + 
rotenone + azide: Azide inhibits electron transport in complex IV. From this group there 
would be an increase in ROS from complex III along with electron flux through cytochrome 
c. Following incubations, cytochrome c was immunocaptured using Dynabeads® Protein 
G immunoprecipitation kit. Cytochrome c and methionine sulfoxide [Met(O)], a marker for 
cytochrome c peroxidase formation, were immunoblotted.  
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Figure 2.13. Schematic of mitochondrial incubations with substrates to test the 
contribution of ROS and electron flow to oxidize cytochrome c: Isolated 
mitochondria were incubated for 50 min with succinate+rotenone, 
succinate+rotenone+TTFA, succinate+rotenone+A.A, succinate+rotenone+azide. TTFA, 
Thenoyltrifluoroacetone; A.A, Antimycin A; cyt c, cytochrome c; Met(O), methionine 
sulfoxide. 
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Incubation of isolated mitochondria with the ETC blockers antimycin A and azide, blocks 
electron flow at complex III and complex IV respectively, causing increase in ROS 
production from complex I and complex III. However, distal blockade of complex IV with 
azide showed approximately 200% increase in the signal as a result of Met(O) formation 
compared to TTFA (blocks complex II) or A.A (blocks complex III) [Ratio Met(O)/cyt c; 
normalized to succ+rot; succ+rot+TTFA: 1.04±0.38; succ+rot+A.A: 0.87±0.16; 
succ+rot+azide: 3.46±1.10 p<0.05 vs. succ+rot+TTFA or succ+rot+A.A]. Azide not only 
increases ROS from complex III but also allows electron flow to cytochrome c as shown 
in Figure 2.14. This data suggests that both ROS and the electron flux into cytochrome 
c were needed to increase the formation of Met(O), which is the marker for cytochrome 
c peroxidase formation. 
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Figure 2.14. ROS and electron flow into cytochrome c was essential for its 
modification. Western blot showing detection of methionine sulfoxide [Met(O)] and 
cytochrome c at 12 kDa. Isolated mitochondria were incubated for 50 min with 
succinate+rotenone, succinate+rotenone+TTFA, succinate+rotenone+A.A, 
succinate+rotenone+azide and then subjected to IP. The eluate containing 
immunoprecipitated cytochrome c was subjected to SDS-PAGE and immunoblotted for 
Met(O) and cytochrome c (control for equal mitochondrial protein loading). Densitometry 
was measured using ImageJ (NIH, Bethesda) and expressed as ratio of Met(O) signal 
to cytochrome c signal (lower panel).  Results were expressed as mean±SE, n=5-7 for 
each group. All results were compared using one-way ANOVA test. *p<0.05 vs. 
Succ+Rot. One representative blot out of seven independent experiments is shown. 
Succ, succinate; Rot, rotenone; TTFA, Thenoyltrifluoroacetone; A.A, Antimycin A; cyt c, 
cytochrome c; Met(O), methionine sulfoxide. 
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II. 3. 10. Cardiolipin content was decreased following distal blockade of electron 
transport chain. 
Cardiolipin, a key mitochondrial inner membrane phospholipid, plays a crucial role in 
ischemia mediated cardiac injury [5, 216]. Experiments performed with different animal 
models using global ischemia showed an overall decrease in the cardiolipin content [203, 
216, 302, 308]. Ischemia increases ROS production resulting in cytochrome c 
peroxidase formation which causes the oxidation and depletion of cardiolipin. Depletion 
of cardiolipin delocalizes cytochrome c from the inner mitochondrial membrane into the 
cytosol thereby activating cell death [264, 276]. 
As shown in Figure 2.13, blockade at cytochrome oxidase of the ETC allows cytochrome 
c to have access to both ROS and electron flux which results in the oxidation of 
methionine residue of cytochrome c turning it to a peroxidase. Further, we asked if the 
formation of cytochrome c peroxidase as a result of distal blockade of ETC in isolated 
mitochondria consequently altered the content or composition of cardiolipin. Isolated 
mitochondria were incubated in KME buffer containing succinate and rotenone with or 
without azide for 90 min. Phospholipids from the mitochondrial incubations were extracted 
and quantified using LC/MS/MS analysis. 
As shown in Figure 2.15, the content of cardiolipin was significantly decreased, by 
approximately 20%, in incubations containing succinate+rotenone+azide when compared 
to incubations containing succinate+rotenone [succ+rot: 48±1 nmol/mg protein; 
succ+rot+azide: 39±2; p<0.05 vs. succ+rot]. This data suggests that the formation of 
cytochrome c peroxidase ultimately results in loss of cardiolipin in isolated mitochondria. 
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Figure 2.15. Content of cardiolipin was decreased following incubation of 
mitochondria with succinate+roteonone+azide. Quantification of cardiolipin content 
by phosphate measurement per mg mitochondrial protein (nmol/mg protein) in isolated 
mitochondria incubated with Succ+Rot and Succ+Rot+Azide for 90min. Results were 
expressed as mean±SE, n=3 for each group. All results were compared using t-test. 
*p<0.05 vs. Succ+Rot. Succ, succinate; Rot, rotenone. 
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II. 4. SUMMARY 
 Ischemia-reperfusion increases the formation of methionine sulfoxide, a mechanistic 
indicator for cytochrome c peroxidase formation. 
 Increase in ROS generation along with electron flow through cytochrome c is 
essential to convert cytochrome c to a peroxidase. 
 As a result of increase in cytochrome c peroxidase activity with distal blockade of 
ETC, cardiolipin is selectively depleted from the mitochondrial membrane. 
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II. 5. DISCUSSION 
Cell culture and in-vitro studies identified a novel function of cytochrome c during non-
physiological stress conditions [264, 276, 301]. During oxidative stress, cytochrome c 
converts to a peroxidase and specifically oxidizes the polyunsaturated molecular 
species of cardiolipin. As a result cardiolipin oxidation and depletion, pro-apoptotic 
proteins, including cytochrome c and Smac/Dialbo are released into the cytosol both of 
which cause cell death via the caspase dependent pathways [276]. Inhibition of 
cytochrome c peroxidase by nitric oxide prevents cardiolipin oxidation and cytochrome c 
loss [299], suggesting that the peroxidase is a potential site that generates 
mitochondrial damage. However, the molecular switch that disrupts the electron 
shuttling function of cytochrome c and converts it to a peroxidase was not identified. In 
addition, the physiological relevance of the cytochrome c peroxidase is unknown. Thus, 
the focus of this study was to identify the role of cytochrome c peroxidase during a 
pathological condition such as ischemia-reperfusion. This work demonstrates that during 
ischemia-reperfusion, an increase in intra-mitochondrial ROS generation coupled with 
the electron flow through the cytochrome c segment of the ETC oxidizes cytochrome c 
at the methionine residue which confers peroxidase activity, resulting in depletion of 
cardiolipin. 
Cardiolipin, a phospholipid unique to mitochondria, is located in the inner membrane 
and is required for the optimal activity of ETC complexes [264]. The close proximity to 
the ETC makes cardiolipin, containing highly enriched oxidatively sensitive linoleic acid 
(C18:2) groups, a prime target for ROS generated during ischemia [309]. During 
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ischemia, ROS from complex III along with electron flow through cytochrome c depletes 
cardiolipin leading to a decrease in complex IV activity [203, 216, 310]. In addition, 
cardiolipin depletion results in the loss of cytochrome c from the inner membrane which 
in turn enhances ROS production from the ETC after ischemic damage. Under normal 
physiologic conditions, cytochrome c shuttles electrons from complex III to complex IV. 
However, under pathological oxidative stress conditions, methionine is oxidized 
disrupting the binding of Met81 to the heme of cytochrome c resulting in the formation of 
cytochrome c peroxidase [264, 271].  
The changes in the cytochrome c heme environment were detected in in-vitro studies by 
CD spectra shifts in the 375-425 nm region (heme moiety), changes in the UV region 
(250-280 nm) as well as the quenching of the Trp59 fluorescence due to the closely 
located heme group [264, 271]. In addition, the disruption of the Fe-Met81 bond can be 
detected by measuring its characteristic absorbance at 695 nm [264, 271]. Yet, the 
cause for the changes in absorbance or fluorescence cannot be confidently attributed to 
cytochrome c oxidation. For example, the loss of the 695-nm absorption in cytochrome 
c may also be due to the nitration of tyrosine residues, which is not a consequence of 
sulfhydryl oxidation in Met81 [273]. However, the changes in absorbance/fluorescence 
can only indicate oxidation of the sixth heme ligand at Met81 but there is no direct 
evidence supporting this speculation. Moreover, the sphectrophotometric approaches 
were used mainly for in-vitro studies wherein cytochrome c was the only protein present 
and so any changes in absorbance/fluorescence can only be attributed to the alterations 
in cytochrome c. However, these approaches cannot be used at a tissue level for 
characterizing cytochrome c peroxidase due to the complex mixture of proteins involved 
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which would make it impractical to attribute the changes in absorbance/fluorescence 
specifically to cytochrome c.  
Murine cytochrome c has two methionines, one at position 66 and the other at position 81, 
whereas in the equine cytochrome c, methionines are located at positions 65 and 80. 
Oxidation of Met81 (in mouse) or Met80 (in horse) results in formation of cytochrome c 
peroxidase. In-vitro radiolysis of equine cytochrome c showed that Met80 is the prime 
target for oxidation [311]. In-vitro studies using HOCl to oxidize cytochrome c were 
shown to disrupt the Fe-Met80 bond of equine cytochrome c mainly by oxidation of 
Met80. Oxidation of Met80 facilitates the reactivity of heme center to H2O2 thereby 
inducing the peroxidase activity [272]. The mass spectrometry approach provided direct 
evidence that methionine residues are oxidized to methionine sulfoxide and that Met80 
oxidation was more favored than Met66 (72% Met80 vs. 23% Met65) [272]. This suggests 
that methionine 80 (the heme ligand) in cytochrome c is the preferred site of oxidation. 
In addition, the HOCl oxidized cytochrome c exhibited an increase in peroxidase activity 
as seen by an increase in ability to oxidize tyrosine to tyrosyl radical (measured by EPR 
spectroscopy) [272] . 
Though, the immunoblotting for methionine sulfoxide from HOCl- treated mitochondria 
supports the formation of cytochrome c peroxidase (Figure 2.8A), identification of site 
specific oxidation of Met81 from mouse hearts would unequivocally confirm the cytochrome 
c peroxidase formation. Hence, in order to confirm the specific oxidation of Met81, we have 
utilized the mass spectrometric approach. In our study, we have shown at a tissue level 
that the cytochrome c immunocaptured from HOCl treated mitochondria showed site 
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specific oxidation of Met81 which is inline with the earlier observation with in-vitro HOCl 
oxidation of commercial cytochrome c (Figure 2.8A).  
Actinomycin D or staurosporine induced apoptosis in cell culture models showed that 
cytochrome c bound to cardiolipin acts as a peroxidase that resulted in cardiolipin 
peroxidation and apoptosis [276]. Also, in-vitro direct measurements of peroxidase 
activity in the liposomes was measured using chemiluminescence, fluorescence and 
electron paramagnetic resonance based assays which determine cytochrome c 
peroxidase activity in the presence of H2O2 [276]. However, these studies functionally 
measure cytochrome peroxidase activity but could not characterize the cytochrome c 
peroxidase formed as a result of oxidative stress. Also, the role of Met81 oxidation in 
cytochrome c peroxidase formation was unclear in these studies. Moreover, the 
cytochrome c peroxidase activity was well characterized in in-vitro liposomal systems 
[271, 276, 299, 312] or non-physiological cell stress models [276] and its physiological 
relevance is still unknown. Thus, the main objective of the present study was to identify 
the cytochrome c peroxidase formation at a tissue level during pathological condition such 
as ischemia-reperfusion. 
Myocardial ischemia damages the mitochondrial electron transport chain resulting in 
decreased rates of mitochondrial respiration [5, 102, 203, 204, 222]. In our study, 25-
min ischemia followed by 30-min reperfusion led to a significant decrease in 
glutamate+malate- and TMPD-dependent respiration (Figure 2.11) which was 
consistent with previous studies [102, 201, 206]. During ischemia, mitochondria are the 
major contributors of ROS production [5, 222]. Complex I and complex III are the major 
sites for ROS generation during ischemia. Antimycin A, given immediately before 
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ischemia, preserved complex IV respiration, cytochrome c content whereas treatment 
with azide did not protect the ischemia-mediated decrease in respiration and loss of 
cytochrome c [254]. This allows us to speculate that the locus of ischemic damage is 
located between complex III and complex IV and that increased ROS and electron flow 
to this segment both contribute to the ischemic damage. Key component of this locus is 
the cytochrome c which can potentially convert into the peroxidase during ischemia-
reperfusion.  
To identify the formation of cytochrome c peroxidase during ischemia-reperfusion, the 
immunocapture approach was used to specifically separate cytochrome c (Figure 2.5) 
from isolated mitochondria and asess the methionine sulfoxide formation. Oxidation of 
Met81, loosens the iron coordination of cytochrome c providing access of the heme 
catalytic center to small molecules like H2O2. As a result, cytochrome c converts to a 
peroxidase which will reduce H2O2 to H2O and simultaneously generate peroxidized 
cardiolipin. Hence, Met(O) formation is the mechanistic indicator for cytochrome c 
peroxidase formation. In this study, we have demonstrated that ischemia-reperfused 
hearts show an approximate 80% increase in the methionine sulfoxide formation 
(Figure 2.12) which supports the role of cytochrome c peroxidase during physiological 
oxidative stress conditions. Further studies will be required to study the contribution of 
cytochrome c peroxidase during ischemia or during early reperfusion. 
Blockade of the ETC at complex I decreases ROS generation and prevents cardiolipin 
depletion [210] which suggests that when electron flow into the cytochrome c-cardiolipin 
segment is limited it may inhibit peroxidase activity of cytochrome. In the present study, 
mitochondrial incubation with succinate+rotenone+TTFA did not increase the formation 
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of cytochrome c peroxidase. This observation suggests that the complex II generated 
ROS did not contribute to the peroxidase formation. The mitochondrial incubation with 
succinate+rotenone+antimycin A also did not increase peroxidase formation which 
suggests that the increase in ROS due to complex III blockade was not sufficient to 
convert cytochrome c to a peroxidase. Interestingly, incubation of mitochondria with 
succinate+rotenone+azide significantly increased the methionine sulfoxide signal as a 
result of cytochrome c peroxidase formation. This observation suggests that along with 
the increase in ROS from complex III, electron flow into cytochrome c was essential for 
oxidizing cytochrome c at the methionine residue resulting in formation of cytochrome 
peroxidase. Thus, from this study we have demonstrated that distal blockade of 
cytochrome c-cardiolipin segment with azide showed increase methionine sulfoxide 
formation when compared to proximal blockade of ETC with TTFA or Antimycin A 
(Figure 2.14). This highlights the importance of electron flow through the cytochrome c 
segment as a key factor which influences peroxidase formation along with increased 
ROS during ischemia-reperfusion. 
Experiments performed with different animal models using global ischemia or in-vivo 
ischemia showed an overall decrease in cardiolipin content [203, 216, 302]. The 
increase in ROS production during ischemia is converted to H2O2 which acts as a 
substrate for cytochrome c peroxidase causing the oxidation of cardiolipin to the 
peroxidized form. Cardiolipin can undergo oxidation at the unsaturated cis double bonds 
of the linoleic (C18:2) fatty acyl chains that will give rise to peroxy-groups: 
(C18:2)3/(C18:2-OOH)1, (C18:2)2/(C18:2-OOH)2, (C18:2)1/(C18:2-OOH)3, (C18:2-OOH)4 
[292]. Furthermore, hydrolysis of the peroxidized cardiolipin results in formation of 
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monolysocardiolipin (degradation product) [229]. Alternatively, the peroxy-acyl groups 
can interact directly with proteins leading to covalent cardiolipin-protein complexes. 
Also, inter-molecular dimerization of cardiolipin by peroxyl bond formation undergoes 
decomposition and finally generates a secondary peroxidation product, 4-hydroxy-2-
nonenal (HNE) [313]. In addition, HNE forms Michael adducts by interacting with the 
nucleophilic groups in cysteine, histidine or lysine residues of the proteins. Also, HNE 
can interact with ε-NH2 groups of Lys residues forming Schiff-bases [314]. The 
decomposed cardiolipin or cardiolipin interacting with proteins is no longer extractable 
by organic solvents and thus cannot be detected [308].  
In this study, we have shown that incubation of isolated mitochondria for 50 min with 
succinate+rotenone+azide enhanced peroxidase formation as detected by increase in 
Met(O) signal but did not alter cardiolipin content (data not shown). Further 
mitochondrial incubation with succinate+rotenone+azide for 90 min resulted in depletion 
of cardiolipin (Figure 2.15). This suggests that peroxidase formation occurs earlier than 
peroxidation of cardiolipin. In addition, the data confirms that the increase in ROS 
generation along with the electron flow through cytochrome c enhanced the peroxidase 
activity of cytochrome c leading to the depletion of cardiolipin from the mitochondria 
(Figure 2.15). Moreover, we were not able to detect any monolysocardiolipin, a 
degradation product of cardiolipin. So, it is possible that the oxidized cardiolipin is 
degraded via hydrolysis or modified to form Michael adducts or Schiff’s bases. Future 
studies to support the depletion of cardiolipin via degradation will include blotting for 
HNE in the mitochondrial incubations. 
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Ischemia decreased cardiolipin content in rabbit heart mitochondria whereas the content 
of other phospholipids was preserved [203]. Also, ischemia did not alter the composition 
of cardiolipin that remained in the mitochondrial membrane [203]. This is consistent with 
our study using distal blockade of ETC wherein cardiolipin content was decreased but 
the remaining cardiolipin composition was not altered (Figure 2.15). In our study, the 
cytochrome c peroxidase formation was increased during ischemia-reperfusion (Figure 
2.12) that recapitulates the role of cytochrome c peroxidase in the depletion of 
cardiolipin in rabbit mitochondria [203]. Rotenone or amobarbital treatment immediately 
before in-situ ischemia markedly improved respiration and attenuated the loss of 
cardiolipin and cytochrome c from the mitochondria [230, 255]. Antimycin A, given 
before ischemia, preserved complex IV respiration and cytochrome c content [254]. On 
the other hand, azide treatment before ischemia resulted in decreased respiration and 
cytochrome c content [254]. These observations from ex-vivo ischemia-reperfusion 
studies strongly supports that the blockade of electron flow into cytochrome c protects 
mitochondria and preserves cardioipin content which conceptually correlates to the 
observations from the in-vitro mitochondrial incubations from our study. 
In summary, the present study showed that cytochrome c converts to cytochrome c 
peroxidase during ischemia-reperfusion. The increase in ROS generation and electron 
flow through the cytochrome c segment were required for the cytochrome c peroxidase 
activity that results in depletion of cardiolipin from the mitochondria (Figure 2.16).  
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Figure 2.16. Schematic showing the formation of cytochrome c peroxidase during 
ischemia-reperfusion. Electron flow into cytochrome c and reactive oxygen species 
from electron transport chain oxidize cytochrome c during ischemia-reperfusion 
converting it into a peroxidase. Cytochrome c peroxidase, converts H2O2 to H2O inturn 
peroxidising cardiolipin thereby depleting it from the mitochondrial membrane. Depletion 
of cardiolipin delocalizes cytochrome c into the cytosol activating apoptotic cascades. 
The peroxidized cardiolipin also alters the mitochondrial dynamics thereby triggering cell 
death.
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CHAPTER III: Apoptosis signaling kinase-1 inhibitor decreases 
mitochondrial damage during ischemia-reperfusion 
 
 
 
 
III. 1. Introduction 
Living organisms, during their lifetime, are exposed to ROS which is released as a 
consequence of several physico-chemical stressors. While small amounts of ROS have 
an important function as signal mediators, their overproduction in cells causes 
pathological redox signaling which induces oxidative stress ultimately leading to cell 
death [315-317]. In order to maintain homeostasis, cells have defense mechanisms to 
counteract the excessive production of ROS. One of the major intracellular defense 
mechanisms against the oxidative stress is the thioredoxin (Trx) system [318].  
III. 1. 1. Thioredoxin/ Thioredoxin reductase system 
Thioredoxin system contains thioredoxin, NADP (H) and thioredoxin reductase; together 
they maintain a reduced intracellular redox state by the reduction of protein thiols. 
Cytosolic thioredoxin-1 (Trx1) and mitochondrial Trx2 are the two major isoforms of 
thioredoxin encoded by two distinct genes. Trx, an antioxidant protein, contains an 
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active site with two cysteine residues which under reduced conditions exist as thiols. 
However, during oxidative stress conditions, the thiols are reversibly oxidized to form an 
intramolecular disulfide bond [319, 320]. Studies from thioredoxin genetic mouse 
models suggest that thioredoxin is essential for survival. Thioredoxin-knockout mice 
have shown that Trx is essential for the early development and morphogenesis of the 
mouse embryo [321]. Thioredoxin-overexpressor transgenic mice are more resistant to 
oxidative stress with longer life spans, compared to the wild-type mice [322].  
The thioredoxin-interacting protein TXNIP, also known as VDUP1 (vitaminD3 up-
regulatedprotein-1) or TBP-2 (thioredoxin-binding protein-2), binds to both thioredoxin 
isoforms (Trx1, Trx2) and negatively regulates Trx ability to scavenge ROS (Figure 
3.1) [323-325]. On the other hand, Trx is bound directly to apoptosis signal-regulating 
kinase 1 (ASK1) that inhibits ASK1 kinase activity [319, 326, 327]. Under oxidative 
stress conditions, TXNIP localized primarily in the nucleus, translocates to cytosol and 
mitochondria where it binds to and oxidizes Trx1 and Trx2, thereby reducing Trx1/Trx2 
binding to ASK1 and allowing for ASK1 phosphorylation/activation (Figure 3.1) [324, 
328, 329]. The interaction between Trx and ASK1 depends on the redox state of Trx, 
which is supported by experimental studies wherein ASK1 fails to interact with the 
oxidized form of Trx or with a Trx mutant in which both active site cysteines are 
replaced with serine residues [330].  
ASK1 belongs to the mitogen-activated protein kinase (MAPK) kinase kinase family that 
activates the MAPK kinase 4 (MKK4)/MKK7-JNK and MKK3/6-p38 pathways through a 
ROS-dependent mechanism in response to various stress conditions including 
ischemia-reperfusion injury, oxidative stress, tumor necrosis factor-α (TNF-α), 
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lipopolysaccharide (LPS), endoplasmic reticulum stress and calcium overload [331-
336]. Activation of these pathways induces cellular responses such as apoptosis, 
differentiation, cell survival, and production of inflammatory cytokines [337, 338]. 
Sustained activation of ASK1 induces apoptosis mainly through mitochondria-
dependent caspase activation [330, 339, 340]. TNFα-induced apoptosis in mouse 
embryonic fibroblasts (MEFS) from ASK1 deficient mice demonstrated that ASK1 is 
required for the execution of ROS-induced apoptosis through JNK/p38 pathways [337]. 
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Figure 3.1. Schematic depicting the activation of ASK1 signaling cascade during 
oxidative stress conditions. TXNIP localized primarily in the nucleus, translocates to 
cytosol and mitochondria where it binds to and oxidizes Trx1 and Trx2, thereby reducing 
Trx1/Trx2 binding to ASK1 and allowing for ASK1 phosphorylation/activation. ASK1 
activation leads to cell death via p38, JNK or mitochondrial dependent pathways. 
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ASK1 is constitutively oligomerized through its C-terminal coiled-coil (CCC) domain, 
which is necessary for its basal activity [341, 342]. Under physiological conditions, Trx 
inhibits the homo-oligomeric interactions through the N-terminal coiled-coil (NCC) 
domain of ASK1 [343]. However, during oxidative stress conditions, Trx dissociates 
from ASK1. ASK1 activates itself by homo-oligomerization of ASK1 through its NCC 
domain thereby resulting in autophosphorylation at the threonine 845 residue (Figure 
3.2)  [342]. Post-translational modification of ASK1, including phosphorylation, regulates 
ASK1 activity. Akt directly phosphorylates ASK1 at Ser83 and negatively regulates 
ASK1 [344, 345]. Moreover, calcium/calmodulin-dependent protein kinase type II 
(CaMKII), in response to calcium influx, also phosphorylates ASK1 and activates the 
ASK1-p38 pathway [336]. In addition to phosphorylation, ubiquitination is shown to 
stabilize ASK1 and is important for the net activation of ASK1 and ROS-induced cell 
death [346]. On the other hand, two protein phosphatases, protein phosphatase 5 and 
serine/threonine protein phosphatase (PP2Cε) inactivate ASK1 by directly 
dephosphorylating Thr845 residue [347, 348].  
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Figure 3.2. Schematic model of ROS-induced activation of ASK1 regulated by Trx. 
ASK1 is constitutively oligomerized through its C-terminal coiled-coil (CCC) domain. Trx 
inhibits the homo-oligomeric interactions through the N-terminal coiled-coil (NCC) 
domain of ASK1. During oxidative stress conditions, Trx dissociates from ASK1. ASK1 
activates itself by homo-oligomerization of ASK1 through its NCC domain thereby 
resulting in autophosphorylation at the threonine 845 residue [319]. Trx, thioredoxin; 
ASK1, Apoptosis signaling kinase 1. 
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III. 1. 2. ASK/p38/JNK activation during ischemia reperfusion injury 
It is well understood that increased ROS production during ischemia-reperfusion 
contributes to cardiac injury. One of the mechanisms through which ischemia-
reperfusion contributes to cell death is via the ROS-dependent activation of JNK/p38 
pathways [349, 350] . JNK and p38 are differentially activated during ischemia-
reperfusion. The p38 pathway is rapidly activated during ischemia and remains active 
during reperfusion whereas JNK is activated only during reperfusion [351-353]. Cloning 
and transfection experiments using cell culture and mouse gene knockout experiments 
have shown that ASK1 is the upstream regulator for JNK and p38 [354, 355].  
Downstream to ASK1, MKK4 and MKK7 regulate JNK [356-358], while MKK3 and 
MKK6 regulate p38 [356, 359]. 
Recent studies in cardiac myocytes have confirmed that ischemia preferentially 
activates ASK1 and thereby MKK6-p38 pathway but does not activate JNK [360]. ASK1-
deficient cardiomyocytes are resistant to H2O2- or calcium-induced cell death [361]. 
Also, ASK1 overexpression negatively regulates heat shock transcription factor-1 (HSF-
1) [362]. In turn, HSF-1 protects heart against ischemia-reperfusion injury [363, 364] by 
inhibiting H2O2-induced JNK activation and apoptosis [365]. Compared to young 
animals, cardiomyocyte apoptosis and infarct size during ischemia-reperfusion is 
increased in aging animals due to inhibition of Trx activity and subsequent disruption of 
Trx-ASK1 interactions [366]. As a result of increased afterload in chronic models of 
heart failure, as in transverse aortic constriction [367] or altered regional mechanical 
stress [368], the effects of increased ASK1 are observed weeks after the insult. 
However, following increased ROS generation and intense neurohormonal activation as 
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a result of cardiac decompensation, the protection of ASK1 deletion against adverse 
cardiac remodeling is evident 2 to 4 weeks after transverse aortic constriction or non-
reperfused acute myocardial infarction [367, 368]. In the cardiomyopathic hamster 
model, adenovirus transfection of a dominant-negative ASK1 mutant gene suppressed 
heart failure progression by preventing cardiomyocyte apoptosis [369]. Together, all 
these studies suggest that ASK1 couples increase in ROS production to induction of cell 
death pathways. 
A study by Watanabe et al., with ASK1-/- (knock-out) mice has shown a >50% decrease 
in infarct size following ischemia-reperfusion [361]. Another study by Liu et al., showed 
that cardiac-specific and inducible overexpression of ASK1 in the heart led to a 2-fold 
increase in infarct size after 60 minutes of regional myocardial ischemia and reperfusion 
[367]. Interestingly, in the absence of ischemia, cardiac specific overexpression of ASK1 
had no baseline effects in the mice [367].  This observation highlights the role of ASK1 
as a cellular redox sensor that is activated by ROS rather than a simple chemical 
mediator of cardiac injury. All the above studies suggest that ASK1 activation through 
p38/JNK pathways contributes to the pathogenesis of myocardial ischemia-reperfusion 
injury. Thus, any manipulations to inhibit ASK1/p38/JNK pathways should provide 
cardioprotection against ischemia-reperfusion injury. 
III. 1. 3. Pharmacological inhibitors of ASK/p38/JNK pathway 
Many recent studies using inhibitor molecules have shown that the components of the 
ASK1-MAPK are potential therapeutic targets for decreasing cardiac injury during 
ischemia-reperfusion [351, 370, 371]. Among such compounds, p38 inhibitors have 
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been extensively studied. In-vitro treatment with a p38 inhibitor prior to ischemia 
protected the cardiac cells from ischemia/reperfusion injury [372-374]. Ex-vivo [375-377] 
and in-vivo studies [378-380] with p38 inhibitor treatment during pre-ischemia reduced 
infarct size and improved left ventricular (LV) function. However, inconsistent findings 
are also reported in which inhibitor treatment prior to ischemia failed to reduce the 
infarct size [381, 382]. Although p38 inhibitors are efficient in reducing cardiac injury in 
animal models, the outcomes from clinical use are disappointing due to their toxicity 
[383-386]. Recently, pre-treatment with an inhibitor of JNK, D-JNKI-1, at the time of left 
coronary artery occlusion was shown to markedly decrease infarct size after reperfusion 
[370]. In addition, an upstream kinase such as ASK1 is an alternative therapeutic target 
which regulates the stress responses through the JNK and p38 pathways and may 
provide less toxic pharmaceutical treatment options [387]. In a very recent study by 
Toldo et al., treatment with ASK1-inhibitor (ASK1-i), GS-459679, at reperfusion led to a 
significant dose-related reduction in infarct size, inhibition of apoptotic cell death, and 
preservation of left ventricular dimension and systolic function at both 24 hours and 7 
days [388].  
Mitochondria are both the targets and sources of damage during cardiac ischemia and 
reperfusion [5, 222]. Myocardial ischemia disrupts the electron transport chain that 
results in decrease in the rate of the integrated respiration and increase in ROS 
generation [5, 222]. This in turn predisposes mitochondria to MPTP opening, 
cytochrome c release and activation of apoptosis [147, 154, 228]. In view of the 
substantial reduction in cardiac injury observed in the in-vivo model with ASK1-i 
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treatment [388], it is of great interest to understand the potential role of mitochondria in 
the observed cardioprotection during ischemia-reperfusion. 
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RESEARCH AIMS 
ASK1 (apoptosis signal regulating kinase 1) is a MAPK (mitogen-activated protein 
kinase) kinase kinase, and its activation during ischemia (ISC)-reperfusion (REP) 
increases cardiac injury through p38 and JNK pathways [320, 360]. ASK1 is considered 
as a cytosolic protein (c-ASK1) [320]. Mitochondrial localized ASK1 (m-ASK1) has 
recently been identified [389]. ASK1 is deactivated when it is bound on its endogenous 
inhibitor, a reduced thioredoxin (Trx). ISC damages the ETC and increases the 
production of reactive oxygen species (ROS) which oxidizes Trx thereby activating 
ASK1 [319]. Earlier work showed that the selective small molecule inhibitor of ASK1 
(ASK1-i) given at reperfusion led to a significant dose-related reduction in infarct size 
measured in-vivo at both 24 hours and 7 days [388].  
Damage to the mitochondrial electron transport chain (ETC) from ischemia (ISC) 
increases oxidant production and favors mitochondrial permeability transition (MPTP) 
during REP [5, 222]. In view of the substantial reduction in cardiac injury observed in the 
in vivo model, the potential role of mitochondria in the protection from ASK1-i treatment 
was studied. 
Specific aim: 
1. To identify whether mitochondria contribute to the cardioprotection confered by 
ASK1 inhibition at reperfusion in the in-vivo model of ischemia-reperfusion. 
III. 2. Materials and Methods 
III. 2. 1. Materials 
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All chemicals and reagents were purchased from Fisher Scientific, Pittsburgh, PA, or 
stated otherwise, except the ones used in mitochondria isolation and mitochondria-
related functional assays, which were purchased from Sigma-Aldrich, Saint Louis, MO. 
Animals 
Animals were purchased and housed as mentioned in Materials and Methods II. 2. 1.  
III. 2. 2. METHODS 
III. 2. 2. 1. Preparation of mouse heart for perfusion 
Hearts from male C57BL/6 mice were excised and perfused using a Langendroff 
perfusion system as explained in Material and Methods II. 2. 2. 1. 
III. 2. 2. 2. Lactate dehydrogenase (LDH) assay  
Lactate dehydrogenase catalyzes the oxidation of lactate as shown in the following 
reaction:  
Lactate + NAD+ ↔ pyruvate + NADH + H+ 
During ischemia, deficiency of oxygen and metabolic substrate depletes cellular ATP 
which leads to loss of cellular integrity. As a result, intracelluar enzymes such as LDH 
and creatine kinase were released into the extracellular space. 
For the assay, the following solutions are made fresh and kept on ice until used: 100 
mM phosphate (pH 7.5), 125.3 mM pyruvate and 11.3 mM NADH. Coronary effluent 
collected during 30 min of reperfusion was tested for LDH release. Reaction was started 
by adding 0.20 ml of effluent to 0.76 ml of 100 mM phosphate buffer which was 
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incubated for 5 min. Following 30 µl of 11.3 mM NADH was added and the baseline 
reading was recorded. Finally 10 µl of 125.3 mM pyruvate was added and the oxidation 
of NADH was monitored as a decrease in absorption at 340 nm. 
III. 2. 2. 3. Isolation of mitochondria, cytosol, and heart tissue homogenates 
Following perfusion, mitochondria were isolated from the hearts as described in 
Materials and Methods II. 2. 2. 2. 
III. 2. 2. 4. Measurement of oxidative phosphorylation in intact mitochondria 
Oxygen consumption in isolated mitochondria was measured using a Clark-type oxygen 
electrode at 30°C as explained in Materials and Methods II. 2. 2. 3. 
III. 2. 2. 5. Measurement of mitochondrial membrane potential 
Membrane potential of intact mitochondria (ΔΨm) was measured using the fluorogenic 
indicator, tetramethylrhodamine methyl ester (TMRM) dye (Invitrogen, Carlsbad, CA) as 
described below. TMRM is a lipophilic cation which accumulates in the mitochondria in 
proportion with membrane potential according to the Nernst equation. As the dye 
accumulates in the mitochondria it exhibits a red shift in both its absorption and 
fluorescence emission spectra. When mitochondria were uncoupled, TMRM was mostly 
in the medium exhibiting excitation spectra at 546 nm whereas when mitochondria were 
coupled or polarized, TMRM accumulates inside the mitochondria exhibiting excitation 
spectra at 573 nm. These properties were used to dynamically monitor ΔΨm of isolated 
mouse heart mitochondria using a ratio fluorescence approach (573/546). Emission 
intensity at 590 nm was recorded by LS55 Fluorescence Spectrometer (PerkinElmer, 
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Waltham, MA). Freshly isolated mitochondria (200 µg) were incubated in respiration 
buffer (100 mM KCl, 50 mM MOPS, 5 mM KPi, 1 mM EGTA) with 0.1 µM TMRM with 
stirring at 30°C. Mitochondria were polarized and depolarized by sequential addition of 5 
mM glutamate + 1.25 mM malate (state 2 respiration) and 0.5 mM ADP (state 3 
respiration: uses protons to produce ATP from ADP by complex V). The membrane 
potential was re-generated by adding 1 nM oligomycin which inhibits complex V 
(state4oligomycin) followed by titration with 25 µM DNP resulting in complete uncoupling of 
of the mitochondria (ΔΨ0). The difference between state 4oligomycin and ΔΨ0 is termed 
ΔΨmax which should correspond to the the physiological ΔΨm (theoretical value is -160 
mV). 
III. 2. 2. 6. Mitochondrial H2O2 net production 
Mitochondria-generated H2O2 was measured by the enzymatic oxidation of the 
fluorogenic indicator Amplex Red (10-acetyl-3,7-dihydroxyphenoxazine) (Invitrogen, 
Carlsbad, CA) in the presence of horseradish peroxidase (HRP) (Sigma-Aldrich, Saint 
Louis, MO) which produces the fluorescence product, resorufin as described below. The 
fluorescence of resorufin (Ex = 530 ± 25nm; Em = 585 ± 30nm) was measured by LS55 
Fluorescence Spectrometer (PerkinElmer, Waltham, MA) with stirring at 30 oC. Isolated 
mouse mitochondria (20µg) were incubated in buffer MMC (120 mM KCl, 5 mM 
KH2PO4, 1 mM EGTA; chelex treated buffer; (all from Sigma-Aldrich, Saint Louis, MO)) 
along with 25 µM Amplex Red and 0.25 units/ml HRP. Glutamate (6.67 mM) + Malate 
(3.33 mM) and succinate (6.67 mM) were used as complex I and complex II substrates 
along with their respective inhibitors rotenone (5 µM) and antimycin A (10 µM) to 
generate maximal complex I dependent and complex III dependent H2O2 production. 
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The amount of H2O2 generated was calculated based on the standard curve with known 
H2O2 concentrations. To show specificity of the assay, bovine liver-derived catalase 
(Sigma-Aldrich, Saint Louis, MO) was added to the reaction mixture incubated with 
succinate in the presence of antimycin A which quenches > 90% of the signal from H2O2 
generation. 
III. 2. 2. 7. Determination of Calcium Retention Capacity 
Calcium Retention Capacity (CRC) was defined as the amount of Ca2+ required to 
trigger a massive Ca2+ release by isolated cardiac mitochondria as described by Ichas 
et al [390]. Mitochondrial tolerance to calcium loading, CRC, is an indicator of the 
resistance of mitochondria to mitochondrial permeability transition pore opening (MPTP) 
following matrix Ca2+ accumulation. Extra-mitochondrial Ca2+ concentration was studied 
in the single-cell ﬂuorimeter (LS 55; PerkinElmer, Waltham, MA) by monitoring the 
decrease in extra-mitochondrial Ca2+ concentration using the fluorescent probe 
Calcium-Green 5N (Invitrogen, Carlsbad, CA) at excitation/emission wavelengths of 
500/530 nm respectively. Calcium-Green fluorescence units were used to calculate the 
amount of mitochondrial Ca2+ uptake by converting the signal to [Ca2+], expressed as 
nmol CaCl2/mg mitochondrial proteins, using an exponential standard curve established 
with increasing amounts of Ca2+. Freshly isolated mitochondria (250 μg proteins) were 
incubated in CRC buffer (150 mM sucrose, 50 mM KCl, 2 mM KH2PO4 and 20 mM 
Tris/HCl, pH 7.4) along with 0.5 mM calcium green and 5 mM succinate for 60 sec with 
stirring at 30 °C. Pulses of calcium (20 nmoles) were added at 60 sec intervals and the 
progressive uptake of Ca2+ by mitochondria was monitored until mitochondrial Ca2+ 
release caused by MPTP opening was observed. CRC, an index of MPTP sensitivity, 
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was calculated as total amount of Ca2+ taken up by mitochondria prior to triggering 
massive Ca2+ release.  
III. 2. 2. 8. Spectrophotometric measurement of activity of mitochondrial enzymes 
Enzyme activities of detergent-solubilized mitochondria were measured 
spectrophotometrically at 30 oC as described below. Frozen mitochondria were thawed 
and solubilized in MSM/EDTA buffer (220 mM mannitol, 70 mM sucrose, 5 mM MOPS, 
2 mM EDTA, pH 7.4) containing 0.5% cholate. The final protein concentration of 
solubilized mitochondria was 1 µg/µl. Calculated enzyme activities were expressed as 
nmol/min per mg of mitochondrial protein or 1/min/mg in case of complex IV. 
III. 2. 2. 8A. NADH-ubiquinone oxidoreductase (complex I) 
Complex I activity was measured as a decrease in reduced nicotinamide adenine 
dinucleotide (NADH) added exogenously. Oxidation of NADH results in decreased 
absorbance at 340 nm which was monitored. Solubilized mitochondria (15 µg) were 
incubated in 1ml buffer containing 50 mM KH2PO4 pH 7.4, 0.1 mM EDTA, 0.2% de-
fatted BSA (w/v), 0.015% sonicated asolectin, 0.2 mM NADH, 20 µg of antimycin A. 
After 2 min of equilibration, 0.05 mM oxidized decylubiquinone (DUQ) was added and 
the decrease in NADH concentration was monitored. Enzyme activities were calculated 
using an extinction coefficient of 6.22 mM-1cm-1 for NADH. Rotenone was used as a 
specific inhibitor of NADH-ubiquinone oxidoreductase activity. Thus, final rotenone-
sensitive complex I activity was determined by subtracting the rate measured in the 
presence of 7.5 µM rotenone from the rate obtained without inhibitor. 
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III. 2. 2. 8B. NADH-ferricyanide reductase (NFR) 
NFR assay measures activity of the rotenone-insensitive proximal portion of complex I, 
which has a functional NADH dehydrogenase activity with non-covalently bound flavin-
mononucleotide (FMN) molecule. NFR activity was recorded as a decrease in 
absorbance at 340 nm due to the oxidation of exogenously added NADH. The reaction 
is carried out in 1ml buffer at pH 7.4 containing 50 mM KH2PO4, 0.1 mM EDTA, 0.2% 
de-fatted BSA (w/v), 0.015% sonicated asolectin, 0.66 mM K3Fe(CN)6 (potassium 
ferricyanide, an artificial electron acceptor from FMN), 2 mM NaN3 and 0.2 mM NADH. 
After the acquisition of a baseline reading, reaction was initiated by addition of 5 µg of 
mitochondrial protein and the NFR activities were calculated using an extinction 
coefficient of 6.22 mM-1cm-1 for NADH. Actual rates of NFR complex were obtained after 
substracting the baseline rates obtained in the absence of mitochondria. 
III. 2. 2. 8C. Succinate-decylubiquinone oxidoreductase (complex II) 
Complex II activity was determined by monitoring the reduction of 2, 6-
dichlorophenolindophenol (DCPIP), a potent acceptor of electrons from complex II-
dependent reduced quinols. The reduction of DCPIP was measured 
sphectrophotometrically as a decrease in absorbance at 600 nm. Buffer at pH 7.4 
containing 50 mM KH2PO4, 1 mM EDTA, 0.1% de-fatted BSA (w/v), 2 mM NaN3, 30 µl 
of DCPIP (of OD of 30 µl in 1 ml of H2O being about 1.8), 0.05 mM oxidized DUQ 
(saturating amounts of exogenous ubiquinone), and 10 µg of mitochondrial protein in a 
total volume of 1ml was incubated for 3 min. After the equilibration period, reactions 
were started by the addition of 20 mM succinate, and the decrease in absorbance at 
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600 nm was monitored. Rates were calculated using DCPIP extinction coefficient of 21 
mM-1cm-1. Theonyltrifluoroacetone (TTFA) was used as a specific inhibitor of succinate-
ubiquinone oxidoreductase activity. TTFA-sensitive rates were calculated by subtracting 
the rate measured in the presence of 1 mM TTFA from the rate without the inhibitor. 
III. 2. 2. 8D. Ubiquinol: cytochrome c oxidoreductase (complex III) 
Complex III activity was measured as an increase in absorbance at 550 nm due to the 
reduction of cytochrome c. Reaction buffer (1 ml) at pH 7.4 containing 50 mM KH2PO4, 
0.05 mM EDTA, 0.125% de-fatted BSA (w/v), 2 µg of mitochondrial protein extract, 3 
mM NaN3 and 0.06 mM cytochrome c was equilibrated for 1 min. After equilibration, the 
reaction was initiated by adding 0.1 mM reduced decylubiquinol (DUQ). Rates were 
calculated using an extinction coefficient of 19.1 mM-1cm-1 for reduced  cytochrome c. 
Antimycin A-sensitive activity was measured by subtracting the rates measured in the 
presence antimycin A (20 mM) from the rate obtained without the inhibitor. 
III. 2. 2. 8E. Cytochrome c oxidase (complex IV) 
Complex IV activity was determined by monitoring the oxidation of exogenously added 
reduced cytochrome c which was measured as a decrease in absorbance at 550 nm. 
Reaction buffer at pH 7.4 containing 50 mM KH2PO4, 0.015% asolectin, 80 µl of 0.89 
mM reduced cytochrome c in a final volume of 1 ml was incubated for 8 min. After the 
equilibration period, reactions were started by adding 2 µg of mitochondrial protein. The 
decrease in absorbance at 550 nm was monitored and the reaction follows substrate 
dependent first order kinetics. Rates were calculated and were expressed as 1/min/mg 
of mitochondrial protein. 
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Reduced cytochrome c was prepared by adding sodium dithionate (Na2S2O4) to 5 ml of 
3 mM oxidized cytochrome c followed by vigorous vortexing. The Na2S2O4 treated 
cytochrome c solution was seperated on Amersham PD-10 column (GE Healthcare Life 
Sciences, Piscataway, NJ) to remove Na2S2O4 from the solution. Collected 3 mM 
reduced cytochrome c was diluted with distilled H2O to a final volume of 10 ml. Reduced 
cytochrome c concentration was measured spectrophotometrically and calculated using 
its extinction coefficient 19.1 mM-1cm-1. One batch of the obtained reduced cytochrome 
c was used for all the samples assayed. 
III. 2. 2. 8F. Citrate synthase 
In Krebs cycle, the formation of citrate from acetyl coenzyme A and oxaloacetate is 
catalyzed by citrate synthase which is an enzyme specific for the mitochondrial matrix. 
Citrate synthase activity assay measures of the rate of generation of mercaptide ion 
when citrate reacts with 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB, Ellman’s reagent). 
The formation of yellow mercaptide ion was quantified spectrophotometrically by 
measuring the absorbance at 412 nm. Mitochondrial protein extracts (2 µg) were added 
to the reaction mixtures containing 0.1 mM DTNB and 0.34 mM acetyl CoA in a final 
volume of 1 ml, and the baseline reading was taken. Next, the reactions were started by 
adding 0.5 mM oxaloacetic acid (OAA) and the increase in absorbance at 412 nm was 
recorded. Activities were calculated using an extinction coefficient of 13.6 mM-1cm-1 for 
mercaptide ion, a result of a side reaction of DTNB with CoA-SH, a product of citrate 
synthase-mediated reaction. 
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III. 2. 2. 9. Western blot analysis 
Proteins were separated using SDS/PAGE electrophoresis system, transferred to the 
PVDF membrane as explained in Materials and Methods II. 2. 2. 6. The membrane is 
incubated with the cytochrome c (BD Biosciences) or α-Tubulin (Abcam) primary 
antibodies followed by Horse Radish Peroxidase (HRP) conjugated anti-mouse or anti-
rabbit secondary antibody. The immunoreactive proteins were visualized using 
Amersham ECL Plus western blotting detection reagents (GE Healthcare Lifesciences, 
Piscataway, NJ) and measured as explained in Materials and Methods II. 2. 2. 6. 
III. 2. 3. STATISTICAL ANALYSIS 
Data were expressed as the mean ± standard error of the mean and the statistical 
analysis were performed as mentioned in Materials and Methods II. 2. 3. 
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III. 3. RESULTS 
Studies from transgenic mouse models have shown that ASK1 is central to ischemia-
reperfusion injury [361, 380]. Pharmacological treatment with ASK1-inhibitor (ASK1-i), 
GS-459679, at the onset of reperfusion decreases infarct size and improves cardiac 
function measured at 24 hr and 7 days [388]. Since cardiac mitochondria are both 
sources and targets of ischemic damage, we hypothesized that ASK1 inhibition would 
change the response of mitochondria to the ischemic insult resulting in cardioprotection 
observed in-vivo. Ischemic insult affects the electron transport chain, which in turn leads 
to decrease in the rate of integrated respiration [5]. 
In our experiments, we have used a Langendorff mouse model of ischemia and 
reperfusion that is established in our laboratory [306]. In this model of ischemia-
reperfusion, the isolated, buffer perfused mouse hearts underwent 25 min of ischemia 
and 30 min of reperfusion followed by isolation of mitochondria. Four groups of mice 
were studied. Time control perfusion and untreated ischemia-reperfusion mice were 
control groups, and were treated with vehicle (DMSO).  ASK1-i (10 µM final 
concentration) was given either before ischemia and during early reperfusion or during 
early reperfusion alone (Figure 3.3). Cardiac function was monitored and lactate 
dehydrogenase (LDH) release during reperfusion was measured as the index of cell 
death in all the four groups. Mitochondria were isolated and oxidative-phosphorylation 
was measured using glutamate, succinate and TMPD/ascorbate as substrates. 
Mitochondrial susceptibility to MPTP opening was studied using the the calcium 
retention capacity (CRC) assay. Mitochondrial membrane potential was measured using 
the TMRM assay.  The Amplex Red assay was used to measure H2O2 release from the 
 129 
 
mitochondria. Spectrophotometric assays to determine changes in ETC complex 
activites were performed. Additonally, changes in specific protein levels were measured 
using Western blotting. 
 
 130 
 
 
 
 
 
 
 
 
 
Figure 3.3. Experimental Protocol. ASK1-i was first dissolved in DMSO as vehicle, 
then diluted into Krebs-Henseleit (K-H) buffer to reach final concentration 10 uM.  
DMSO (0.001%) was added into K-H buffer for time control and ischemia-reperfusion 
hearts. EQ, equilibration; ISC-ischemia; REP- reperfusion. 
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III. 3. 1. ASK1-i treatment improves cardiac function in mouse hearts following 
ischemia-reperfusion 
Cardiac function was monitored in hearts that underwent TC perfusion, ISC-REP, 
ASK1-i before and after ISC, ASK1-i during reperfusion. The left ventricular developed 
pressure (LVDP) and diastolic pressure were recorded. In the four groups, the LVDP 
was similar in each group at the end of equilibration perfusion (Figure 3.4) [TC 
perfusion: 84±3 mm Hg; ISC-REP: 79±7; ASK1-i before and after ISC: 74±5; ASK1-i 
during reperfusion: 75±5; p=ns]. In untreated ISC-REP hearts and ASK1-i treatment 
before and after ISC, LVDP was markedly decreased during reperfusion compared with 
the pre-ischemic value [ISC-REP: 26±5 mm Hg; ASK1-i before and after ISC: 15±5; 
p<0.05 vs. TC perfusion]. In contrast, ASK1-i administration only during early 
reperfusion significantly increased LVDP during 60 min reperfusion compared with the 
untreated hearts or ASK1-i treatment before and after ISC [ASK1-i during reperfusion: 
42±3 mm Hg; p<0.05 vs. ISC-REP] (Figure 3.4). 
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Figure 3.4. ASK1-i treatment during reperfusion improves cardiac function in 
mouse hearts following ischemia-reperfusion. Left ventricular developed pressure 
(LVDP) was recorded (as mm Hg) in TC perfusion, ISC-REP, ASK1-i before and after 
ischemia, ASK1-i during reperfusion groups. There were no differences in LVDP among 
the four groups at 15 minutes of equilibration (EQ) before the onset of ischemia (A). 
ASK1-i treatment during reperfusion improved the recovery of LVDP during reperfusion 
compared with untreated hearts (B). Results were presented as mean±SE. All results 
were compared using one-way ANOVA test. *p<0.05 vs. TC perfusion; #p<0.05 vs. ISC-
REP. n= 6-7 in all groups.  
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There were no differences in diastolic pressure between groups (TC perfusion, ISC-
REP, ASK1-i before and after ISC, ASK1-i during reperfusion) at the end of the 15 min 
equilibration perfusion (15 min) [TC perfusion: 9±2 mm Hg; ISC-REP: 9±1; ASK1-i 
before and after ISC: 9±1; ASK1-i during reperfusion: 8±1; p=ns] (Figure 3.5). 
Ischemia-reperfusion markedly increased diastolic pressure in untreated hearts [ISC-
REP: 31±8 mm Hg; p<0.05 vs. TC perfusion]. ASK1-i treatment before ischemia had no 
effect on the increased diastolic pressure [ASK1-i before and after ISC: 49±7 mm Hg; 
p<0.05 vs. TC perfusion] whereas ASK1-i administration during early reperfusion 
significantly decreased diastolic pressure during 60 min reperfusion compared with the 
untreated hearts or ASK1-i treatment before and after ISC [ASK1-i during reperfusion: 
17±5 mm Hg; p<0.05 vs. ISC-REP] (Figure 3.5). Thus, from the data it was clear that 
cardiac function following ischemia-reperfusion were substantially improved by ASK1-i 
given during early reperfusion. 
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Figure 3.5. ASK1-i treatment during reperfusion improves cardiac function in 
mouse hearts following ischemia-reperfusion. Diastolic pressure was recorded (as 
mm Hg) in TC perfusion, ISC-REP, ASK1-i before and after ischemia, ASK1-i during 
reperfusion groups. There were no differences in diastolic pressure among the four 
groups at 15 minutes of equilibration (EQ) before the onset of ischemia (A). ASK1-i 
treatment during reperfusion lowered diastolic pressure during ischemia and reperfusion 
compared with untreated hearts (B). Results were presented as mean±SE. All results 
were compared using one-way ANOVA test. *p<0.05 vs. TC perfusion; #p<0.05 vs. ISC-
REP. n= 6-7 in all groups.  
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III. 3. 2. ASK1-i treatment decreases cardiac injury in mouse hearts following 
ischemia-reperfusion 
To assess myocardial cell damage, we examined the lactate dehydrogenase (LDH) 
release into the coronary effluent during the 30 min reperfusion period. Ischemia-
reperfusion increased total LDH release into the coronary effluent when compared to 
TC perfusion [TC perfusion: 198±89; ISC-REP: 890±65; p<0.05] (Figure 3.6). ASK1-i 
given before ischemia and during the initial 10 minutes of reperfusion attenuated 
myocardial injury as observed from the decrease in LDH release during reperfusion 
[ASK1-i before and after ISC: 560±83; p<0.05 vs. ISC-REP].  Remarkably, treatment 
only during early reperfusion was as protective as given before ischemia as it 
decreased LDH release during reperfusion to a similar extent [ASK1-i before and after 
ISC: 533±61; p<0.05 vs. ISC-REP] (Figure 3.6). Thus, the in-vitro model used for the 
study of mitochondrial function recapitulates the in-vivo observation of cardioprotection 
by treatment only during reperfusion. 
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Figure 3.6. ASK1-i treatment decreases cardiac injury in mouse hearts following 
ischemia-reperfusion. LDH release, a marker for myocardial injury, was measured and 
expressed as mU/min/ g wet tissue. ASK1-i treatment decreased the amount of LDH 
release compared to untreated hearts. Results were presented as mean±SE. All results 
were compared using one-way ANOVA test. *p<0.05 vs. TC perfusion, #p<0.05 vs. ISC-
REP. All results were compared using one-way ANOVA test. n=6-7 in all groups. LDH, 
lactate dehydrogenase. 
 
 137 
 
III. 3. 3. ASK1-i treatment during ischemia-reperfusion does not alter the protein 
yield or citrate synthase activity in the mitochondria. 
Following, mitochondrial isolation, protein concentration was measured by Lowry 
method using BSA as a standard and sodium deoxycholate as a detergent to solubilize 
the mitochondria. Citrate synthase activity was quantified in cholate-solubilized frozen-
thawed mitochondria by measuring the rate of 5,5′-dithiobis (nitrobenzoic acid)-reactive 
reduced coenzyme A (412 nm).  
The protein yield of isolated mitochondria following 25 min of untreated ischemia and 30 
min of reperfusion was similar to the protein yield in the time control perfusion group 
(Figure 3.7A). The protein yield averaged 26.2±2.4 mg/g wet weight in TC perfusion vs. 
25.0±1.5 mg/g in ISC-REP hearts respectively (p=ns). As shown in Figure 3.7A, the 
yields of mitochondria were also similar in ASK1-i treated groups [ASK1 before and 
after ISC: 21.9±1.5; ASK1 during reperfusion: 26.4±0.8; p=ns vs. ISC-REP].  
To assess whether the relative purity of the mitochondria following isolation was similar 
in TC perfusion, ISC-REP and ASK1-i treated groups, activity of citrate synthase, the 
marker enzyme for mitochondrial matrix, was measured. From isolated mitochondria in 
all the four groups, the specific activity of citrate synthase was similar in all groups 
(Figure 3.7B) [TC perfusion: 3445±194; ISC-REP: 3277±232; ASK1-i before and after 
ISC: 3314±265; ASK1-i during reperfusion: 3239±183; p=ns].  
Thus, following ischemia-reperfusion or ASK1-i treatment during ISC-REP, there is an 
unchanged protein yield of mitochondria along with similar marker enzyme activity. This 
confirms that neither ischemia-reperfusion nor the treatment with ASK1-i significantly 
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modified the recovery and purity of the mitochondria. In order to understand the role of 
ASK1 on mitochondrial functioning during ischemia reperfusion, we proceeded with the 
measurement of oxidative phosphorylation in untreated and ASK1-i treated groups. 
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Figure 3.7. ASK1-i treatment in mouse hearts following ischemia-reperfusion did 
not alter the mitochondrial protein yield and citrate synthase activity. The protein 
content of the isolated mitochondria from C57BL6 mice was similar in TC perfusion, 
ISC-REP, ASK1-i before and after ischemia, ASK1-i during reperfusion groups (A). As a 
mitochondria-specific enzymatic marker, citrate synthase activity was measured in all 
samples tested (B). Results were presented as mean±SE. All results were compared 
using one-way ANOVA test. n= 6-7 in all groups. 
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III. 3. 4. ASK1-i treatment improved oxidative phosphorylation following ischemia-
reperfusion in heart mitochondria. 
In order to investigate if ASK1 influences cardiac mitochondrial respiration, the rates of 
oxidative phosphorylation were studied in mitochondria isolated from four groups: time 
control perfusion, untreated ischemia-reperfusion, ASK1-i given either before ischemia 
and during early reperfusion or during early reperfusion alone using different substrates 
that donate electrons to the electron transport chain. Glutamate+malate was used as a 
complex I substrate, succinate (in the presence of rotenone) as a complex II substrate, 
and TMPD/ascorbate (with rotenone) as an electron donor to complex IV via 
cytochrome c. As shown in Figure 3.8, mitochondrial respiratory function was 
substantially decreased following ischemia and reperfusion. The maximal rates of 
oxidative phosphorylation were obtained by addition of saturating 2 mM ADP when 
glutamate+malate, succinate or TMPD/ascorbate was used as the substrate. The 
maximal rate of respiration using a complex I substrate, glutamate+malate, (complex 
I→complex III→complex IV) was decreased by approximately 50% (TC: 417±32 
nAO/min/mg protein; ISC-REP: 202±12, p<0.05) (Figure 3.8A). Succinate-dependent 
(complex II→complex III→complex IV) maximal integrated respiration rates showed a 
significant decrease, approximately 30% (TC: 617±65 nAO/min/mg protein; ISC-REP: 
425±23, p<0.05) (Figure 3.8B) whereas TMPD/ascorbate-dependent (complex IV) 
respiration was lowered by approximately 30% (TC: 1776±167 nAO/min/mg protein; 
ISC-REP: 1275±43, p<0.05) (Figure 3.8C) following ischemia-reperfusion. Consistent 
with previously published data [102, 209], ISC-REP increased uncoupling of the 
mitochondria indicated by augmented state 4 rates when using different substrates 
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(Table 3.1). Augmented uncoupling of respiration following ISC-REP is the result of 
increased permeability of the inner mitochondrial membrane. Respiratory control ratios 
(RCRs) were reduced after ISC-REP independently of the substrates used (Table 3.1). 
As a next step, the rates of uncoupled respiration by addition of 2, 4-ditrophenol (DNP) 
were measured. DNP is a protonophore that carries protons across the mitochondrial 
membrane. In its presence, the electron transport chain works independently from the 
phosphorylation apparatus. Therefore, the use of DNP allows us to test the relative 
contributions of electron transport chain and ATP synthase/ANT/Pi transporter to the 
decreased rates of oxidative phosphorylation. The DNP-uncoupled respiration with 
glutamate+malate and succinate was reduced to a similar extent when compared to the 
ADP stimulated maximal rates (Table 3.1). This result suggests that the decrease in 
respiration was not caused by defects in ATP synthase, adenine nucleotide translocase 
(ANT) or phosphate (Pi) transporter, but was indeed localized to the electron transport 
chain. 
Treatment with ASK1-i before ischemia and during reperfusion improved the maximal 
ADP-stimulated glutamate respiration rate by approximately 50% (300±21 nAO/min/mg 
protein, p<0.05) compared to ISC-REP (Figure 3.8A). Furthermore, the maximum state 
3 rates with glutamate+malate in the presence of DNP uncoupler were improved 55% 
(375±18 nAO/min/mg protein, p<0.05 vs. ISC-REP) which was comparable with the 
results without DNP (Table 3.1). Apparently, the phosphorylation aparatus did not 
contribute to the improvement of complex I-dependent respiration. Also, succinate-and 
TMPD/ascorbate-dependent respiration rates were not significantly improved following 
ASK1-i treatment before ischemia and during early reperfusion (Table 3.1). 
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Remarkably, administration of ASK1-i only during reperfusion was sufficient to protect 
the maximal complex I mitochondrial oxidative phosphorylation (381±13 nAO/min/mg 
protein, p<0.05) compared to ISC-REP (Figure 3.8A). Respiratory control ratios (RCRs) 
were improved following ASK1-i treatment only during reperfusion independently of the 
type of substrates used (Table 3.1). Furthermore, the DNP-uncoupled respiration on 
glutamate+malate and succinate was improved to the similar extent (Table 3.1) which 
suggests that the increase in respiration was due to protection of the electron transport 
chain. Remarkably, the ASK1-i treatment during early reperfusion alone was 
comparable to the regimen that included ASK1-i pre-treatment before ischemia.  
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Figure 3.8. ASK1-i treatment during reperfusion improves glutamate+malate, 
succinate and TMPD+ascorbate dependent oxidative phosphorylation following 
ischemia-reperfusion. Oxygen consumption by intact mitochondria was measured by 
Clark-type electrode at 30 oC as described in Materials and Methods. Incubations 
contained: 20 mM glutamate with 5 mM malate (A), 20 mM succinate with 7.5 µM 
rotenone (B), or 1 mM TMPD/20 mM L-ascorbate with 7.5 µM rotenone (C). Maximum 
rates of state 3 respiration with 2 mM ADP are shown (A and B). For TMPD/Asc-
dependent respiration azide-sensitive data are depicted (C). Results were expressed as 
nanoatoms of atomic oxygen/min/mg of mitochondrial protein and were presented as 
mean±SE. * p<0.05 vs. TC perfusion, #p<0.05 vs. ISC-REP. All results were compared 
using one-way ANOVA test. n= 6-7 in all groups. 
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Table 3.1. Rates of oxidative phosphorylation in heart mitochondria isolated from 
TC perfusion, ISC-REP and ASK1-i treated groups.  
 
ASK1-i treatment during ischemia-reperfusion affects mitochondrial oxidative 
phosphorylation. Mitochondria were isolated and rates of respiration were recorded. 
Based on state 3 and state 4 rates, respiratory control ratios (RCRs) were calculated. 
During recording of 2 mM ADP-dependent maximal state 3 rate, uncoupler 2,4-
dinitrophenol (DNP) was added to establish relative contribution of phosphorylation 
apparatus and the ETC. Results were presented as mean±SE. Values of state 3, state 
4, 2 mM ADP and DNP rates were expressed in nanoatoms of atomic oxygen/min/mg of 
mitochondrial protein. All results were compared using one-way ANOVA test. *p<0.05 
vs. TC perfusion; #p<0.05 vs. ISC-REP. n=6-7 in all groups. ADP, adenosine di-
phosphate; TMPD, N,N,N′,N′-tetramethyl-p phenylenediamine; RCR, respiratory control 
ratio; DNP, 2,4-dinitrophenol.  
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III. 3. 5. Mitochondrial membrane potential was similar/unaffected by ASK1-i 
treatment during ischemia-reperfusion. 
Mitochondrial membrane potential (ΔΨm) is an integral component of cellular energy 
homeostasis and normal cellular function. It is a major indicator of mitochondrial 
membrane intactness which reflects the pumping of protons across the inner membrane 
during the process of electron transport and oxidative phosphorylation [36]. TMRM 
(tetramethylrhodamine methyl ester) is a permeant cationic fluorescent probe whose 
accumulation in the mitochondria depends on high trans-membrane potential (the matrix 
being negative) maintained by functional mitochondria [36]. However, dissipation of the 
mitochondrial transmembrane potential by protonophores (DNP) or inhibitors of electron 
transport chain eliminates the selective mitochondrial association with TMRM dye. 
Therefore, the intactness of the inner mitochondrial membrane was measured by 
dynamic changes in the TMRM fluorescence signal in mitochondria isolated from ASK1-
i treated and untreated groups [36].  
The maximum membrane potential that the mitochondria could generate (ΔΨmax), was 
expressed as a difference between fully polarized mitochondria in the presence of 1 nM 
oligomycin (state 4oligomycin) and fully uncoupled mitochondria following addition of 25 µM 
DNP (Ψ0). Addition of oligomycin inhibits proton translocation through ATP synthase. 
Due to the activity of ETC in the presence of excess of substrates, the protons were still 
being moved from matrix to the intermembrane space. Therefore, the measured state 
4oligomycin represents the maximal inner membrane polarization state. Values of ΔΨmax 
from TC perfusion, ISC-REP and ASK1-i treatment groups (Figure 3.9) indicate that 
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even though ISC-REP and ASK1-i treatment altered glutamate+malate respiration, they 
did not affect the ability to generate normal proton motive force in mitochondria.  
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Figure 3.9. ASK1-i treatment during ischemia-reperfusion did not alter the 
maximum mitochondrial potential, ΔΨmax. ΔΨm was measured in 200 µg of intact 
mitochondria using 0.1 µM TMRM, a fluorescent dye that accumulates in polarized 
mitochondria. (A) ΔΨmax, maximum potential that mitochondria were capable to 
generate defined as the difference in membrane potential between fully polarized 
mitochondria in the presence of 1 nM oligomycin (state 4oligomycin) and fully uncoupled 
mitochondria after sequential titration with 25 µM DNP (Ψ0). All results were compared 
using one-way ANOVA test. *p<0.05 vs. TC perfusion. n=6-7 in all groups. RFU, relative 
fluorescence units. 
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III. 3. 6. ASK1-i treatment does not decrease the net H2O2 release following 
ischemia-reperfusion 
To assess ROS production in the isolated heart mitochondria, we measured net H2O2 
release from these organelles. In normally respiring mitochondria superoxide generation 
from the electron transport chain is low [80]. Due to this reason, the isolated intact 
mitochondria were supplied with excess quantity of metabolic substrates which results 
in the depletion of ADP and establishment of higher ROS-generating state 4 of 
mitochondrial respiration.  
The maximal capacity of complex I to produce H2O2 by inhibition of complex I with 
rotenone was studied. Specific inhibitors were present during the time of incubation of 
isolated mitochondria with respiration substrates. As shown in Figure 3.10, ischemia 
significantly increased the maximal capability of complex I to generate H2O2 [TC 
perfusion: 103±12 pmol/mg protein/30min; ISC-REP: 213±22; p<0.05]. On the other 
hand, ASK1-i treatment during ischemia and early reperfusion showed a trend towards 
increase in the maximal complex I H2O2 production which was not significant when 
compared to ISC-REP [ASK1-i before and after ISC: 275±37 pmol/mg protein/30min] 
(Figure 3.10). However, this increasing trend was not observed in the mouse hearts 
which underwent ASK1-i treatment only during reperfusion [ASK1-i during reperfusion: 
187±29 pmol/mg protein/30min; p<0.05 vs. ASK1-i before and after ISC] (Figure 3.10). 
 The maximal capacity of complex III to generate H2O2 was determined using succinate 
in the presence of rotenone and antimycin A. From Figure 3.11, it is clear that 
ischemia-reperfusion increased the maximal capability of complex III to H2O2 net 
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release [TC perfusion: 654±62 pmol/mg protein/30min; ISC-REP: 1010±87; p<0.05]. On 
the other hand, ASK1-i treatment during ischemia and early reperfusion significantly 
increased the maximal complex III H2O2 production when compared to ISC-REP [ASK1-
i before and after ISC: 1528±118 pmol/mg protein/30min] (Figure 3.11). Conversely, 
mouse hearts which underwent ASK1-i treatment only during reperfusion did not 
additionally increase the ROS release from complex III when compared to ISC-REP 
group [ASK1-i during reperfusion: 1013±63 pmol/mg protein/30min; p<0.05 vs. ASK1-i 
before and after ISC] (Figure 3.11). 
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Figure 3.10. ASK1-i treatment does not decrease the maximal net H2O2 production 
from complex I following ischemia-reperfusion. Intact mitochondria were isolated 
and incubated with glutamate+malate+rotenone followed by measurement of H2O2 net 
production using Amplex Red and HRP. Results were expressed as pmol/mg/30min 
and were presented as mean±SE. All results were compared using one-way ANOVA 
test. *p<0.05 vs. TC perfusion; $p<0.05 vs. ASK1-i before and after ischemia. n=6-7 in 
all groups.  
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Figure 3.11. ASK1-i treatment does not decrease the net H2O2 production from 
complex III following ischemia-reperfusion. Intact mitochondria were isolated and 
incubated with succinate+rotenone+antimycin A followed by measurement of H2O2 net 
production using Amplex Red and HRP. Results were expressed as pmol/mg/30min 
and were presented as mean±SE. All results were compared using one-way ANOVA 
test. *p<0.05 vs. TC perfusion; #p<0.05 vs. ISC-REP; $p<0.05 vs. ASK1-i before and 
after ischemia. n=6-7 in all groups.  
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III. 3. 7. ASK1-i treatment during ischemia-reperfusion decreases MPTP 
susceptibility in mitochondria. 
Damage to the electron transport chain from ischemia increases the production of 
reactive oxygen species and predisposes to the onset of mitochondrial permeability 
transition (MPTP) [246].  As shown in Figure 3.10 and 3.11, the production of reactive 
oxygen species was not affected by ASK1-i treatment. MPTP is triggered during 
reperfusion by calcium overload leading to subsequent opening of the permeability 
transition pore followed by increased permeability of the inner and outer mitochondrial 
membranes.  This increase in membrane permeability results in cellular necrosis 
(increased infarct size) as well as the release of mitochondrial proteins that activate 
programmed cell death pathways [246].   
Calcium Retention Capacity (CRC) was used to assess the susceptibility to MPTP 
opening in isolated mitochondria. Representative original tracings of CRC are shown for 
TC perfusion and ISC-REP groups in the upper panel of Figure 3.12A. From the 
tracings, it is clear that ischemia-reperfusion increases the mitochondrial susceptibility 
to undergo MPTP, manifest by a decreased tolerance of mitochondria to exogenous 
calcium before MPTP occurs. The release of calcium from the mitochondrial matrix 
indicated MPTP opening. In TC perfusion group, CRC averaged 640±32 nmol CaCl2/mg 
protein which was markedly decreased during ISC-REP to 344±11 nmol CaCl2/mg 
protein [p<0.05] (Figure 3.12B). Remarkably, treatment with ASK1-i before ischemia 
and during reperfusion significantly decreased mitochondrial susceptibility to calcium-
induced MPTP as shown by their improved CRC [ASK1-i before and after ISC: 480±16 
nmol CaCl2/mg protein; p<0.05 vs. ISC-REP] (Figure 3.12B). However, treatment only 
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during reperfusion was as protective as treatment that was given before ischemia as 
noticed in the improved CRC indicating decreased sensitivity to MPTP opening [ASK1-i 
before and after ISC: 451±12 nmol CaCl2/mg protein; p<0.05 vs. ISC-REP] (Figure 
3.12B). 
Differences between TC perfusion, ISC-REP and ASK1-i treatment groups were not due 
to a preferential selection of “good” mitochondria in the ASK1-i treated groups during 
the isolation process. This was confirmed by the protein content or the citrate synthase 
activity between the three groups which provided a strong evidence of a similar 
recovery of mitochondria from all the four groups.  
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Figure 3.12. ASK1-i treatment decreases MPTP susceptibility in mitochondria 
following ischemia-reperfusion. The upper panel shows a representative original 
tracing of CRC measurement during time control (TC) perfusion and ischemia (ISC)-
reperfusion (REP) (A). The number of calcium pulses to elicit MPTP opening was 
markedly decreased after ischemia-reperfusion compared with time control. ASK1-i 
treatment given before and after ischemia, during reperfusion alone improved CRC 
when compared with untreated hearts (B). Data were expressed as mean ± SE. All 
results were compared using one-way ANOVA test. * p<0.05 vs. TC perfusion, # p<0.05 
vs. ISC-REP. N= 6-7 in all groups. 
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III. 3. 8. ASK1-i treatment during ischemia-reperfusion decreases cytochrome c 
release from mitochondria into cytosol 
Mitochondrial electron transport chain (ETC) is both the source and target for ischemic 
damage [5, 222]. The sequence of events leading to mitochondrial ischemic damage 
involves damage to ETC, increase in mitochondrial membrane permeability, depletion of 
cytochrome c and activation of apoptotic pathways [5, 79, 156, 222]. From the earlier 
data, it is clear that ASK1-i treatment improved oxidative phosphorylation through ETC 
(Figure 3.8) and decreased the susceptibility to MPTP opening (Figure 3.12). As a next 
step, we would like to test whether the ASK1-i treatment has any effect on the 
cytochrome c release from the mitochondria into the cytosol. Therefore, we measured 
cytochrome c content in cytosols from hearts subjected to ISC-REP with or without 
ASK1-i treatment or TC perfusion.  
Western blot analysis revealed a significant increase in release of cytochrome c into the 
cytosols of ISC-REP hearts (Figure 3.13) which is consistent with the earlier published 
data. ISC-REP enhanced the release of cytochrome c from the mitochondria when 
compared to TC perfusion [densitometric ratio of cyt c/α-tubulin; TC perfusion: 
0.286±0.090; ISC-REP: 0.818±0.223; p<0.05]. In contrast, from the densitometric 
measurements, both ASK1-i treatment before and after ischemia [ratio of cyt c/α-tubulin; 
ASK1-i before and after ISC: 0.211±0.082; p<0.05] and during reperfusion alone [ratio 
of cyt c/α-tubulin; ASK1-i during reperfusion: 0.276±0.110; p<0.05] significantly reduced 
the cytochrome c release into the cytosol from the mitochondria when compared to ISC-
REP (Figure 3.13). Therefore, this data suggests that ASK1-i treatment improves 
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complex I, II and IV-dependent respiration in ischemic mitochondria by decreasing 
susceptibility to MPTP opening thereby retaining cytochrome c in the mitochondria.  
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Figure 3.13. ASK1-i decreases cytochrome c release from mitochondria into 
cytosol. Mitochondrial protein extracts (10 µg) from TC perfusion, ISC-REP, ASK1-i 
treated groups were resolved by SDS-PAGE and immunoblotted against cytochrome c 
and porin (mitochondrial loading control). Data were expressed as mean±SE. All results 
were compared using one-way ANOVA test. *p<0.05 vs. TC perfusion, #p<0.05 vs. ISC-
REP. A representative blot from six independent experiments is shown. 
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III. 3. 9. Complex III maximal enzymatic activities were increased upon ASK1-i 
treatment during reperfusion 
Various reports indicate that the initial site of ischemic damage to the ETC is complex I 
and with increasing duration of the insult, it progresses to complex III and IV [5, 222]. 
Therefore, as a next step, maximal activities of complex I, II and III were measured to 
investigate if ASK1-i treatment during ischemia and reperfusion or reperfusion alone 
protects against damages to complexes. As an internal ‘loading’ control, the activity of 
matrix-localized citrate synthase (one of the Kreb’s cycle enzymes) was also assayed. 
Spectrophotometric analysis of individual respiratory chain complexes is achieved by 
total disruption of both mitochondrial membranes using freeze-and-thaw technique and 
additional solubilization with 0.5 % sodium cholate. This technique dissects the entire 
electron transport chain into single complexes therefore their maximum enzymatic 
activity (zero order) in the presence of excess substrates (electron donors and 
acceptors) was measured.  
Citrate synthase rates were equal and within a normal range (2500-3000 nmol/min/mg) 
among all the four groups, indicating similar relative purity of mitochondria isolated from 
the heart tissue (Table 3.2). Measurement of ubiquinol: cytochrome c oxidoreductase 
(complex III) activity has shown that ISC-REP decreased complex III enzymatic activity 
by approximately 30% (TC perfusion: 7403±335 nmol/min/mg protein; ISC-REP: 
5385±392; p<0.05) when compared to the TC perfusion which localizes the defect 
within the electron transport chain (Figure 3.14). This data along with OXPHOS data 
and Western blotting for cytochrome c suggests that the slower rates of 
glutamate+malate, succinate and TMPD/ascorbate respiration in ISC-REP mitochondria 
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were likely atleast in part due to the impaired enzymatic activity of complex III or 
cytochrome c loss. Interestingly, ASK1-i treatment during early reperfusion showed a 
significant improvement, approximately 30% (7892±341 nmol/min/mg protein; p<0.05), 
when compared to ISC-REP group (Figure 3.14).  
As depicted in Table 3.2, ischemia did not affect the maximal activity of complex I in 
mitochondria isolated from mice hearts with or without ASK1-i treatment during 
ischemia-reperfusion. Additionally, the rotenone-insensitive activity of NADH 
dehydrogenase (NFR), the proximal part of complex I was measured. ISC-REP did not 
decrease maximal enzymatic rates of NFR in ASK1-i treated and untreated groups. 
Complex II activity was not decreased by ischemia when compared to the TC perfusion 
and ASK1-i treatment has no effect on the basal enzymatic rates.  
Decrease in ETC activities may be caused by changes in expression of particular 
subunits of respiratory complexes. ETC activity can also be affected by the loss, 
damage or functional inactivation of protein subunits [214]. ETC activities can also 
modulated by post-translational modifications, including S-nitrosylation or 
phosphorylation [22, 61, 208, 215]. Identification of the mechanistic reason for 
improvement in the complex III activity with ASK1-i treatment during reperfusion will be 
one of the future directions of this project. 
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Figure 3.14. ASK1-i treatment during reperfusion improves the maximal activity of 
complex III in heart mitochondria. Integrity of isolated mouse heart mitochondria was 
disrupted by freeze-and-thaw procedure followed by solubilization with 0.5% (final v/v) 
cholate in MSM/EDTA buffer and adjusted to final protein concentration of 1 μg/ul. All 
enzymatic activities were measured spectrophotometrically using over-saturating 
amounts of specific substrates and inhibitors (zero rate kinetics) as outlined in Materials 
and Methods and expressed as nanomole of substrate decreased or product increased 
per minute per mg of mitochondrial protein [nmol/min/mg]. Data are presented as 
mean±SE. A difference of p<0.05 was considered significant. *p<0.05 vs. TC perfusion, 
#p<0.05 vs. ISC-REP. All results were compared using one-way ANOVA test. n=6-7 in 
all groups. 
 
 
 
 
 161 
 
 
Table 3.2. ETC-related enzyme activities of the isolated mitochondria from TC 
perfusion, ISC-REP, ASK1-i treated groups. 
 
ASK1-i treatment during reperfusion increases maximum activity of complex III 
following ischemia-reperfusion. Complex I, II and IV activities were not altered in all 
the four groups. Mitochondria were isolated, cholate-solubilized and enzymatic activities 
of individual ETC complex and of citrate synthase were determined 
spectrophotometrically as described in Materials and Methods. All results were 
expressed in nmol/min/mg or 1/min/mg in case of complex IV. Values were expressed 
as mean±SE (in nmol.min-1.mg protein-1); n=6-7 experiments. Complex I, 
NADH:decylubiquinone oxidoreductase; NFR, NADH:ferricyanide oxidoreductase; 
Complex II, succinate-ubiquinone oxidoreductase; Complex III, ubiquinol-cytochrome c 
oxidoreductase; Complex IV, cytochrome c oxidase; CS, citrate synthase. ISC-REP, 
ischemia-reperfusion; ASK1-i, apoptosis signaling kinase 1 inhibitor. All results were 
compared using one-way ANOVA test. *p<0.05 vs. TC perfusion; #p<0.05 vs. ISC-REP. 
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III. 4. SUMMARY 
 ASK1-i treatment during ISC-REP limits damage to mitochondria by: 
1. Preservation of oxidative phosphorylation 
2. Increased resistance to mitochondrial permeability transition.  
3. Attenuation of damage to the respiratory chain. 
4. Decrease in release of cytochrome c from mitochondria.  
 Interestingly, treatment at the onset of REP with a cell-permeable small molecule 
inhibitor of ASK1 limits mitochondrial-driven cardiac injury. 
 This is the likely the mechanism of the sustained myocardial salvage previously 
observed in-vivo in a preclinical model of STEMI treated by reperfusion. 
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III. 5. DISCUSSION 
ASK1 belongs to the mitogen-activated protein kinase (MAPK) kinase kinase family that 
activates the MAPK kinase 4 (MKK4)/MKK7-JNK and MKK3/6-p38 pathways through a 
ROS-dependent mechanism during ischemia-reperfusion [320, 331, 360]. Studies from 
ASK1 genetic mouse models suggest that ASK1 contributes to the pathogenesis of 
myocardial ischemia-reperfusion injury [361, 367]. Hence, pharmacological treatment 
using inhibitor molecules for components of the ASK1-MAPK pathway may potentially 
decrease cardiac injury during ischemia-reperfusion [388]. In a recent study, 
pharmacological treatment with ASK1-inhibitor (ASK1-i) at reperfusion led to a 
significant dose-related reduction in infarct size, inhibition of apoptotic cell death, and 
preservation of cardiac function at both 24 hours and 7 days [388]. Since cardiac 
mitochondria are both sources and targets of ischemic damage, we hypothesized that 
mitochondria could have a possible role in the cardioprotection observed in the in-vivo 
pretreatment with ASK1-i inhibitor. In the current study, we found that the cell-
permeable small molecule inhibitor of ASK1 given at the onset of reperfusion protects 
mitochondrial ETC, decreases susceptibility to MPTP opening and retains cytochrome c 
in the mitochondria thereby decreasing mitochondrial driven cardiac injury. Thus, this 
study provides a major translationally relevant pharmacologic strategy to attenuate the 
cardiac injury which starts at the time of reperfusion.  
Mitochondria sustain progressive damage during myocardial ischemia including the 
electron transport chain, leading to decreased rates of oxidative phosphorylation [203, 
204]. Ischemia decreased complex I activity due to increased ROS generation as a 
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result of electron leakage from the complex [102, 201, 205-207]. Additionally, complex I 
undergoes ischemia-mediated post-translational modifications including phosphorylation 
[208] and S-nitrosylation [57]. Ischemia-induced damage to NADH ferricyanide 
oxidoreductase (NADH dehydrogenase, NFR), a component of the complex I, appears 
likely due to the loss of the flavin mononucleotide (FMN) component [206, 207]. During 
ischemia, complex II activity was decreased due to loss of protective glutathionylation of 
key sulfhydryl groups [62] whereas complex III activity was decreased as a result of the 
functional inactivation of iron-sulfur protein subunit [214]. Moreover, ischemia damages 
cytochrome c oxidase by phosphorylation of COXI, COXIVi1, and COXVb subunits 
causing functional inactivation of the complex [215] and also by selective depletion of 
cardiolipin [216-218]. While the complex I defect occurs early, as ischemia continues 
damage increases and involves complex III and cytochrome oxidase.  
In our study, 25-min ischemia followed by 30-min reperfusion led to a significant 
decrease in glutamate+malate-, succinate- and TMPD-dependent respiration. 
Respiratory control ratios (RCRs) were reduced after ISC-REP independently of the 
type of substrates used due to slight increase in state 4 and a significant decrease in 
state 3 rates (Table 3.1). The decrease in integrated respiration was consistent with 
previous studies of ischemia-reperfusion [102, 201, 206]. The decrease in integrated 
respiration was not a result of alterations in the phosphorylation apparatus, which 
consists of ATP synthase, adenine nucleotide and phosphate transporters (DNP rates in 
Table 3.1), thereby localizing the damage to the ETC. Indeed, we observed that 
complex III activity was decreased (Table 3.2). From the observations including 
decreased complex III activity (Table 3.1 and Figure 3.14) along with the loss of 
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cytochrome c (Figure 3.14), it is clear that the distal part of ETC was the key target of 
ischemic damage. 
Ischemic damage to the electron transport chain facilitates ROS generation and sets the 
stage for myocardial injury during reperfusion. Complex I, in ETC, is one of the major 
sites for ROS generation during ischemia. The predicted sites of ROS generation from 
complex I are the FMN, iron sulfur cluster N2, and the two tightly bound ubiquinones 
[85, 92, 94, 95, 101, 219]. Ischemia increased maximal ROS generation from complex I 
following blockade with rotenone which localizes the the site for ROS generation 
proximal to the ubiquinone binding site (Figure 3.10) [92]. In this study, the increased 
production of H2O2 with succinate as the substrate in the presence of rotenone indicates 
that complex III remains a key site for ROS generation during ischemia (Figure 3.11) 
[85, 109, 207, 240]. In addition, the blockade of distal ETC with antimycin A increases 
ROS generation from complex III (Figure 3.11) [78, 219]. Most of the ROS generated at 
complex III are from the Qo center, whereas the Qi center can be a site for ROS 
generation, especially when electron flow into the Qo center of complex III is limited [85, 
105]. Moreover, increase in ROS production from complex I and complex III can also 
occur due to blocks in distal ETC including cytochrome c peroxidase formation, damage 
to complex III (Figure 3.14) and cytochrome c loss (Figure 3.13) with ischemia-
reperfusion [219]. Under these conditions, eventhough there was no complex I damage 
(Table 3.2) [78, 85, 219], complex I and complex III generate ROS due to increased 
relative reduction and electron leak [78, 85, 92] which augments the impact of direct 
ischemic damage to ETC. 
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In the present study, ischemia-reperfusion increased the susceptibility to MPTP opening 
(Figure 3.12). Increased calcium availability during reperfusion enhances mitochondrial 
calcium loading [244, 245, 391] which in concert with mitochondrial oxidative damage  
(ROS) predisposes to the onset of MPTP during reperfusion [154, 197]. Opening of 
MPTP releases cytochrome c and other pro-apoptotic proteins that cause cell death 
[147, 148]. Moreover, ischemia also depletes cardiolipin that provides binding sites on 
the inner membrane for cytochrome c [260, 264, 275] as a result of the peroxidase 
activity of cytochrome c. Depletion of cardiolipin [216, 219] or the oxidative modification 
of cardiolipin [223, 271, 296, 309, 392] diminishes the affinity of cytochrome c for 
cardiolipin delocalizing cytochrome c from the inner mitochondrial membrane to the 
intermembrane space [224, 227]. In normal conditions the outer membrane is 
impermeable to cytochrome c. However, during ischemia, the loss of BCL-2 triggers 
oligomerization of the pro-apoptotic BAX and BAK in the outer membrane forming pores 
[146, 229]. This leads to an increase in the permeability of the outer membrane allowing 
delocalization of cytochrome c from the inter-membrane space into the cytosol [149]. 
Furthermore, loss of cytochrome c also inhibits respiration, leading to further increase in 
ROS production from complex I [94, 102, 393]. This oxidative damage to mitochondrial 
ETC, further increases susceptibility to MPTP (Figure 3.12) that leads to the loss of 
cytochrome c (Figure 3.13) [228, 394] potentially creating a vicious cycle of 
mitochondrial-driven oxidative injury leading to activation of apoptotic cascades. Thus 
ischemic damage to the ETC promotes MPTP opening as a mechanism of 
mitochondrial-dependent cardiac injury during reperfusion, translating ischemic 
mitochondrial damage into reperfusion injury. 
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ASK1 is a serine/threonine protein kinase bound directly to thioredoxin and regulates 
cell death via p38 and c-Jun N-terminal kinase pathways [395]. During oxidative stress, 
thioredoxin is oxidized which dissociates from ASK1 resulting in activation of ASK1 
through phosphorylation of Thr845 [395]. The inhibitor of ASK1 (ASK1-i), GS-459679, 
competes with the binding pocket of Trx in ASK1 thereby inhibiting ASK1 activation and 
decreasing cell death. Treatment with ASK1-inhibitor (ASK1-i), at reperfusion led to a 
significant dose-related reduction in infarct size, inhibition of apoptotic cell death, and 
preservation of left ventricular dimension and systolic function at both 24 hours and 7 
days of reperfusion [388]. The protective effects of ASK1 inhibition during early 
reperfusion [388] were highly consistent with ASK1 genetic models wherein ASK1-
knock out mice decreased infarct size [361] and ASK1 overexpressor mice showed 2-
fold increase in infarct size [367] following ischemia-reperfusion. Interestingly, cardiac 
overexpression of ASK1 in the absence of ischemic injury had no effects in the mice, 
which proves that ASK1 acts as a cellular sensor, rather than a simple mediator of injury 
[395].  
In this study, we have shown that treatment with ASK1-i before ischemia and during 
reperfusion significantly improved glutamate respiration whereas the succinate-and 
TMPD/ascorbate-dependent respiration rates were not (Table 3.1). Interestingly, ASK1-i 
treatment pre- and post-ischemia decreased susceptibility to MPTP opening (Figure 
3.12) thereby preventing cytochrome c release from mitochondria (Figure 3.13). We 
have also shown that, ASK1-i treatment during ischemia and early reperfusion showed 
a significant increase in the levels of net H2O2 generated from complex I and III (Figure 
3.10, 3.11) measured following ISC-REP. This suggests that physiological interaction of 
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Trx with ASK1 is important for the Trx antioxidant defense system to scavenge ROS 
release during ischemia [396-398] which probably is a reason why treatment before and 
after ischemia showed an additional significant increase in ROS release from complex I 
and complex III compared to ISC-REP.  
Prevention of ischemic damage to the ETC by pharmacologic intervention before 
ischemia salvages myocardium during reperfusion [209, 231, 399, 400]. However, the 
clinical potential of these approaches are obviously limited because of the 
unpredictability of clinical ischemic events. Thus, pharmacologic treatment at the onset 
of reperfusion has great clinical relevance for the reduction of myocardial injury during 
reperfusion [401, 402]. Remarkably, administration of ASK1-i only during reperfusion 
protected maximal respiration through complex I, complex II and compex IV (Figure 
3.8). Interestingly, pre-treatment with ASK1-i significantly increased the complex III 
activity (Figure 3.14). In addition, pre-treatment with ASK1-i inhibits MPTP opening 
(Figure 3.12) thereby decreases apoptosis by preventing cytochrome c release (Figure 
3.13) from mitochondria. To summarize, these results support the observed increased 
rates of integrated respiration following  ASK1-i treatment during reperfusion was 
indeed due to protection from damage to the distal ETC. Sites of protection include 
complex III and retention of cytochrome c as a result of decreased susceptibility to 
MPTP opening. Hence, the ASK1-i treatment during early reperfusion alone protected 
mitochondria from ETC driven myocardial injury comparable to the regimen that 
included ASK1-i pre-treatment before ischemia. 
Differences in the above mentioned observations in mitochondrial respiration, ETC 
complex activities and MPTP susceptibility between control, treated and untreated 
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groups were not due to a preferential selection of “good” mitochondria in the treatment 
groups during the isolation process. The reason for the above conclusion was because 
neither the protein content (Figure 3.7A) nor the citrate synthase activity (marker for 
matrix) (Figure 3.7B) differed between the four groups which provided a strong 
evidence of a similar recovery and relative purity of mitochondria from the heart 
irrespective of ASK1-i treatment. This finding is consistent with published work that the 
protein yield or the activity of citrate synthase, a mitochondrial matrix marker enzyme, 
was unaltered [102, 204, 214]. 
Complex III (ubiquinol: ferricytochrome c oxidoreductase, EC 1.10.2.2) is a dimeric 
complex with a molecular mass of 485 kDa that is involved in the transfer of electrons 
from ubiquinol to oxidized cytochrome c coupled to proton translocation [403]. Each 
monomer consists of 11 subunits, three of which, namely, cytochrome b, cytochrome c1 
and the iron-sulfur protein (ISP), have prosthetic groups involved in the electron transfer 
[66]. Myocardial ischemia decreased complex III activity following in-vivo coronary 
occlusion in the canine model [206] and following global ischemia in the isolated rat 
heart [201, 214]. Electron paramagnetic resonance (EPR) signal from the ISP subunit 
containing the [2Fe-2S] cluster decreases after ischemia suggesting that it is the 
disruption of the cluster that decreases complex III activity. The content of the ISP 
subunit, cytochromes b and c1 were unchanged by ischemia [214]. Thus, ischemia 
decreases complex III activity as a result of the functional inactivation of iron-sulfur 
protein subunit without degradation of the ISP subunit or the remaining eleven subunits 
of the complex. In addition, ischemia depletes inner membrane enriched phospholipid, 
cardiolipin [5, 204, 216]. During ischemia excessive generation of ROS converts 
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cytochrome c to a “peroxidase” leading to oxidation and depletion of cardiolipin. Fusion 
of mitochondria from ischemic-reperfused hearts with cardiolipin-liposomes resulted in 
an almost full restoration of complex III activity which highlights the importance of 
cardiolipin for optimal activity of complex III [404].   
ASK1-i treatment during reperfusion improved ETC function by restoring complex III 
activity. Hence, it can be predicted that the functional inactivation of ISP subunit is a 
reversible phenomenon. Future studies may include studying the EPR signal of ISP 
subunit to identify the functional restoration of the ISP catalytic site and the relationship 
to the improved complex III activity. In addition, it would be interesting to study if ASK1-i 
treatment restored complex III activity by preserving cardiolipin content. Future studies 
are required to study the contribution of ASK1-i treatment in preventing cytochrome c 
peroxidase formation thereby preserving the cardiolipin content which can be probable 
mechanism through which both complex III activity and cytochrome c content are 
restored. Also, ASK1 is a MAPK kinase kinase and its possible role in phosphorylation 
of complex III subunits need to be elucidated. Hence, another possible mechanism 
through which the inhibitor of ASK1 improves complex III activation is by preventing 
phosphorylation of complex III subunits thereby decreasing its damage. 
Ischemia-damaged mitochondria remain as sources of ROS production and the 
activators of apoptosis as reperfusion continues [5, 222]. In order for the post-ischemic 
myocyte to fully recover from ischemia, these damaged mitochondria must eventually 
undergo repair or removal, through the processes of mitochondrial remodeling or 
autophagy [138, 192, 193]. Moreover, an approach such as ASK1-i treatment during 
reperfusion modulates ETC during the course of reperfusion by improving mitochondrial 
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function, retaining cytochrome c leading to a decrease in the signal for mitophagy.  
Decreasing mitophagy will prevent the transition to the post-infarction ischemic 
cardiomyopathy state. We anticipate that the ASK1-i-mediated protection of 
mitochondria during ischemia favors a pro-survival mitochondrial phenotype and 
prevents the maladaptive remodeling of the mitochondria by preserving fusion proteins 
throughout reperfusion. The preservation of fusion proteins will favor the maintenance of 
mitochondrial membrane potential and bioenergetic function, and will also decrease the 
stimulus for activation of mitophagy thereby decreasing tissue injury observed after 
prolonged reperfusion.  
In summary, the major finding of the present study was that pharmacological inhibition 
of ASK1 protects the heart during reperfusion via the modulation of mitochondria that 
sustained damage during ischemia. This mitochondrial-based mechanism of 
cardioprotection enhanced the functional integrity of the inner mitochondrial membrane 
retaining cytochrome c thereby decreasing cell death (Figure 3.15). 
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Figure 3.15. Postulated mechanismof cardioprotection with ASK1-i during 
ischemia-reperfusion. The cell-permeable small molecule inhibitor of ASK1 given at 
the onset of reperfusion protects mitochondrial ETC, decreases susceptibility to MPTP 
opening and retains cytochrome c in the mitochondria thereby decreasing mitochondrial 
driven cardiac injury. ASK1, apoptosis signaling kinase 1; MPTP, mitochondrial 
permeability transition pore opening, Trx, Thioredoxin; ROS, reactive oxygen species.
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CHAPTER IV: CONCLUDING REMARKS 
 
 
 
 
Excessive generation of ROS during oxidative stress conditions oxidize methionine 
residues in proteins forming methionine sulfoxide and can result in loss of protein’s 
function [405, 406]. Cytochrome c is a small heme protein that transfers electrons 
between respiratory complexes III and IV located in the inner membrane of 
mitochondria. Excessive generation of reactive oxygen species (ROS) oxidizes a key 
methionine residue (Met81) of cytochrome c converting it into a pathological peroxidase 
[264, 271, 406]. Cytochrome c peroxidase oxidizes and depletes cardiolipin releasing 
pro-apoptotic proteins into the cytosol activating cell death cascades [264, 276]. In order 
to maintain homeostatis, living organisms have developed a complex and cyclic defense 
system, the methionine sulfoxide reductase system, comprising enzymatic and non-
enzymatic antioxidants to restore the cytochrome c function [407, 408]. 
Methionine sulfoxide reductases (MSR) are redox repair enzymes which reduce both 
free and protein bound Met(O) back to methionine (Met) in the presence of thioredoxin 
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[407, 408].  Oxidized Trx is inactive and unable to bind to ASK1 thereby activating ASK1 
and causing cell death via p38/JNK pathways [319, 327, 396]. The oxidized thioredoxin 
formed is reduced by thioredoxin reductase at the expense of NADPH. Thioredoxin 
reductases (TrxR) are oxido-reductases that reduce the active site disulfide in Trx 
maintaining the pool of reduced Trx [409]. Reduced Trx can bind to ASK1 at the N-
terminal coiled coil (NCC) domain and inactivates ASK1 by directing it for ubiquitination 
and degradation [319, 326, 327]. The net result is the catalytic scavenging of ROS by 
NADPH (Figure 4.1). Hence, it is clear that the cytochrome c and ASK1 cause cell 
injury through an inter-connected mechanism which is not yet explored during ischemia-
reperfusion. 
Isoforms of MSRB, MSRB2 and MSRB3B, contain an N-terminal mitochondrial targeting 
sequence, localizing them to mitochondria [405, 407]. In a recent study, mouse MSRA 
was shown to be important in cytochrome c repair and protection against cataract [410]. 
Another study showed that cytosolic MSRA protects the heart from ischemia-
reperfusion damage [411]. These studies highlight the pathological role of methionine 
sulfoxidation in causing cell death and the importance of redox enzymes, methionine 
sulfoxide reductases, in decreasing cell injury. 
Through this study we propose a novel pathway through which mitochondria trigger cell 
death during ischemia-reperfusion. Excessive generation of ROS and limited NADPH 
availability, during ischemia-reperfusion burdens and interferes with the methionine 
redox enzyme system. As a result the cytochrome c oxidized at methionine residue 
during ischemia is not effectively repaired by MSRB. Oxidized cytochrome c converts to 
a peroxidase creating an altered electron flow thereby oxidizing and depleting cardiolipin 
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from the mitochondrial membrane. In addition, high levels of ROS that exceed the 
capacity of the antioxidant system may lead to an increase in oxidized thioredoxin pool 
that activates ASK1 and result in cell death. 
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Figure 4.1. Schematic of the antioxidant defense system created by oxidation and 
reduction of methionine residues. ROS is oxidized to Met(O) which is reduced back 
to Met by MSRB, with the formation of a disulfide bond. The oxidized MSRB is reduced 
by thioredoxin, forming a disulfide bond. Oxidation of thioredoxin activates ASK1. 
Oxidized thioredoxin is reduced by thioredoxin reductase containing a selenocysteine 
residue which is then reduced by NADPH. The net result is that ROS is reduced at the 
expense of NADPH. Met, methionine; MSRB, methionine sulfoxide reductase B; Trx, 
thioredoxin; TrxR, thioredoxin reductase; NADPH, nicotinamide adenine dinucleotide 
phosphate.
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